Miruvor
Sign up
The short answer

What studies of respiratory physiotherapy / pulmonary rehabilitation found

156papers on respiratory physiotherapy / pulmonary rehabilitation
1,696people in 31 studies testing respiratory physiotherapy / pulmonary rehabilitation alone
6randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, randomised trials and compared with another group, not randomised and studies with no comparison group (very low certainty): 17 findings, all C.

10 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 6 findings, all C.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, respiratory physiotherapy / pulmonary rehabilitation might help some people, but research can’t show it yet. For long COVID and ME/CFS studied together, respiratory physiotherapy / pulmonary rehabilitation might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 156 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Respiratory physiotherapy / pulmonary rehabilitation · Long COVID is hereRespiratory physiotherapy / pulmonary rehabilitation · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness23 studies · 1,256 people took part in respiratory physiotherapy / pulmonary rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); few people (206 in all); the studies disagree; randomised trials found mixed results.

Randomised trials5 studies · 206 people with results

Studies disagree about breathlessness.

Studies disagree about whether Respiratory physiotherapy / pulmonary rehabilitation helps breathlessness. Mixed results · very low certainty C

  • Some concerns about bias (RoB 2)
  • Few people (206 in all)
  • The studies disagree

Compared with another group, not randomised42 in the study · twice a week over a six-week period · twice a week, over a six-week period

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on breathlessness in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Few people (42 in all)
  • Effect size 0.02 (very small)
  • The benefit is very small

How big was the difference?

0.02, very small. The effect size compares respiratory physiotherapy / pulmonary rehabilitation with control group (g2).

Studies with no comparison group17 studies · 1,127 people with results

Breathlessness improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • Only people who finished were analysed
See the 23 studies
  1. The home-based breathing and chest mobility exercise improves cardiorespiratory functional capacity in long COVID with cardiovascular comorbidities: a randomized study. (2024)

    People in the study
    46 randomised
    Dose
    three times weekly for 12 weeks
    Outcome
    PEFR, L/min (SD) peak expiratory flow rate
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Effects of inspiratory muscle training on exercise capacity, muscle oxygenation and strength, physical activity, and dyspnea in patients with post-COVID-19 syndrome and pulmonary involvement: a randomized controlled triple-blinded study. (2026)

    People in the study
    40 randomised
    Dose
    once daily for approximately 30 min over 8 weeks
    Outcome
    MIP (%) maximal inspiratory pressure
    Effect
    worse
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  3. A Pulmonary Telerehabilitation Program Improves Exercise Capacity and Quality of Life in Young Females Post-COVID-19 Patients. (2023)

    People in the study
    48 randomised
    Dose
    60 to 80 minutes per session, three sessions per week for 6 weeks
    Outcome
    forced vital capacity (FVC) spirometry
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  4. Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study. (2024)

    People in the study
    37 randomised · 18 started · 16 analysed
    Dose
    twelve remote, asynchronous four-week sessions, three PTR sessions per week until 12 sessions were completed
    Outcome
    respiratory rate
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  5. Is telerehabilitation effective for treating infectious pulmonary diseases such as COVID-19 following late hospital discharge? A randomized blinded clinical trial (2024) preprint

    People in the study
    56 randomised
    Dose
    50-minute sessions, twice a week, for a total of 12 weeks, totaling 22 sessions offered; one-three sets of 6–10 repetitions, twice a week for 12 weeks
    Outcome
    FVC (AB) spirometry
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  6. Impact of respiratory muscle training on clinical and functional parameters in COVID-19 recovered patients. (2023)

    People in the study
    42 in the study
    Dose
    twice a week, over a six-week period
    Outcome
    Dyspnea, n (%)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Selection of participants
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  7. Breathe Better After COVID: The Impact of a Two-Week Pulmonary Rehabilitation Program on Pulmonary Function, Inflammatory Markers, and Quality of Life in Post-COVID Syndrome. (2025)

    People in the study
    77 in the study
    Dose
    every two hours, seven days a week
    Outcome
    FVC forced vital capacity
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  8. Effects of pulmonary rehabilitation on functional and psychological parameters in post-acute sequelae of SARS-CoV-2 infection (PASC) patients. (2024)

    People in the study
    55 in the study
    Dose
    two to three times a week
    Outcome
    MMRC modified medical research council scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  9. Low-intensity rehabilitation in persistent post COVID-19 dyspnoea: the value of Spa health resort as appropriate setting. (2024)

    People in the study
    187 in the study
    Dose
    12 therapy sessions, each consisting in about 2-3 hours of daily therapy, disbursed for 12 consecutive days in two weeks (excluding Sundays)
    Outcome
    improvement in the dyspnoea sensation
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  10. Pulmonary Rehabilitation for Post-COVID-19. (2023)

    People in the study
    56 with outcome data
    Dose
    3 times/wk
    Outcome
    Shortness of Breath Questionnaire (SOBQ) Shortness of Breath Questionnaire
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  11. Application of a therapeutic exercise program to improve physical condition in patients with post-COVID-19 syndrome (2022)

    People in the study
    5 in the study
    Dose
    —
    Outcome
    Single Breath Counting
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  12. Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study. (2026)

    People in the study
    134 in the study · 115 with outcome data
    Dose
    15 min in seated position, including ventilatory control exercises and inspiratory muscle training initial load at 30% of MIP, with incremental increases weekly (≥2 cm H2O); 5 days per week, 5 days per week; IMT 1 set of 10 repetitions twice daily in week 1, progressing to 2 sets of 10 twice daily in week 2, up to a maximum of 5 sets of 10 repetitions twice daily
    Outcome
    Dyspnoea (Borg 0–10), after 6MWT Borg scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  13. Home-Based Pilot Pulmonary Program for Dyspneic Patients Post-COVID-19. (2023)

    People in the study
    19 in the study · 18 started · 18 with outcome data
    Dose
    two sets of 10 repetitions, twice per day
    Outcome
    Pulmonary symptoms (COPD test) chronic obstructive pulmonary disease (COPD) Assessment Test (CAT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  14. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study. (2022)

    People in the study
    —
    Dose
    —
    Outcome
    peak flow
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  15. Motor and Respiratory Tele-Rehabilitation in Patients with Long COVID-19 after Hospital Discharge: An Interventional Study. (2024)

    People in the study
    28 started · 23 with outcome data
    Dose
    up to five times per week
    Outcome
    FVC forced vital capacity (FVC)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  16. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study. (2024)

    People in the study
    46 in the study
    Dose
    10 times per daily visit
    Outcome
    Borg scores after the 6MWT Borg Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  17. Effectiveness of pulmonary rehabilitation in post-COVID-19 patients: A pre- and post-interventional study. (2024)

    People in the study
    155 in the study
    Dose
    —
    Outcome
    Resting (before walk test ) mean SpO2 six-minute walk test (6MWT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  18. Physical Medicine and Rehabilitation Management in Patients with Long COVID-19 and Thymoma-associated Myasthenia Gravis: A Case Report (2024)

    People in the study
    1 in the study
    Dose
    twice a week, for a total of 6 times
    Outcome
    single breath count test
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  19. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Belastungsdyspnoe
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  20. Réhabilitation respiratoire dans la dyspnée chronique en post-COVID : expérience du service de pneumologie de Chartres (2023)

    People in the study
    46 in the study
    Dose
    3 séances hebdomadaires
    Outcome
    syndrome d’hyperventilation
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  21. Novel Respiratory Therapy for the Improvement of Post COVID Condition Symptoms: A Case Series. (2025)

    People in the study
    —
    Dose
    6–12 sessions of weekly 1-hour group telehealth sessions combined with 2–4 individual sessions
    Outcome
    parameters of DB measured
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  22. [Benefits of a pulmonary rehabilitation program for patients with long COVID: Impact of initial severity, disease duration, and presentation type on clinical outcomes]. (2025)

    People in the study
    158 in the study · 110 started
    Dose
    —
    Outcome
    mMRC dyspnea scale modified Medical Research Council (mMRC) dyspnea scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  23. Efficacy of a rehabilitation protocol on pulmonary and respiratory muscle function and ultrasound evaluation of diaphragm and quadriceps femoris in patients with post-COVID-19 syndrome: a series of cases. (2022)

    People in the study
    9 in the study
    Dose
    twice a week for six weeks
    Outcome
    peak expiratory flow
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue11 studies · 628 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (132 in all); the studies disagree.

Randomised trials3 studies · 132 people with results

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on fatigue in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (132 in all)
  • The studies disagree

Compared with another group, not randomised42 in the study · twice a week over a six-week period · twice a week, over a six-week period

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on fatigue in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Few people (42 in all)
  • Effect size 0.04 (very small)
  • The benefit is very small

How big was the difference?

0.04, very small. The effect size compares respiratory physiotherapy / pulmonary rehabilitation with control group (g2).

Studies with no comparison group7 studies · 531 people with results

Fatigue improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The studies disagree
  • The paper's own effect size: 0.45 (Cohen's d)

Combination: CBT and psychotherapy + Respiratory physiotherapy / pulmonary rehabilitation + interactive digital resource32 randomised

The breath and mind connection in young people with post-COVID syndrome: feasibility and acceptability of a pilot randomised co-designed intervention. (2026): 11-item Chandler Fatigue Score (0–33), no clear difference.

Shown, not counted: respiratory physiotherapy / pulmonary rehabilitation was given together with other treatments.

See the 11 studies
  1. Improved functional exercise capacity after primary care pulmonary rehabilitation in patients with long COVID (PuRe-COVID): a pragmatic randomised controlled trial. (2025)

    People in the study
    81 randomised · 76 started · 76 analysed
    Dose
    36 individual 1:1 sessions (three 30 min sessions per week), five consecutive phases with progressively increasing exercise intensity
    Outcome
    CIS-fatigue at 12 weeks Checklist Individual Strength
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Low
  2. Effects of inspiratory muscle training on exercise capacity, muscle oxygenation and strength, physical activity, and dyspnea in patients with post-COVID-19 syndrome and pulmonary involvement: a randomized controlled triple-blinded study. (2026)

    People in the study
    40 randomised
    Dose
    once daily for approximately 30 min over 8 weeks
    Outcome
    Fatigue Severity Scale (9–63 points) Fatigue Severity Scale (FSS)
    Effect
    worse
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  3. Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study. (2024)

    People in the study
    37 randomised · 18 started · 16 analysed
    Dose
    twelve remote, asynchronous four-week sessions, three PTR sessions per week until 12 sessions were completed
    Outcome
    perceived effort (Borg scale) after 1 min sit-to-stand test Borg scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  4. Impact of respiratory muscle training on clinical and functional parameters in COVID-19 recovered patients. (2023)

    People in the study
    42 in the study
    Dose
    twice a week, over a six-week period
    Outcome
    Fatigue, n (%)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Selection of participants
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Energy/fatigue Short Form Health Survey (SF–36)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  6. Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study. (2026)

    People in the study
    134 in the study · 115 with outcome data
    Dose
    15 min in seated position, including ventilatory control exercises and inspiratory muscle training initial load at 30% of MIP, with incremental increases weekly (≥2 cm H2O); 5 days per week, 5 days per week; IMT 1 set of 10 repetitions twice daily in week 1, progressing to 2 sets of 10 twice daily in week 2, up to a maximum of 5 sets of 10 repetitions twice daily
    Outcome
    Fatigue (Borg 0–10), before 6MWT Borg scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  7. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study. (2022)

    People in the study
    —
    Dose
    —
    Outcome
    VAS-F Visual Analog Scale for Fatigue
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  8. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study. (2024)

    People in the study
    46 in the study
    Dose
    10 times per daily visit
    Outcome
    VAS scores before the 6MWT Visual Analogue Scale
    Effect
    worse
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  9. Physical Medicine and Rehabilitation Management in Patients with Long COVID-19 and Thymoma-associated Myasthenia Gravis: A Case Report (2024)

    People in the study
    1 in the study
    Dose
    twice a week, for a total of 6 times
    Outcome
    fatigue severity scale
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  10. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Fatigue
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  11. Application of a therapeutic exercise program to improve physical condition in patients with post-COVID-19 syndrome (2022)

    People in the study
    5 in the study
    Dose
    —
    Outcome
    Borg fatigue
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety6 studies · 500 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; only people who finished were analysed; the studies disagree; the paper's own effect size: 0.12 (Cohen's g).

Studies with no comparison group6 studies · 500 people with results

Low mood or anxiety improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • Only people who finished were analysed
  • The studies disagree
  • The paper's own effect size: 0.12 (Cohen's g)

Combination: CBT and psychotherapy + Respiratory physiotherapy / pulmonary rehabilitation + interactive digital resource32 randomised

The breath and mind connection in young people with post-COVID syndrome: feasibility and acceptability of a pilot randomised co-designed intervention. (2026): Strengths and Difficulties Questionnaire, Impact Score, no clear difference.

Shown, not counted: respiratory physiotherapy / pulmonary rehabilitation was given together with other treatments.

See the 6 studies
  1. Effects of pulmonary rehabilitation on functional and psychological parameters in post-acute sequelae of SARS-CoV-2 infection (PASC) patients. (2024)

    People in the study
    55 in the study
    Dose
    two to three times a week
    Outcome
    HADS hospital anxiety and depression scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Panic disorder Patient Health Questionnaire
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Réhabilitation respiratoire dans la dyspnée chronique en post-COVID : expérience du service de pneumologie de Chartres (2023)

    People in the study
    46 in the study
    Dose
    3 séances hebdomadaires
    Outcome
    dépression
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Clinical outcome of supervised pulmonary telerehabilitation program among adult patients with post-acute COVID-19 symptoms (PACS): A case series. (2023)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    24 sessions, 2–3 sessions per week
    Outcome
    HADS Anxiety Hospital Anxiety and Depression Scale
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  5. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Angst
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  6. Concurrent aerobic and strength training program in post-COVID adult patients. (2022)

    People in the study
    26 in the study
    Dose
    —
    Outcome
    anxiety and depression scale Hospital Anxiety and Depression Scale
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression5 studies · 466 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; the paper's own effect size: 0.29 (Cohen's g).

Studies with no comparison group5 studies · 466 people with results

Depression improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on depression in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The paper's own effect size: 0.29 (Cohen's g)
See the 5 studies
  1. Pulmonary Rehabilitation for Post-COVID-19. (2023)

    People in the study
    56 with outcome data
    Dose
    3 times/wk
    Outcome
    Patient Health Questionnaire-9 (PHQ-9) Patient Health Questionnaire-9
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study. (2022)

    People in the study
    —
    Dose
    —
    Outcome
    Hamilton Depression Rating Scale (HAM-D) Hamilton Depression Rating Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Depression Patient Health Questionnaire
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study. (2024)

    People in the study
    46 in the study
    Dose
    10 times per daily visit
    Outcome
    PHQ9 scores
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Depressivität
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain3 studies · 394 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (42 in all); effect size 0.00 (very small); the benefit is very small.

Compared with another group, not randomised42 in the study · twice a week over a six-week period · twice a week, over a six-week period

Pain improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on pain in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Few people (42 in all)
  • Effect size 0.00 (very small)
  • The benefit is very small

How big was the difference?

0, very small. The effect size compares respiratory physiotherapy / pulmonary rehabilitation with control group (g2).

Studies with no comparison group2 studies · 364 people with results

Studies disagree about pain.

Studies disagree about whether Respiratory physiotherapy / pulmonary rehabilitation helps pain. Mixed results · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The studies disagree
  • The paper's own effect size: 0.11 (Cohen's d)
See the 3 studies
  1. Impact of respiratory muscle training on clinical and functional parameters in COVID-19 recovered patients. (2023)

    People in the study
    42 in the study
    Dose
    twice a week, over a six-week period
    Outcome
    Chest pain, n (%)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Selection of participants
    Moderate. comparison group: matched The groups were matched based on age, sex and BMI.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Pain Short Form Health Survey (SF–36)
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Schmerz
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety4 studies · 232 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; the paper's own effect size: 0.26 (Cohen's g).

Studies with no comparison group4 studies · 232 people with results

Anxiety improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The paper's own effect size: 0.26 (Cohen's g)
See the 4 studies
  1. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study. (2022)

    People in the study
    —
    Dose
    —
    Outcome
    Hamilton Anxiety Rating Scale (HAM-A) Hamilton Anxiety Rating Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Generalized anxiety Patient Health Questionnaire
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study. (2024)

    People in the study
    46 in the study
    Dose
    10 times per daily visit
    Outcome
    GAD anxiety scores Generalized anxiety disorder
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Réhabilitation respiratoire dans la dyspnée chronique en post-COVID : expérience du service de pneumologie de Chartres (2023)

    People in the study
    46 in the study
    Dose
    3 séances hebdomadaires
    Outcome
    anxiété
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Autonomic symptoms2 studies · 160 people took part in respiratory physiotherapy / pulmonary rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the studies disagree.

Studies with no comparison group2 studies · 160 people with results

Studies disagree about autonomic symptoms.

Studies disagree about whether Respiratory physiotherapy / pulmonary rehabilitation helps autonomic symptoms. Mixed results · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • The studies disagree
See the 2 studies
  1. Effectiveness of pulmonary rehabilitation in post-COVID-19 patients: A pre- and post-interventional study. (2024)

    People in the study
    155 in the study
    Dose
    —
    Outcome
    Resting mean pulse rate (before walk test) six-minute walk test (6MWT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Application of a therapeutic exercise program to improve physical condition in patients with post-COVID-19 syndrome (2022)

    People in the study
    5 in the study
    Dose
    —
    Outcome
    blood pressure
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning24 studies · 961 people took part in respiratory physiotherapy / pulmonary rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (282 in all); the studies disagree; randomised trials found mixed results.

Randomised trials6 studies · 282 people with results

Studies disagree about daily functioning.

Studies disagree about whether Respiratory physiotherapy / pulmonary rehabilitation helps daily functioning. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (282 in all)
  • The studies disagree

Studies with no comparison group18 studies · 823 people with results

Daily functioning improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • Only people who finished were analysed
  • The studies disagree
  • The paper's own effect size: 0.56 (Cohen's d)
See the 24 studies
  1. The home-based breathing and chest mobility exercise improves cardiorespiratory functional capacity in long COVID with cardiovascular comorbidities: a randomized study. (2024)

    People in the study
    46 randomised
    Dose
    three times weekly for 12 weeks
    Outcome
    Body’s energy expenditure, METS (%) metabolic equivalent
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Improved functional exercise capacity after primary care pulmonary rehabilitation in patients with long COVID (PuRe-COVID): a pragmatic randomised controlled trial. (2025)

    People in the study
    81 randomised · 76 started · 76 analysed
    Dose
    36 individual 1:1 sessions (three 30 min sessions per week), five consecutive phases with progressively increasing exercise intensity
    Outcome
    change in 6 min walk distance (6MWD) at 12 weeks 6 min walk distance
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  3. Effects of inspiratory muscle training on exercise capacity, muscle oxygenation and strength, physical activity, and dyspnea in patients with post-COVID-19 syndrome and pulmonary involvement: a randomized controlled triple-blinded study. (2026)

    People in the study
    40 randomised
    Dose
    once daily for approximately 30 min over 8 weeks
    Outcome
    Physical activity duration (> 3MET) (min/day) multisensory metabolic holter
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  4. A Pulmonary Telerehabilitation Program Improves Exercise Capacity and Quality of Life in Young Females Post-COVID-19 Patients. (2023)

    People in the study
    48 randomised
    Dose
    60 to 80 minutes per session, three sessions per week for 6 weeks
    Outcome
    6MWT 6-minute walk test
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  5. Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study. (2024)

    People in the study
    37 randomised · 18 started · 16 analysed
    Dose
    twelve remote, asynchronous four-week sessions, three PTR sessions per week until 12 sessions were completed
    Outcome
    physical capacity 1 min sit-to-stand test
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  6. Is telerehabilitation effective for treating infectious pulmonary diseases such as COVID-19 following late hospital discharge? A randomized blinded clinical trial (2024) preprint

    People in the study
    56 randomised
    Dose
    50-minute sessions, twice a week, for a total of 12 weeks, totaling 22 sessions offered; one-three sets of 6–10 repetitions, twice a week for 12 weeks
    Outcome
    Stair climbing test
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  7. Personalized pulmonary rehabilitation program for patients with post-acute sequelae of COVID-19: A proof-of-concept retrospective study. (2024)

    People in the study
    23 in the study · 17 with outcome data
    Dose
    3‐month, 2 or 3 times a week
    Outcome
    Post COVID Functional Status Scale post‐COVID‐19 Functional Status scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  8. Pulmonary Rehabilitation for Post-COVID-19. (2023)

    People in the study
    56 with outcome data
    Dose
    3 times/wk
    Outcome
    6-min walk test (6MWT) distance 6-min walk test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  9. Effects of pulmonary rehabilitation on functional and psychological parameters in post-acute sequelae of SARS-CoV-2 infection (PASC) patients. (2024)

    People in the study
    55 in the study
    Dose
    two to three times a week
    Outcome
    6MWT 6-minute walk test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  10. Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study. (2026)

    People in the study
    134 in the study · 115 with outcome data
    Dose
    15 min in seated position, including ventilatory control exercises and inspiratory muscle training initial load at 30% of MIP, with incremental increases weekly (≥2 cm H2O); 5 days per week, 5 days per week; IMT 1 set of 10 repetitions twice daily in week 1, progressing to 2 sets of 10 twice daily in week 2, up to a maximum of 5 sets of 10 repetitions twice daily
    Outcome
    6MWT, m 6 min walk test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  11. Home-Based Pilot Pulmonary Program for Dyspneic Patients Post-COVID-19. (2023)

    People in the study
    19 in the study · 18 started · 18 with outcome data
    Dose
    two sets of 10 repetitions, twice per day
    Outcome
    Functional performance (6-minute walk test), meters six-minute walk test (6-MWT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  12. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    Physical functioning Short Form Health Survey (SF–36)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  13. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study. (2022)

    People in the study
    —
    Dose
    —
    Outcome
    6 MWD 6-min walk distance
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  14. Motor and Respiratory Tele-Rehabilitation in Patients with Long COVID-19 after Hospital Discharge: An Interventional Study. (2024)

    People in the study
    28 started · 23 with outcome data
    Dose
    up to five times per week
    Outcome
    walked distance instrumented Six-Minutes Walking Test (i6MWT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  15. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study. (2024)

    People in the study
    46 in the study
    Dose
    10 times per daily visit
    Outcome
    StS test Sit-to-Stand test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  16. Effectiveness of pulmonary rehabilitation in post-COVID-19 patients: A pre- and post-interventional study. (2024)

    People in the study
    155 in the study
    Dose
    —
    Outcome
    Mean distance covered in meters six-minute walk test (6MWT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  17. Concurrent aerobic and strength training program in post-COVID adult patients. (2022)

    People in the study
    26 in the study
    Dose
    —
    Outcome
    6MWT 6 Minute Walk Test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  18. Effect of Supervised Home-Based Training on Functional Outcome in Severe Exercise Intolerance in Post-COVID Syndrome (2021)

    People in the study
    1 in the study
    Dose
    progressive metabolic equivalent of task level training, for 6 weeks
    Outcome
    progressive MET level activities
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  19. Novel Respiratory Therapy for the Improvement of Post COVID Condition Symptoms: A Case Series. (2025)

    People in the study
    —
    Dose
    6–12 sessions of weekly 1-hour group telehealth sessions combined with 2–4 individual sessions
    Outcome
    daily function
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  20. Physical Medicine and Rehabilitation Management in Patients with Long COVID-19 and Thymoma-associated Myasthenia Gravis: A Case Report (2024)

    People in the study
    1 in the study
    Dose
    twice a week, for a total of 6 times
    Outcome
    daily activities independently
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  21. Réhabilitation respiratoire dans la dyspnée chronique en post-COVID : expérience du service de pneumologie de Chartres (2023)

    People in the study
    46 in the study
    Dose
    3 séances hebdomadaires
    Outcome
    endurance
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  22. Clinical outcome of supervised pulmonary telerehabilitation program among adult patients with post-acute COVID-19 symptoms (PACS): A case series. (2023)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    24 sessions, 2–3 sessions per week
    Outcome
    Exercise capacity on the 6‐minute walk test Six-Minute Walk Test
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  23. Application of a therapeutic exercise program to improve physical condition in patients with post-COVID-19 syndrome (2022)

    People in the study
    5 in the study
    Dose
    —
    Outcome
    Barthel index Barthel
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  24. [Benefits of a pulmonary rehabilitation program for patients with long COVID: Impact of initial severity, disease duration, and presentation type on clinical outcomes]. (2025)

    People in the study
    158 in the study · 110 started
    Dose
    —
    Outcome
    6MWT 6-minute walk test (6MWT)
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life9 studies · 687 people took part in respiratory physiotherapy / pulmonary rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (94 in all); the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 94 people with results

Studies disagree about quality of life.

Studies disagree about whether Respiratory physiotherapy / pulmonary rehabilitation helps quality of life. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (94 in all)
  • The studies disagree

Studies with no comparison group7 studies · 640 people with results

Quality of life improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • Only people who finished were analysed
See the 9 studies
  1. The home-based breathing and chest mobility exercise improves cardiorespiratory functional capacity in long COVID with cardiovascular comorbidities: a randomized study. (2024)

    People in the study
    46 randomised
    Dose
    three times weekly for 12 weeks
    Outcome
    EuroQoL, score (%) EuroQoL EQ-5D questionnaire
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. A Pulmonary Telerehabilitation Program Improves Exercise Capacity and Quality of Life in Young Females Post-COVID-19 Patients. (2023)

    People in the study
    48 randomised
    Dose
    60 to 80 minutes per session, three sessions per week for 6 weeks
    Outcome
    HRQOL Short Form Health Survey-36
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  3. Effects of pulmonary rehabilitation on functional and psychological parameters in post-acute sequelae of SARS-CoV-2 infection (PASC) patients. (2024)

    People in the study
    55 in the study
    Dose
    two to three times a week
    Outcome
    CAT chronic obstructive pulmonary disease assessment test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Breathe Better After COVID: The Impact of a Two-Week Pulmonary Rehabilitation Program on Pulmonary Function, Inflammatory Markers, and Quality of Life in Post-COVID Syndrome. (2025)

    People in the study
    77 in the study
    Dose
    every two hours, seven days a week
    Outcome
    WHOQOL-BREF psychological domain
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study. (2026)

    People in the study
    134 in the study · 115 with outcome data
    Dose
    15 min in seated position, including ventilatory control exercises and inspiratory muscle training initial load at 30% of MIP, with incremental increases weekly (≥2 cm H2O); 5 days per week, 5 days per week; IMT 1 set of 10 repetitions twice daily in week 1, progressing to 2 sets of 10 twice daily in week 2, up to a maximum of 5 sets of 10 repetitions twice daily
    Outcome
    PedsQL at 6M and 12M follow-up Pediatric Quality of Life Inventory
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  6. Effectiveness of pulmonary rehabilitation in post-COVID-19 patients: A pre- and post-interventional study. (2024)

    People in the study
    155 in the study
    Dose
    —
    Outcome
    Mobility
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  7. Clinical outcome of supervised pulmonary telerehabilitation program among adult patients with post-acute COVID-19 symptoms (PACS): A case series. (2023)

    People in the study
    13 in the study · 9 with outcome data
    Dose
    24 sessions, 2–3 sessions per week
    Outcome
    SGRQ St. George's Respiratory Questionnaire
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  8. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    Lebensqualität
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  9. Application of a therapeutic exercise program to improve physical condition in patients with post-COVID-19 syndrome (2022)

    People in the study
    5 in the study
    Dose
    —
    Outcome
    Fantastic test Fantastic
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms5 studies · 478 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; the paper's own effect size: 0.24 (Cohen's d).

Studies with no comparison group5 studies · 478 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The paper's own effect size: 0.24 (Cohen's d)

Combination: CBT and psychotherapy + Respiratory physiotherapy / pulmonary rehabilitation + interactive digital resource32 randomised

The breath and mind connection in young people with post-COVID syndrome: feasibility and acceptability of a pilot randomised co-designed intervention. (2026): Wellness Score (0–100%), no clear difference.

Shown, not counted: respiratory physiotherapy / pulmonary rehabilitation was given together with other treatments.

See the 5 studies
  1. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition. (2025)

    People in the study
    140 in the study
    Dose
    —
    Outcome
    General health Short Form Health Survey (SF–36)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Is pulmonary rehabilitation an effective programme to manage post-COVID breathlessness? (2022)

    People in the study
    131 in the study · 88 with outcome data
    Dose
    —
    Outcome
    improvement in their symptoms
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Novel Respiratory Therapy for the Improvement of Post COVID Condition Symptoms: A Case Series. (2025)

    People in the study
    —
    Dose
    6–12 sessions of weekly 1-hour group telehealth sessions combined with 2–4 individual sessions
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  4. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19]. (2023)

    People in the study
    224 in the study
    Dose
    —
    Outcome
    PROs in beiden Subgruppen
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. Concurrent aerobic and strength training program in post-COVID adult patients. (2022)

    People in the study
    26 in the study
    Dose
    —
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Both together

Symptoms

Anxiety1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised360 in the study · 6 months

Anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on anxiety in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    anxiety
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Breathlessness1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised360 in the study · 6 months

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on breathlessness in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    changes in PaCO₂
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
Sleep1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.

Compared with another group, not randomised360 in the study · 6 months

Sleep improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on sleep in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    sleep quality
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Daily life and health overall

Daily functioning1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised360 in the study · 6 months

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    exercise capacity
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Overall symptoms1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); effect size 0.32 (small).

Compared with another group, not randomised360 in the study · 6 months

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Effect size 0.32 (small)

How big was the difference?

0.32, small. The effect size compares respiratory physiotherapy / pulmonary rehabilitation with usual care.

See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    composite early clinical benefit rate
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Quality of life1 study · 120 people took part in respiratory physiotherapy / pulmonary rehabilitation Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised360 in the study · 6 months

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of Respiratory physiotherapy / pulmonary rehabilitation on quality of life in ME/CFS or long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study (2026) preprint

    People in the study
    360 in the study
    Dose
    —
    Outcome
    quality of life
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

Stopping because of side effects6 studies

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

Systematic reviewPublished 2023Searched to up until April 2023

A Systematic Review of Telemedicine-Driven Pulmonary Rehabilitation after the Acute Phase of COVID-19. (2023)

“The findings from this systematic review suggest that telemedicine-driven pulmonary rehabilitation can have beneficial effects on physical and mental health, quality of life, and pulmonary function in patients recovering from the acute phase of COVID-19.”
“these results should be interpreted with caution due to differences in study populations and varying severity of COVID-19 among participants.”

All papers

  1. Long-term outcomes following a pulmonary telerehabilitation trial for people with respiratory post-acute sequelae of COVID: a 12-month follow-up study.2026 · randomised trial · 50 randomised · 29 analysed
    Summary

    This prospective, observational 12-month follow-up of a multi-site, assessor-blinded randomized controlled trial asked whether physical and psychological outcomes changed after a 4-week pulmonary telerehabilitation programme versus usual care in people with respiratory post-acute sequelae of COVID attending a Post-COVID Respiratory Clinic. Fifty participants were enrolled; 29 (58%) completed the 12-month follow-up, and all were analysed as one group because the trial found no significant between-group differences. The programme was individualized exercise and education in a group format; usual care involved an educational pamphlet on managing symptoms and any required medical follow-up. Outcomes included the 1-minute sit-to-stand test (primary), 5-repetition sit-to-stand test, CAT, C19-YRS, SF-36, HADS, FSS and K6+. At 12 months, the 1-minute sit-to-stand test did not improve significantly (1.5 points, CI: –1.3 to 4.2). The 5-repetition sit-to-stand test (–1.4 s, CI: –2.7 to –0.1), CAT (–4.1 points, CI: –6.8 to –1.4), and some C19-YRS and SF-36 domains improved significantly. Reasons for not participating included not interested (n = 4), too busy (n = 4), unable due to “brain fog” (n = 1), or no reason (n = 12). Treatment-related harms were not reported.

  2. Fully remote versus hybrid supervision of pulmonary telerehabilitation in COVID-19: a randomized clinical trial.2025 · randomised trial · 49 started · 67 analysed
    Summary

    This randomised trial with a parallel observational cohort enrolled patients with persistent respiratory dysfunction after hospitalisation for COVID-19 pneumonia at a Brazilian public hospital. Of 49 patients who began and were randomised, 28 were assigned to fully remote supervision (G1) and 21 to hybrid remote and face-to-face supervision (G2) of a 12-week pulmonary telerehabilitation program performed at home at least three times a week. A non-intervention group of 37 patients received general guidance and outpatient follow-up. Data from 67 participants were analysed: 30 who completed the program (13 G1 and 17 G2) and 37 non-intervention patients. The primary outcome was six-minute walk distance (6MWD); quality of life was assessed with SF-36. Post-rehabilitation 6MWD was 559.6 m in G1 and 535.2 m in G2 (P=0.427), and the paper reports no statistically significant difference between supervision modalities. The 6MWD increase was 164.5 m in G1 and 154.2 m in G2. Comparing the intervention group with the non-intervention group, the increase in 6MWD was 140.53 m versus 16.8 m (P=0.002), and at T3 the intervention group had higher 6MWD (P<0.001). The non-intervention group did not show a significant improvement (P=0.317). No incidents or adverse events were reported. The paper reports a 39% dropout, with 42% of dropouts citing improvement.

  3. The home-based breathing and chest mobility exercise improves cardiorespiratory functional capacity in long COVID with cardiovascular comorbidities: a randomized study.2024 · randomised trial · 46 randomised
    Summary

    This single-blind randomized controlled trial enrolled 46 long COVID patients with cardiovascular comorbidities at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia. Participants were randomly assigned to an intervention group (n = 23) or control group (n = 23). The intervention group received home-based breathing and chest mobility exercise three times weekly for 12 weeks plus a home-based cardiac rehabilitation program; the control group received only home-based cardiac rehabilitation. Both groups performed a 30-minute mild-to-moderate aerobic exercise program five times a week. At the end of the 12th week, 23 patients from each arm were analyzed statistically after imputation for missing data. The intervention group had higher mean PEFR (502.61 vs 411.30 L/min; p = .031), PCF (465.22 vs 365.65 L/min; p = .016), and 6-MWT (467.39 vs 415.00 m; p = .032). Bottom chest circumference differed between groups (5.18 vs 4.13 cm; p = .01), while upper and middle chest circumference did not. METS and predicted VO2 peak were not significantly different (p = .15 and p = .11), and EuroQoL quality of life did not differ significantly (p = .87). One intervention and two control patients were lost to follow-up due to non-adherence and transportation issues. The authors report no major cardiovascular events or adverse effects related to the study.

  4. Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study.2024 · randomised trial · 37 randomised · 18 started · 16 analysed
    Summary

    This pilot study examined a pulmonary telerehabilitation (PTR) program in young adults with post-COVID-19 conditions (PCC). Thirty-seven students' medical files were reviewed; 18 were eligible and randomly assigned, and 16 participants (8 in each group) were analyzed. Participants were students diagnosed with PCC at Universidad de Las Américas in Quito, Ecuador. The experimental group received a four-week PTR program with twelve remote, asynchronous sessions of diaphragmatic breathing and aerobic exercises; the control group received no treatment. Outcomes included SpO2, heart rate (HR), respiratory rate (RR), blood pressure, physical capacity (1 min sit-to-stand test), cardiorespiratory capacity (6-Minute Walk Test), and perceived exertion (Borg scale). The paper reports a significant interaction for HR (p < 0.014) and RR (p < 0.001), with the EG decreasing HR by 4 and RR by 8.7 after treatment. Physical capacity showed a significant interaction (p < 0.006), with the EG increasing by 4.9, and cardiorespiratory capacity significantly increased in the EG by 217.5 m (p < 0.002). Perceived effort after the sit-to-stand test changed significantly in both groups (CG: p < 0.006; EG: p < 0.001; CG: 1.1; EG: 2.4 points). SpO2 showed no significant interaction (p > 0.143), blood pressure no significant interaction (p > 0.207), and Borg after 6MWT no significant interaction (p > 0.106). One participant discontinued the intervention.

  5. Effect of home-based pulmonary rehabilitation on exercise capacity in post COVID-19 patients: a randomized controlled trail.2024 · randomised trial · 68 randomised · 60 analysed
    Summary

    This randomized controlled trial enrolled 68 patients with post COVID-19 syndrome, aged 40 to 70 years, at an outpatient clinic at Beni-Suef University. Participants were allocated to a rehabilitation group or a control group; 60 patients (30 per group) were analysed after 8 patients (four in each group) dropped out for follow-up assessments due to non-specific reasons. The rehabilitation group received a home-based pulmonary rehabilitation exercise program (regular walking, respiratory muscle training, and resisted training) plus usual medical care; the control group received no exercise program plus usual medical care. Interventions lasted up to 12 weeks. Outcomes measured before and after intervention were the Chalder fatigue scale, 6MWT, PFI, SF-36, and mMRC dyspnea scale. After intervention, the rehabilitation group had a lower Chalder fatigue mean (11.1 ± 0.94 vs 13.4 ± 2.1; p<0.001), higher 6MWT (439.7 ± 25.3 vs 347 ± 32.7; p<0.001), higher PFI (52.3 ± 10.3 vs 36.7 ± 4.2; p<0.001), and higher SF-36 total score (66.4 ± 3.7 vs 47.6 ± 2.6; p<0.001). mMRC after intervention differed (p=0.008): rehabilitation No 3 (10%), Mild 19 (63.3%), Moderate 8 (26.7%); control No 0 (0%), Mild 11 (36.7%), Moderate 19 (63.3%). Side effects were not reported.

  6. Is telerehabilitation effective for treating infectious pulmonary diseases such as COVID-19 following late hospital discharge? A randomized blinded clinical trial2024 · randomised trial · 56 randomised · preprint
    Summary

    This randomized controlled trial evaluated a low-moderate telerehabilitation exercise protocol on physical and respiratory capacities in severe post-COVID-19 patients two to four months after hospital discharge. Participants were recruited from medical records of ICU patients at a single hospital. The trial randomized 56 participants (28 telerehabilitation, 28 control). The telerehabilitation group received 50-minute sessions twice a week for 12 weeks, totaling 22 sessions offered; the control group did not receive any rehabilitation intervention. Assessments included spirometry, handgrip strength, stair climbing test, chair stand test, short physical performance battery, postural balance and flexibility. The paper reports significant improvements in handgrip strength in the dominant limb (p < 0.001) and non-dominant limb (p = 0.003), and in postural balance (p < 0.001). The abstract states no significant changes were found in other physical or respiratory parameters, while the results text states FEV1 showed a significant improvement in the TrG (p = 0.040). Four participants in the telerehabilitation group withdrew at the beginning of intervention due to difficulties with the technology required for the sessions, leaving 24; all 28 control participants completed the study. Harms were not reported. The authors state limitations included challenges related to the environment and technological availability of the telerehabilitation methodology.

  7. A 14-Day Therapeutic Exercise Telerehabilitation Protocol of Physiotherapy Is Effective in Non-Hospitalized Post-COVID-19 Conditions: A Randomized Controlled Trial.2023 · randomised trial · 52 randomised · 48 analysed
    Summary

    This randomized, controlled, parallel, two-arm trial enrolled 52 people with post-COVID-19 conditions who were non-hospitalized; 48 completed the trial, with 24 in the experimental group and 24 in the control group. Participants were recruited through public information in the media and had doctor-diagnosed post-COVID-19 conditions and a positive PCR more than 40 days ago. The experimental group received a 14-day therapeutic exercise telerehabilitation protocol of breathing- and strength-based exercises, performed once a day with 12 repetitions per exercise each day for 30 min and controlled by a physical therapist via videoconference. The control group had relative home rest, consisting of daily activities without associated physical efforts. Outcomes were measured on day 1 and day 14: BS, MD12, VAFS, 30STST, and 6MWT. The paper reports statistically significant improvement between groups in all study variables, favoring the experimental group, and within-group differences in the experimental group (p < 0.05) in all variables, while the control group had no significant within-group differences (p > 0.05) in any variable. Largest effects were reported for BS, MD12, and 30STST (p < 0.001). No side effects were recorded during the intervention. There were two losses in the control group and two losses in the experimental group. The authors state limitations: only short-term follow-up when the exercise program finished, so medium- and long-term benefits cannot be discussed, and remote assessments may limit extrapolation and depend on self-assessment.

  8. A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study2026 · compared with another group · 360 in the study · preprint
    Summary

    This prospective controlled cohort study enrolled 360 hospitalized patients with chronic lung disease and post-COVID syndrome. Patients received integrated multidisciplinary care (n = 120), comprising pharmacotherapy, psychological support, and pulmonary rehabilitation, or usual care (n = 240). Treatment duration was not reported; follow-up was at 6 months. Primary outcomes were changes in PaCO₂, FEV₁% predicted, and CT abnormality extent; patient-reported outcomes, functional capacity, and inflammation were also assessed. Integrated care was associated with greater improvements in gas exchange, lung function, radiological resolution, quality of life, anxiety, exercise capacity, and inflammation (all P < 0.001). The composite early clinical benefit rate was higher with integrated care (51.7% vs 37.5%, P = 0.011). At 6 months, sleep quality was better and symptom-related medication use was lower, while rehospitalization and exacerbation rates were similar between groups. The paper did not report harms, withdrawals, or the numbers who started or were analysed. No side-effect counts were reported.

  9. [Rehabilitation of patients with post-COVID syndrome depending on C(159)T polymorphism of SD-14 gene].2025 · compared with another group · 97 in the study
    Summary

    This study enrolled 97 patients with COVID-19 past history and PCS diagnosis who underwent rehabilitation in the Department of Pulmonology of the I.M. Sechenov Research Institute of Physical Methods of Treatment, Medical Climatology and Rehabilitation (Yalta). Patients received comprehensive rehabilitation including climatotherapy, physical therapy, massage, aromatherapy, respiratory therapy and pharmaceutical treatments as medically indicated; the treatment course was 21 days. Patients were divided into 3 groups after genetic analysis: CC 30, CT 45 and TT 22; randomisation is not reported. Outcomes included clinical symptoms, dyspnea questionnaires, pulmonary function, SpO2, 6МШТ, laboratory values, HADS and SF-36 before and after rehabilitation. Within-group improvements were reported for cough, dyspnea, physical activity, OCD, SpO2, 6МШТ and some HADS/SF-36 domains in various genotype groups. mMRC and BDI/TDI showed no significant dynamics in any group. Between genotypes, SpO2 change differed for CC vs CT (p1=0,032), 6МШТ for CC vs TT (p2=0,043), HADS anxiety for CC vs CT (p1=0,010) and CT vs TT (p3=0,040), SF-36 role physical for CC vs CT (p1=0,011), role emotional for CC vs TT (p2=0,047), and ВАШ for CC vs TT (p2=0,048). The authors reported a negative tendency of cholesterol increase in CC and CT. No counts of side effects or withdrawals are reported. The authors note that sanatorium-resort organizations receive patients without severe respiratory failure who meet selection criteria.

  10. Hybrid Pulmonary Rehabilitation Improves Cardiorespiratory Exercise Fitness in Formerly Hospitalised Long COVID Patients.2025 · compared with another group · 42 in the study
    Summary

    This single-centre, non-randomised, propensity-matched feasibility study in Greece included 42 previously hospitalised adults with long COVID and excessive fatigue. Patients received a hybrid pulmonary rehabilitation programme: 8 supervised outpatient sessions (twice weekly for 4 weeks) followed by 24 home-based sessions (3 times/week for 8 weeks), or usual care in which patients were instructed to be physically active. Assessments were at baseline and 12 weeks. In the PR group, peak work rate improved by 19 ± 10 Watt and peak oxygen uptake by 2.4 ± 3.0 mL/kg/min; 6 min walk distance increased by 72 ± 69 metres; FACIT improved by 15 ± 10 and mMRC by 1.4 ± 1.0. In usual care, only mMRC improved, by 0.7 ± 1.0; there was no difference in WRpeak (p = 0.205), VO2peak (p = 0.565) or 6 min walk distance (p = 0.274). Patients completed 23 out of 24 remote sessions (94%). Side effects were not reported. The authors state limitations including a relatively small sample size, that randomisation was not feasible due to ethical considerations, and that the usual care group was composed of patients unable to attend for personal reasons; they also note the study focused on acute effects and long-term follow-up is important.

  11. Impaired Endothelial Function in Individuals With Post-Acute Sequelae of COVID-19: Effects of Combined Exercise Training.2025 · compared with another group
    Summary

    This paper reports two studies in individuals with post-acute sequelae of COVID-19 (PASC). Study II, the intervention study, compared combined exercise training (n = 14) with controls (n = 14). The combined exercise program included aerobic, resistance, and inspiratory muscle training administered for 8 weeks. The paper states that endothelial function was measured before and after the intervention; peak oxygen uptake (VO2peak), dyspnea, and fatigue were also assessed. In the exercise group, endothelial function was reported as 4.73 ± 1.5% at baseline and 7.98 ± 2.4% after the intervention; the control group was reported as 5.31 ± 2.5% and 6.30 ± 2.5%, with an interaction effect of P = .008. The exercise group was reported to have improvement in VO2peak from 38.3 ± 6.4 ml/min/kg to 42.8 ± 7.3 ml/min/kg (P < .001) and a reduction in dyspnea and fatigue compared to the control group (P < .001). The text does not report side effects or harms for either arm, and it does not report withdrawals. Setting and the number analysed are not reported. The authors state: “Having PASC is associated with impaired endothelial function, but combined exercise training effectively restores it, making it a promising lifestyle intervention for vascular function in PASC.” Limitations are not reported.

  12. The Impact of Metabolic Syndrome on the Outcomes of Rehabilitation in Post-COVID-19 Patients.2025 · compared with another group · 146 in the study
    Summary

    This prospective observational study asked how metabolic syndrome influences outcomes of inpatient post-COVID-19 rehabilitation at St. Charles Borromeo Rehabilitation Hospital in Szczecin. One hundred and forty-six patients with COVID-19 were enrolled and 146 were included in the final analysis; 84 patients (57.5%) had metabolic syndrome and 62 patients (42.5%) did not. Both groups received a comprehensive inpatient program six times per week for a minimum of 2 weeks and a maximum of 6 weeks: breathing exercise 30 min per day, aerobic training 90 min per day, and strength and endurance training. Assessments were performed on the first day of rehabilitation and on the final day. The paper reports 6MWT distance improvements in the metabolic syndrome group (p < 0.001) and in the group without metabolic syndrome (p < 0.001), and FEV1% predicted improvements (p = 0.025 and p = 0.021, respectively). A direct between-group comparison of the change is not reported. Patients who worsened or stopped and side effects or withdrawals are not reported. The authors conclude that comprehensive rehabilitation after COVID-19 benefits all patients regardless of metabolic syndrome. They state limitations including variability in time from recovery to rehabilitation initiation and lack of long-term follow-up.

  13. Pulmonary rehabilitation in follow-up and inpatient rehabilitation for Long COVID: twelve months of follow-up.2024 · compared with another group · 344 in the study
    Summary

    This longitudinal, prospective observational study enrolled 344 Long COVID patients from four German rehabilitation facilities: 253 in inpatient rehabilitation (IR) and 91 in follow-up rehabilitation (FuR). Rehabilitation was multidisciplinary pulmonary rehabilitation and lasted 27 days. At the end of rehabilitation, data were available from 241 IR and 89 FuR patients; at twelve months, 172 IR and 63 FuR patients answered. The study compared IR and FuR groups without randomisation. Over rehabilitation, most COVID-19 symptoms decreased with statistical significance. Subjective health scales improved with effect sizes between 0.55 (cognitive fatigue) and 1.40 (physical fatigue) in IR and between 0.45 (anxiety) and 1.32 (physical fatigue) in FuR (P<0.01). One year after rehabilitation, most effects remained at a moderate level. After twelve months, an increase in neurocognitive symptoms was observed in FuR patients; word-finding difficulties rose from 6.6% at baseline to 27.4% at follow-up (P<0.01). Restrictions in fatigue and mental health outcomes increased at follow-up. Return to work at twelve months was 86.9% in IR and 88.6% in FuR (P=0.535), while median time from rehabilitation to return to work was 1 week in IR and 5.5 weeks in FuR (P<0.01). One person abandoned rehabilitation treatment, two individuals were transferred back to the hospital, and eleven participants did not complete the end-of-rehabilitation questionnaire. No withdrawals due to harms were reported. The authors state that without a COVID-19 comparison group it was not possible to determine whether improvements were due to rehabilitation or natural regeneration.

  14. Effectiveness of tele-exercise training on physical fitness, functional capacity, and health-related quality of life in non-hospitalized individuals with COVID-19: The COFIT-HK study.2024 · compared with another group · 42 in the study · 41 with outcome data
    Summary

    This controlled clinical trial enrolled 42 physically inactive, non-hospitalized adults aged 35–59 years with a history of COVID-19 within 6 months; 41 were included in the final analysis (21 in the tele-exercise group and 20 in the control group). The tele-exercise group received an 8-week online supervised multicomponent low-to-moderate intensity exercise program (respiratory muscle, aerobic and resistance training), 60 min per practical session, three times per week, plus the same routine at home two additional times per week, for a total exercise duration of 180 min per week. The control group received standardized educational leaflets based on WHO guidelines for post-COVID-19 rehabilitation and did not participate in the tele-health exercise program. Outcomes included body composition, blood pressure, handgrip strength, 30-second sit-to-stand, arm flexibility, peak expiratory flow, Bruce Protocol end time, estimated VO2max, and SF-12 PCS and MCS. In the tele-exercise group, handgrip strength (p=0.032), arm flexibility (p=0.011), 30-second sit-to-stand (p<0.001), PCS (p=0.027) and MCS (p=0.032) improved after 8 weeks. Between groups, PCS (p=0.03) and MCS (p=0.04) showed greater improvements with tele-exercise; other outcomes did not show significant group differences. Exercise adherence was 80.4 ± 7.5 % of prescribed sessions. No incidence of adverse events related to training was reported; one control participant did not attend the posttest due to scheduling issues. The authors state limitations including lack of objective daily physical activity assessment.

  15. The role of Toll-like receptor 4 Asp299Gly genetic polymorphism in rehabilitation of patients with post-COVID syndrome2024 · compared with another group · 92 in the study
    Summary

    This clinical and genetic study enrolled 92 patients with post-COVID syndrome, aged 21 to 75, referred for rehabilitation after COVID-19 with predominantly lung involvement and residual respiratory disorders. All patients received comprehensive rehabilitation including climatotherapy, exercise therapy, massage, aromatherapy, respiratory therapy and medications by indications; duration was not reported. Groups were formed by TLR4 Asp299Gly genotype: 22 patients were AA homozygotes, 37 were AG heterozygotes and 33 were GG homozygotes. Assessments at admission and discharge included clinical symptom scores, laboratory and functional tests, the 6-minute walk test, dyspnea scales, HADS and SF-36. The text reports positive dynamics in all groups, most successfully in the AG group. It reports significant between-group differences in changes in FVC and PEF between AA and AG, and in 6MWT between AG and GG; the AG group's walk distance increase was 49 m versus 13 m in GG. For clinical symptom scores, the text states no statistically significant between-group differences. The text did not report harms, side effects, adverse events, or discontinuations for harms. Limitations were not reported in the text.

  16. Improvements in Dyspnea Following Traditional Pulmonary Rehabilitation in Patients With Long COVID.2024 · compared with another group · 92 in the study · 74 with outcome data
    Summary

    This retrospective study asked whether traditional pulmonary rehabilitation (PR) was associated with changes in dyspnea in outpatients from The Miriam Hospital’s Pulmonary Rehabilitation Program in Providence, RI. Of 92 people referred, 18 dropped out, and 74 completed the program and were allocated to analysis: 17 Long-COVID, 28 COPD, and 29 Long-COVID+CRD. Participants attended PR 2–3 times per week for 8 weeks, on average; the program comprised exercise (aerobic and resistance training), breathing retraining, and multi-disciplinary education. The study compared the Long-COVID group with a COPD group and a Long-COVID+CRD group. Dyspnea was assessed with the CRQ-SR and the Modified Medical Research Questionnaire, and six-minute walk distance was measured. All groups had significant (P < .01) improvements in dyspnea as assessed by the CRQ-SR, meeting the minimal clinically important difference at the end of PR. Long-COVID participants had a larger improvement in dyspnea on the CRQ-SR compared with Long-COVID+CRD and COPD. Long-COVID was the only group with a clinically significant reduction in Modified Medical Research Questionnaire scores (P = .002). No group differences in six-minute walk distance improvement at discharge were detected (P = .34). Long-COVID participants reported significant improvements in six-minute walk distance (+85 m). Side effects were not reported.

  17. [Pneumological Rehabilitation in Long COVID - A Comparative Exploratory Longitudinal Study of Long COVID and Asthma/COPD Rehabilitees].2024 · compared with another group · 305 in the study
    Summary

    This multicentre longitudinal observational study enrolled 305 rehabilitees: 172 with Long COVID and 133 in an age-matched comparison group with asthma bronchiale or COPD. Participants were COVID-19 rehabilitees aged 18–65 in pneumological rehabilitation; the duration of rehabilitation was not reported. The comparison group received pneumological rehabilitation for asthma/COPD. Questionnaires were administered at the beginning and end of rehabilitation and 6 and 12 months after rehabilitation. Outcomes included subjective health, work-related outcomes, rehabilitation contents and aftercare. At twelve months, the abstract reports significant health effects in both groups, with the Long COVID group showing the stronger improvements in most outcomes (interaction effect p<0.01). Despite these successes, the Long COVID group still had strong COVID symptoms 12 months after rehabilitation. One year after rehabilitation, 89% returned to working life. Side effects and withdrawals were not reported; no side-effect events were given. The authors conclude that most rehabilitees benefit health-wise and occupationally from pneumological medical rehabilitation, and that its contents appear partly suitable for Long COVID patients, while indication-specific therapy use differed between groups.

  18. Pulmonary Rehabilitation Program Is an Effective Treatment Approach for Post-COVID-19 Syndrome Patients.2024 · compared with another group · 72 in the study · 60 with outcome data
    Summary

    This prospective before-and-after trial asked whether an 8-week pulmonary rehabilitation program changes functional capacity, balance and musculoskeletal strength in post-COVID-19 syndrome. Seventy-two patients with persistent symptoms and major pulmonary convalescence were referred for initial evaluation 1 to 2 months after hospitalization for SARS-CoV-2; 60 completed an 8-week program of 45-min sessions 3 times/week with stationary cycle-ergometer and resistance exercises. The study compared pre- and post-program values and mild/moderate (41) with severe/critical (19) groups. Outcomes were TUG, HGS, DASI, 6MWT and derived variables. The abstract reports both groups showed significant (p < 0.001) improvements in TUG, HGS, DASI D6MWT, 6MWS and DSP after the program, with no intergroup differences; the discussion states only the mild/moderate subgroup showed significant handgrip improvement. Delta gains were higher in the severe/critical group but not statistically significant. Attendance was 85%, absence <15%; 12 did not complete (eight economic reasons, four clinically unstable: two with SpO2 <78% not corrected, two with palpitations). One mild/moderate patient had exercise-induced desaturation at initial evaluation, corrected with oxygen; one severe/critical patient had exacerbation and desaturation at final evaluation. Authors state the primary limitation was absence of a control group.

  19. Effects of pulmonary rehabilitation on ventilation dynamics measured during exertion in patients with post-acute COVID-19 syndrome: A cross-sectional observational study.2024 · compared with another group · 65 in the study
    Summary

    We read an observational cross-sectional study of 65 patients with post-acute COVID-19 syndrome (PACS) seen at a clinic in Rio de Janeiro, Brazil. The paper compared 33 patients who had undergone pulmonary rehabilitation (PR-PACS) with 32 who had not (NPR-PACS). The PR-PACS group had completed individualized resistance, strength and inspiratory muscle training for 8 weeks, 2–3 times a week for 3–4 hours each. Participants underwent Spiropalm®-equipped six-minute walk test (6MWT) with inspiratory capacity measurement, spirometry, impulse oscillometry (IOS) and lung ultrasound. The PR-PACS group walked farther: 437 ± 92 vs 361 ± 79 m, p = 0.001. Dynamic hyperinflation occurred in 2 (6.1%) PR-PACS participants and 12 (37.5%) NPR-PACS participants; ΔIC was 0.4 (0.2–0.6) vs 0 (-0.1–0.2) L, p < 0.001, and ΔIC (%) was 27.8 (16.4–46) vs 7.1 (-6.9–14), p < 0.001. Abnormal IOS was less frequent in the PR-PACS group: 8 (28.6%) vs 20 (66.7%), p = 0.003. Abnormal spirometry was 7 (21.2%) vs 10 (31.3%), p = 0.36; abnormal lung ultrasound was 13 (39.4%) vs 14 (43.8%), p = 0.72. One (3%) PR-PACS participant and 3 (9.4%) NPR-PACS participants desaturated during the 6MWT. The paper did not report withdrawals attributed to harms. The authors state limits: no causal role can be assumed because of the observational design; no data before PR; no diffusing capacity or computed tomography.

  20. Rehabilitation-Induced Benefits Do Not Differ between Men and Women with Long Covid-19 Syndrome2023 · compared with another group · 30 started · 27 with outcome data
    Summary

    This retrospective, single-centre cohort study asked whether a hybrid pulmonary rehabilitation programme produced different changes in men and women with long COVID-19 after hospital discharge at Sotiria General Hospital in Athens, Greece. Thirty people started the programme and 27 were analysed: 15 men and 12 women. The programme lasted 12 weeks and combined 8 outpatient sessions followed by 24 home-based sessions; outpatient training was for 4 weeks at two sessions per week, and home training for 8 weeks at three sessions per week. Outcomes included respiratory and peripheral muscle strength, functional capacity, quality of life, anxiety and depression, exercise capacity and daily activity. PImax increased by 15±20 cmH2O in women (p=0.008) and by 10±16 cmH2O in men (p=0.048). Quadriceps strength increased by 3.1±3.7 kg in women (p=0.025) and by 4.8±5.0 kg in men (p=0.001). Handgrip strength increased by 1.3±3.5 kg in women (p=0.328) and by 5.0±5.2 kg in men (p=0.001), with greater improvement in men (p=0.047). Six-minute walk distance improved by 89±58 m in men (p=0.001) and by 52±69 m in women (p=0.009), with no difference between groups (p=0.143). The magnitude of improvement in anxiety was greater in women (p=0.001). Adherence to remote sessions was 94% in men and 95% in women. Three women dropped out: one due to new health issues and two without a stated reason. Other side effects were not reported.

  21. Telemedicine in pulmonary rehabilitation - benefits of a telerehabilitation program in post-COVID-19 patients: a controlled quasi-experimental study.2023 · compared with another group · 148 in the study · 100 with outcome data
    Summary

    This quasi-experimental, prospective, longitudinal nonrandomized study enrolled 148 subjects who signed informed consent in Spain during confinement; the first 74 were assigned to the experimental group and the following 74 to a waiting-list control group. Participants were post-COVID-19 patients in the postacute phase with persistent respiratory symptoms who had not received vaccination and were recruited through social websites and COVID-19 patients associations. The experimental group received a Respiratory Telerehabilitation Program guided by a specialized physical therapist through a web platform, with 10 online sessions three times a week over a 22-day program; it included breathing exercises, self-stretching, yoga-based pranayama, progressive muscular relaxation, and mindfulness. The control group was on a waiting list. Outcomes included respiratory rate, heart rate, percutaneous oxygen saturation, Mahler’s Dyspnea Index, State-Trait Anxiety Inventory, and EQ-5D quality of life. With a loss percentage of 32%, 50 subjects of each group completed the protocol. In the experimental group, pre–post improvements were significant for state anxiety (p < 0.001), trait anxiety (p = 0.004), quality of life (p < 0.001), Mahler’s dyspnea (p < 0.001), respiratory rate (p < 0.001), oxygen saturation (p < 0.001), and heart rate (p < 0.001). The control group improved in all variables, but differences were not statistically significant except Mahler’s dyspnea (p = 0.001) and quality of life (p = 0.043). Between-group percentage changes were statistically significant in all outcomes in favor of the experimental group. Side effects were not reported. The authors state limitations including no disease stratification and inability to assess exercise capacity.

  22. Telerehabilitation Intervention in Transitional Care for People with COVID-19: Pre-Post Study with a Non-Equivalent Control Group.2023 · compared with another group · 49 in the study
    Summary

    This pre-post study with a non-equivalent control group evaluated a telerehabilitation intervention for people with injuries associated with SARS-CoV-2 infection in hospital-community transitions in a Portuguese university hospital center in Lisbon and Vale do Tejo. It included 49 people: 24 in the intervention group and 25 in the control group. The intervention combined telerehabilitation with educational strategies: exercises at home supervised by video calls and telemonitoring over 12 weeks, three sessions per week, followed by a maintenance phase of two weeks with one session per week, for a total of 38 supervised sessions each lasting approximately 60 minutes. The control group received usual care and physical activity education. Outcomes included post-COVID functionality, fatigue, dyspnea, activity limitations, perceived effort, heart rate, saturation, anxiety and depression, and the Sit to Stand Test. Post-intervention, the intervention group was reported to have lower heart rate (p = 0.005), better PCFS (p < 0.0001), improvement in fatigue and dyspnea (both p < 0.0001), personal care (p = 0.034), leisure activities (p = 0.01), STS (p < 0.0001), lower perceived exertion (p < 0.0001), increased HR during STS (p = 0.001), and lower anxiety (p = 0.004) and depression (p < 0.0001) compared with the control group. Within the intervention group, all variables showed significant variations except LCADL total impact on activities of daily living. There were no adverse events, and adherence was high.

  23. Breathing retraining in patients with chronic fatigue syndrome: a pilot study.2008 · compared with another group · 20 in the study
    Summary

    This pilot controlled clinical trial with repeated measures enrolled 20 patients fulfilling diagnostic criteria for CFS from consecutive visitors to the Chronic Fatigue Clinic of the Vrije Universiteit Brussel. Of these, 15 with synchronous breathing entered a no-intervention control group and 5 (25%) with asynchronous breathing formed the experimental group and received 20–30 minutes of breathing retraining in one session. The control group received no intervention, with approximately 30minutes between assessments. Pulmonary function testing measured respiratory rate, tidal volume, total lung capacity, vital capacity, inspiratory capacity, expiratory reserve volume, residual volume, MIP and MEP. Immediately postintervention, compared with no treatment, breathing retraining resulted in a decreased respiratory rate (p<0.001) and an increased tidal volume (p<0.001). Apart from respiratory rate and tidal volume, no other respiratory variables responded to the session. Each single patient in the experimental group responded with a decrease in respiratory rate and concomitant increase in tidal volume. Posttreatment respiratory rate values were within the healthy range for all treated patients, but were outside that range in 5 of 15 control subjects. Harms and withdrawals were not reported. The authors state limits including small sample size, lack of a gold standard for analysing breathing motion, lack of control and placebo treatment, no direct physical function measure, and no follow-up assessment.

  24. Dysautonomia and Postural Orthostatic Syndrome of Hypocapnia in Long COVID Syndrome.2026 · no comparison group · 50 in the study
    Summary

    This retrospective single-centre observational study took place in a long COVID outpatient clinic and analysed routine data. Fifty adults with a diagnosis of long COVID syndrome underwent a NASA lean test. Of these, 31 were referred for targeted respiratory rehabilitation using the Papworth method, delivered by a senior physiotherapist as five face-to-face breathing retraining sessions; 13 of the 31 completed the programme, and 2 of the 31 started but did not complete it. Questionnaires and the lean test were repeated after the fifth session. Comparing pre- and post-rehabilitation values in completers, the Malmö POTS score changed (59.3 ± 19.8 vs. 42.3 ± 21.6, p = 0.0033), BPAT score changed (5.7 ± 1.9 vs. 2.1 ± 1.0, p < 0.0001) and mean arterial pressure changed (99.2 ± 10.2 vs. 93.8 ± 8.2 mmHg, p = 0.0065). There was no significant change in end-tidal CO2 or heart rate. Changes in HADS depression and anxiety scores, Nijmegen questionnaire scores, fatigue severity scores and diastolic blood pressure did not reach statistical significance. There was no control group. The authors state that limitations include the relatively small sample size and the lack of a control group.

  25. Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study.2026 · no comparison group · 134 in the study · 115 with outcome data
    Summary

    This quasi-experimental, single-arm pre–post study evaluated a 5-week pulmonary rehabilitation programme in children and adolescents with paediatric post-COVID-19 condition (PPCC) at a specialised outpatient unit. Of 134 patients deemed eligible after screening, 115 completed the programme and were included in the final analysis; there was no control group. The programme consisted of ten supervised sessions (2 sessions per week) plus a structured home-based exercise programme. Assessment was before rehabilitation, immediately after, and at 6M and 12M follow-up. The primary outcome, 6MWT distance, changed from 509 ± 87 m to 546 ± 86 m (mean difference 37 m, 95% CI 23–52; p < 0.001). Peds FACIT-F fatigue scores changed from 25.00 ± 10.94 to 34.28 ± 12.48 (mean difference 9.3, 95% CI 7.1–11; p < 0.001), PImax from 70.46 ± 25.98 to 85.84 ± 29.27 cmH2O (mean difference 15, 95% CI 11–20; p < 0.001), PSC from 23.50 ± 9.18 to 18.99 ± 9.05 (mean difference −4.5, 95% CI −6.2 to −2.9; p < 0.001), and PedsQL global health from 50.40 ± 17.87 to 61.44 ± 19.44 (mean difference 11, 95% CI 7.1–15; p < 0.001). BMI showed no significant change (p = 0.920). Two participants discontinued voluntarily and three did not complete due to attendance below 50% of supervised sessions. Side effects were not reported. Limits include no randomised control group, single-centre design, unmonitored home adherence, PImax in a subset, and self-reported fatigue/quality of life.

  26. Adapted Physical Activity Protocol Improves Health-Related Quality of Life and Psychological Outcomes in Long COVID: A Prospective Longitudinal Study.2025 · no comparison group · 50 in the study
    Summary

    This single-center, prospective, longitudinal observational study enrolled 50 patients with long COVID at the Physical Medicine and Rehabilitation Department of Mohamed Kassab Institute of Orthopedics, Manouba, Tunisia. All 50 completed the study protocol. Participants received a 6-week individualized outpatient Adapted Physical Activity protocol with two 30-minute sessions per week. There was no control group. Assessments were at baseline (E1), immediately post-intervention (E2), and 5–7 months post-intervention (E3). Outcomes included SF-12 health-related quality of life, HADS anxiety and depression, and mMRC dyspnea. The paper reports significant improvements in SF-12 physical and mental scores across time points (p<0.001). Normal physical HRQOL rose from 16% at baseline to 90% at E2 and 66% at E3; normal mental HRQOL rose from 18% to 86% at E2 and 66% at E3. Normal anxiety scores rose from 26% to 82% at E2 and 56% at E3; normal depression scores rose from 24% to 66% at E2 and 52% at E3. Dyspnea prevalence decreased from 86% at baseline to 52% at E2 and 42% at E3. Harms were not reported, and the paper does not report withdrawals for harms. The authors state that the absence of a control group limits causal inference and that self-reported data may introduce bias.

  27. Muscle Strength Loss in Women with COVID-19 and the Restorative Role of Physiotherapy.2025 · no comparison group · 42 in the study
    Summary

    This single-center observational prospective cohort study enrolled 42 women recovering from COVID-19. Participants received an 8-week physiotherapy program with resistance training, functional mobility exercises, respiratory physiotherapy, and stretching and posture correction exercises, three times per week for approximately 60 min. There was no control group. Outcomes were measured at baseline and post-intervention: handgrip strength, Manual Muscle Testing for quadriceps and hamstrings, 6-Minute Walk Test, 30-Second Sit-to-Stand Test, spirometry (FVC, FEV1), SF-36, and Fatigue Severity Scale. Right-handgrip strength changed from 18.5 ± 4.2 kg to 22.8 ± 4.6 kg (p < 0.001); left-handgrip from 17.2 ± 4.1 kg to 21.1 ± 4.5 kg (p < 0.001); 6MWT distance from 382 ± 62 m to 438 ± 57 m (p < 0.001); FVC from 2.6 ± 0.5 L to 3.0 ± 0.6 L (p < 0.01); FEV1 from 2.1 ± 0.4 L to 2.5 ± 0.5 L (p < 0.01); fatigue score from 5.4 ± 0.8 to 3.2 ± 0.7 (p < 0.001); SF-36 from 55.3 ± 8.7 to 68.9 ± 9.5 (p < 0.001). Vaccinated participants showed greater 6MWT improvement (p = 0.03) and vitality increase (+14.5 vs. +10.2, p = 0.04); handgrip, Sit-to-Stand, FVC, FEV1, and fatigue differences by vaccination status were p > 0.05. Harms were not reported. The authors state limitations: no control group, small sample of 42, no follow-up beyond the intervention, and only women included.

  28. Exercise-Driven Comprehensive Recovery: Pulmonary Rehabilitation's Impact on Lung Function, Mechanics, and Immune Response in Post-COVID-19 Patients.2025 · no comparison group · 104 in the study · 33 started · 33 with outcome data
    Summary

    This single-group clinical study asked whether a 12-week pulmonary rehabilitation program would change lung function, lung mechanics, muscle strength and clinical measures in patients with moderate to severe post-COVID-19. Participants were referred by family physicians after hospital discharge to the Laboratory of Pulmonary Immunology and Exercise. The report states that 104 patients were initially enrolled, but only 33 accepted to participate and completed the study; no control group without rehabilitation was included. The program combined treadmill aerobic training for 30 min at 70% to 80% of maximal heart rate three times per week with resistance training of 8 to 12 repetitions per set, three sets, three sessions per week, for 12 weeks. Evaluations were before and after the 12-week period; post-training evaluation occurred 24 h after the last exercise session. The study reports changes from baseline, not between-group results. It reports p-values for body weight, BMI, waist circumference, fat mass, fat-free mass, resting heart rate, systolic and diastolic blood pressure, SpO2%, FeNO, hand grip strength, MIP/MEP, several lung-function measures and several lung-mechanics measures. It reports no change for R5Hz-R20Hz, Fres and X5Hz (p > 0.05). Harms and withdrawals due to harms were not reported. The text conflicts on SpO2% (reduction vs improvement), Z5Hz (reduced vs significantly increased), and X5Hz (reduced vs no change).

  29. Breathe Better After COVID: The Impact of a Two-Week Pulmonary Rehabilitation Program on Pulmonary Function, Inflammatory Markers, and Quality of Life in Post-COVID Syndrome.2025 · no comparison group · 77 in the study
    Summary

    This prospective, interventional, non-randomized clinical trial enrolled 77 participants with post-COVID syndrome from post-COVID care clinics in Rzeszów. Participants received a 14-day inpatient pulmonary rehabilitation program with 12 supervised sessions delivered six times a week; sessions lasted approximately 45 min. Components included early in-bed mobilization, supervised exercise training, diaphragmatic breathing and respiratory muscle training, incentive spirometer exercises, aerobic and muscle strengthening exercises, body balance therapy, motivational breathing therapy, and patient education. There was no control group. Assessments were made at baseline and on day 14 and included pulmonary function, blood gas parameters, inflammatory markers, and WHOQOL-BREF quality of life. The paper reports improvements in FVC from 75% to 78.4%, FEV1 from 78.2% to 80.5%, PEF from 78.7% to 81%, TLC from 67.3% to 71%, DLCO from 67.8% to 74%, PaO2 from 59.4 mmHg to 67 mmHg, and PaCO2 from 35 mmHg to 38 mmHg (p < 0.001 for these reported comparisons). Quality-of-life physical scores rose from 41 to 56 points (p < 0.01); psychological and environmental domains improved by +6.7 points and +9.2 points (p < 0.001). Females showed greater improvements than males in psychological (16 vs. 0 points) and environmental (13 vs. 7 points) domains (p < 0.05). The intervention was described as well tolerated; the paper did not report counts of harms or withdrawals for harms. The authors state limitations including the non-randomized design and absence of a control group, limited scale, no six-minute walk test, no medium- or long-term effect assessment, and behavioral changes not objectively assessed.

  30. Individually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post-Acute Sequelae of COVID-19: A Feasibility Study With Mixed Methods.2025 · no comparison group · 13 in the study
    Summary

    This single-arm, open-label feasibility study enrolled 13 adults with post-acute sequelae of COVID-19 and persistent respiratory symptoms from two specialized clinics in Calgary, Canada, between March 2022 and March 2023. Participants received an individualized respiratory physiotherapy program of 8 sessions, each lasting 1 h, delivered in person and virtually; components included education and self-management with the Stop-Rest-Pace approach and heart-rate monitors, breathing pattern retraining, and return-to-activity exercise. There was no comparison group. The program was considered feasible based on recruitment of 13 participants, 100% retention, and completion of 99% of supervised sessions; no adverse events occurred during the sessions. All participants completed post-intervention assessments, but two participants declined the post-6MWT. Baseline-to-post-intervention improvements were reported for EQ-5D index, EQ-VAS, EQ usual activities, EQ pain/discomfort, PCFS, and several self-efficacy items; EQ mobility, EQ self-care, EQ anxiety/depression, and cough VAS were not statistically significant. 6MWT changes were not statistically significant, with clinically meaningful increases in 3/7 participants; four participants did 1-min STST instead and all improved repetitions (range: 4–20). On PGIC, 10 of 13 felt much to very much improved. Eight interviews identified positive aspects and benefits. The authors state limitations including no control group, small sample, possible selection and nonresponse bias, and unclear sustainability.

  31. Effectiveness of circuit training in pulmonary rehabilitation for patients with COPD, post-COVID syndrome and asthma.2025 · no comparison group · 30 in the study
    Summary

    This prospective, quasi-experimental study enrolled 30 patients (15 COPD, 11 post-COVID, 4 asthma) and assessed them before and after a 12-week supervised circuit training program delivered four times per week in 60-min sessions; there was no comparison group. Assessments included spirometry (FEV1, FVC, TLC, IVC), six-minute walk distance (6MWD), and the modified Medical Research Council (mMRC) dyspnea score. In COPD patients, FEV1 increased by 7.7% of the predicted value (P < 0.001), FVC by 5.7% (P < 0.01), and 6MWD by 59 m (P < 0.01), with mMRC decreasing from 3.2 ± 0.8 to 1.4 ± 0.6 (P < 0.01). In post-COVID participants, FEV1 increased by 9.1% (P < 0.001), FVC by 6.6% (P < 0.001), and 6MWD by 82 m (P < 0.01), while mMRC improved from 3.5 ± 0.9 to 1.4 ± 0.6 (P < 0.01). Asthma patients showed a 4.9% increase in FEV1 (P = 0.012), a 3.5% increase in FVC (P = 0.045), and a 41-m increase in 6MWD (P < 0.01), with mMRC improving from 2.7 ± 0.7 to 1.5 ± 0.5 (P < 0.01). IVC improved in all groups (P ≤ 0.051). There were no adverse events; adherence exceeded 85%. The authors report no limitations.

  32. Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition.2025 · no comparison group · 140 in the study
    Summary

    This retrospective study of medical records examined 140 persons with post-COVID condition admitted to inpatient pulmonary rehabilitation treatment at the Schön Klinik Berchtesgadener Land, Germany. Treatment duration was M = 26.9, SD = 11.0 days. Treatment elements included diagnostic assessments, medical treatment, endurance and strength training, patient education, respiratory physiotherapy, relaxation techniques, occupational therapy, psychological support, and nutrition counseling. There was no control group; the study compared self-reported mental and physical health at admission and discharge. Measures included the Patient Health Questionnaire, Primary Care PTSD screen, and Short Form Health Survey, plus pulmonary functioning at admission. From admission to discharge, somatic symptoms severity decreased (M = 13.7, SD = 5.2 to M = 12.0, SD = 5.8; d = 0.45, p < 0.001), depressive symptoms severity decreased (M = 11.5, SD = 5.0 to M = 9.0, SD = 5.5; d = 0.60, p < 0.001), and stress decreased (M = 6.9, SD = 3.8 to M = 5.7, SD = 4.0; d = 0.42, p < 0.001). Physical functioning increased (M = 47.3, SD = 24.0 to M = 57.6, SD = 25.3; d = 0.56, p < 0.001), energy/fatigue increased (M = 26.6, SD = 16.9 to M = 35.2, SD = 21.9; d = 0.45, p < 0.001), and emotional well-being increased (M = 57.3, SD = 20.2 to M = 64.5, SD = 20.4; d = 0.44, p < 0.001). The paper states panic disorder, eating disorders, and PTSD did not change. Alcohol use disorder was 0/138, 0.0% at admission and 1/133, 0.8% at discharge. Side effects and withdrawals due to harms were not reported. The authors state results are limited to inpatients in Germany and may not translate to other healthcare systems.

  33. Responders to a rehabilitation program for adults with post-COVID-19 condition: An observational study.2025 · no comparison group · 101 in the study · 95 with outcome data
    Summary

    This observational retrospective study explored which clinical characteristics were associated with response to a 4-week respiratory rehabilitation program in adults with post-COVID-19 condition (PCC). Adults with PCC admitted consecutively to the Physical and Rehabilitation Medicine department for the program were eligible. One hundred and one people participated in the RR protocol, and 95 were analyzed. The face-to-face program was delivered in groups of 5 to 6 adults with PCC and included muscle strengthening exercises for all four limbs, cardio-respiratory endurance training on cycle, ventilatory mechanics exercises, and therapeutic education sessions. There was no comparison group; the main outcome was a composite criterion combining improvement on the 6-minute walk test and the 1-minute sit-to-stand test, measured on the first and last day of treatment. From the 95 participants analyzed, 49 were considered RR responders, corresponding to 52% of the sample. The paper reports that responders were younger, had less severe maximal Borg dyspnea during CPET, had no history of intensive care during COVID-19 infection, and exhibited cognitive fog. Six participants were not included: 2 did not complete the protocol for medical reasons, and 4 did not perform either test of the primary outcome. The authors state that these findings need confirmation in a prospective study with a calculated sample size to ensure statistical power. The present work had no financial support and no competing interests.

  34. Effect of a Structured Tele Based Post COVID-19 Rehabilitation Program in the Indian Population.2024 · no comparison group · 53 in the study
    Summary

    This study assessed a structured tele-based post-COVID-19 rehabilitation program in the Indian population. A total of 53 patients with post-COVID-19 syndrome were included. The program was delivered remotely via WhatsApp video or Zoom calls and consisted of warm-up exercises, breathing exercises, aerobic and strength training, yoga, cooldown exercises, and regular educational sessions. The duration was not reported. There was no comparison group. Outcomes included VAS score for fatigue, 1-minute sit-to-stand test, post-COVID-19 functional status scale, and health-related quality of life. The abstract reports significant improvement in VAS score for fatigue (t = 8.6, S, p < 0.001), 1-minute sit-to-stand steps (t = 5.9, S, p < 0.001), and health-related quality of life (Z = 5.9, S, p < 0.001). Side effects and withdrawals were not reported in the abstract. The authors conclude that the structured tele-based program is effective in patients and feasible for delivery of rehabilitation to patients unable to participate in center-based rehabilitation.

  35. Motor and Respiratory Tele-Rehabilitation in Patients with Long COVID-19 after Hospital Discharge: An Interventional Study.2024 · no comparison group · 28 started · 23 with outcome data
    Summary

    Twenty-eight adults with long COVID started a home-based motor and respiratory tele-rehabilitation program after discharge from inpatient rehabilitation at two centres in Italy and Switzerland; 23 completed and were included in the analysis. The program lasted three weeks, following a four-week multidisciplinary inpatient rehabilitation course. It used a respiratory muscle training device (SpiroTiger) for breathing exercises up to five times per week and a motor rehabilitation device (Euleria home) for free-body exercises three to five times per week. There was no control group; outcomes were measured before inpatient rehabilitation (T0), at discharge (T1), and after tele-rehabilitation (T2). Motor function was assessed with the instrumented Six-Minutes Walking Test; respiratory function with FVC and MVV; handgrip strength and a satisfaction questionnaire were also recorded. Walked distance increased by 18.3% from baseline and by approximately 73 m between baseline and final assessment; the paper reports >50 m change from baseline to hospital-based rehabilitation and <25 m during tele-rehabilitation. Significant improvements (p < 0.05) in motor and respiratory function were reported, while maximum isometric force showed no significant variation and stride length did not reach significance. Mean SUS scores were 85.5/100 for the respiratory device and 84.1/100 for the motor device. Five participants withdrew; no adverse events occurred during the home-based program. The authors note a small sample, no control group, and preliminary outcomes.

  36. Low-intensity rehabilitation in persistent post COVID-19 dyspnoea: the value of Spa health resort as appropriate setting.2024 · no comparison group · 187 in the study
    Summary

    This prospective observational cohort study enrolled 187 adults with post COVID-19 persistent dyspnoea at Margherita di Savoia’s Baths, Italy; 144 reported fatigue. It aimed to explore a Spa rehabilitation treatment on post COVID-19 dyspnoea and fatigue. All received 12 therapy sessions, about 2-3 hours daily over 12 consecutive days in two weeks, starting at least 3 months after acute COVID-19. There was no comparator group and no randomisation. Upon completion, 165 out of 187 (88.2%) reported dyspnoea improvement and 116 out of 144 (80.6%) fatigue improvement; 116 of 144 (80.6%) improved in both. In Table 3, 17 of 144 (11.8%) had both symptoms not improved. In 118 patients assessed with Borg and Barthel, mean Borg was 3.60±1.30 before and 1.41±0.67 after, median Delta Borg -2.0; 60 of 118 (50.8%) reached clinically significant BED improvement. Mean Barthel was 74.00±13.72 before and 86.55±8.81 after, median Delta Barthel +10; 61 of 118 (51.7%) reached clinically significant BPL improvement; 37 (31.4%) reached minimal improvement in both. Twenty-three patients were excluded for not completing all 12 sessions. Side effects were not reported. Risk factors for lack of dyspnoea improvement included BMI above 30 Kg/m2 (OR 0.22; 95% CI 0.11-0.46), phenotype 4 (OR 0.11; 95% CI 0.01-0.93) and respiratory comorbidities (OR 0.31; 95% CI 0.14-0.68; p=0.003).

  37. Personalized pulmonary rehabilitation program for patients with post-acute sequelae of COVID-19: A proof-of-concept retrospective study.2024 · no comparison group · 23 in the study · 17 with outcome data
    Summary

    This retrospective proof-of-concept study asked whether a personalized pulmonary rehabilitation program affects physical fitness, quality of life and quantified thorax CT in long-COVID/PASC. Patients were from MedImprove in Kontich, Flanders, Belgium; ME/CFS was an exclusion. Between August 2021 and October 2022, 25 subjects presented, 23 were proposed to participate, and 17 (5 male; 12 female; mean age 42 ± 13 years) completed and were analysed. The 3-month program included cycling, treadmill walking, arm exercises, strength training and inspiratory muscle training, 2 or 3 times a week. There was no control group; assessments were before and after. Questionnaires improved: PCFS p < 0.001, Borg p = 0.005, EuroQol index p = 0.003, EuroQol VAS p = 0.004, HADS anxiety p = 0.014, HADS depression p = 0.009. 6MWD increased from 497 to 577 m (p < 0.001); the abstract reports 329 to 365 m. VO2max changed from 21 to 24 mL/kg/min (p = 0.007), peak load from 116 to 141 Watt (p < 0.001). Mean PFT values showed no significant differences; TLC was 96 to 100 (p = 0.054). Air trapping showed no significant difference (p = 0.925). BV5 changed from 64.8 to 62.4 (p = 0.020) in the table; text says 648% to 624%. Airway volume increased from 56.3 to 60.2 mL (p = 0.013). Six of 23 did not complete: 1 foot surgery, 1 metatarsal fracture, 2 felt better after 6 weeks and stopped to return to work, 2 stopped without reason.

  38. Effects of pulmonary rehabilitation on functional and psychological parameters in post-acute sequelae of SARS-CoV-2 infection (PASC) patients.2024 · no comparison group · 55 in the study
    Summary

    This retrospective study used electronic medical records from Allegheny Health Network. It included 55 patients diagnosed with PASC who were referred to a pulmonary rehabilitation (PR) program; there was no comparison group. PR sessions were held two to three times a week, with the schedule typically spanning three months, and the average follow-up period was 3.8 months post-rehabilitation. The study compared pre- and post-PR functional and psychological test results. The 6MWT distance changed from 895 ft to 1,300 ft (mean change 405, 95% CI [333, 477]). CR reps changed from 8.83 to 13.13 (change 4.31), TUG from 12.76 to 9.50 seconds (change −3.50), and gait speed from 1.03 to 1.30 m/s (change 0.27). MMRC changed from 2.13 to 0.89 (change −1.20), SOBQ from 50.64 to 21.82 (change −28.55), HADS from 11.36 to 7.78 (change −3.59), and CAT from 18.21 to 8.60 (change −9.66). PHQ-9 scores changed from 1.71 to 2.33 (change 0.63) and were not statistically significant (p = 0.740). Harms were not reported. The authors state limitations include lacking randomization and a control group.

  39. The Effects of Six Weeks Pulmonary Rehabilitation on Functional and Psychological Outcomes in Long-COVID Patients: Preliminary Results from Serbian Single Center Study.2024 · no comparison group · 46 in the study
    Summary

    This prospective single-arm study was conducted at the Clinic for Pulmonary Diseases at the University Clinical Center of Serbia. It included 46 patients diagnosed with COVID-19 who were referred 6 months after COVID-19 resolution for outpatient rehabilitation with extended symptoms including dyspnea and fatigue. Participants received a respiratory rehabilitation program for six weeks (five days per week), including ipratropium bromide inhalation, breathing exercises, chest expansion exercises, stationary bicycle cycling for 10 min, and treadmill for 10 min at 4 km per hour. Outcomes were tested on admission and at discharge. The paper reports StS median values of 24 on admission and 25 at discharge (p = 0.011), PHQ9 median values of 7 and 3 (p < 0.001), GAD anxiety median values of 2.5 and 2 (p = 0.005), and 6MWT distances of 506 m and 588 m (p < 0.001). It also reports lower SpO2 before the 6MWT (p = 0.007), higher VAS scores before the 6MWT (p = 0.036), and higher respiratory rate before the StS test (p = 0.005). Harms and withdrawals were not reported.

  40. Effectiveness of pulmonary rehabilitation in post-COVID-19 patients: A pre- and post-interventional study.2024 · no comparison group · 155 in the study
    Summary

    This pre-experimental study at a teaching hospital pulmonary medicine department enrolled 155 post-COVID patients (males, 102 and female, 53) to assess pulmonary rehabilitation for functional capacity and health-related quality of life. The intervention had six components: education, breathlessness relieving exercises, postural correction, aerobic training, strength training and stretching exercises, carried out twice a week for eight weeks in supervised, home-based or hybrid modes, with no control group. Before and after rehabilitation, the six-minute walk test showed resting mean pulse rate changed from 94.02 (16.14) to 89.38 (14.25), P = 0.001; resting mean SpO2 from 95.34 (2.90) to 96.30 (1.83), P < 0.0001; mean distance from 209.22 (159.12) to 287.97 (125.78) meters, P < 0.0001; mean desaturation from 2.64 (2.58) to 2.91 (2.69), P = 0.416, not significant. EQ-5D-5L 'No problem' counts increased for mobility 30 (19.4) to 103 (66.5), self-care 70 (45.2) to 145 (93.5), usual activity 37 (23.9) to 80 (51.6), pain and discomfort 71 (45.8) to 100 (64.5), anxiety and depression 100 (64.5) to 128 (82.6), and sleep 107 (69.0) to 126 (81.3), with reported significant P values for each domain. Completion was 50 (32.3%) supervised, 42 (27.1%) home-based, and remaining hybrid (40.6%); results in these groups were similar. There was no mortality among enrolled participants during follow-up; dropouts are mentioned in a flow chart, and withdrawals and harms were not reported. The authors state limitations including no control group and no non-COVID respiratory cohort.

  41. Safety and Efficacy of Pulmonary Rehabilitation for Long COVID Patients Experiencing Long-Lasting Symptoms.2024 · no comparison group · 47 in the study
    Summary

    This prospective observational study enrolled 47 patients admitted for inpatient pulmonary rehabilitation because of long COVID symptoms more than six months after confirmed COVID-19 infection. Patients were treated at two pulmonary rehabilitation centers in France. The four-week program included a mean of 26 individualized endurance training sessions, 12 individualized resistance training sessions and a mean of eight sessions of individualized patient education, dyspnea management and psychosocial counseling. No control group was used. Outcomes were evaluated pre- and post-PR. The text reports significant score changes for 6 min walking distance (61 [28 to 103] m), mental SF-12 (10 [6 to 13]), physical SF-12 (9 [6 to 12]), MoCA (1 [0 to 3]), MFI-20 fatigue (−19 [−28 to −8]), DYSPNEA-12 (−7 [−9 to −2]), mMRC (−1 [−1 to 0]), Nijmegen questionnaire (−8 [−11 to −5]), HADS anxiety (−4 [−5 to −2]), HADS depression (−2 [−4 to −1]) and PTSD checklist (−8 [−12 to −4]). The number of persistent symptoms per patient was reduced from six to three, and average assessed symptoms fell from 5.5 ± 2.3 to 2.7 ± 1.9. Muscle strength changes were not statistically significant (p-value = 0.10). No adverse events were reported for the 96% of patients who completed the program; two patients did not complete the program due to personal reasons. Three cases of partial deterioration were reported: n = 1 for physical quality of life and n = 2 for physical-affective dyspnea.

  42. Pulmonary Rehabilitation for Post-COVID-19.2023 · no comparison group · 56 with outcome data
    Summary

    This observational study enrolled consecutive patients with post-COVID-19 admitted to three separate outpatient pulmonary rehabilitation (PR) programs. A total of 56 patients completed the PR program. The program consisted of 8-12 wk of PR sessions 3 times/wk. Data were gathered at the initial visit and discharge. There was no comparison group; outcomes were compared within the same patients before and after PR. The primary outcome was change in 6-min walk test (6MWT) distance. Secondary outcomes included the Shortness of Breath Questionnaire (SOBQ), modified Borg dyspnea scale, Patient Health Questionnaire-9 (PHQ-9), and Lung Information Needs Questionnaire (LINQ). At baseline, mean 6MWT was 313.3 ± 193.8 m. On average, 6MWT improved by 84.3 m after PR (P < .0001). Apart from the modified Borg dyspnea scale, there was improvement across secondary outcomes: SOBQ (-16.9 points), PHQ-9 (-2.6 points), and LINQ (-4.2 points); all P < .05. The abstract does not report side effects, withdrawals, or patients who worsened. It does not state limitations. The authors conclude that pulmonary rehabilitation showed a promising positive effect in post-COVID-19 and should be considered for post-COVID-19 patients.

  43. Réhabilitation respiratoire dans la dyspnée chronique en post-COVID : expérience du service de pneumologie de Chartres2023 · no comparison group · 46 in the study
    Summary

    This paper reports a respiratory rehabilitation (RR) programme in an outpatient unit for patients with persistent post-COVID dyspnea. Forty-six patients participated in the programme for 6 weeks at 3 sessions per week. The paper reports no comparison group; no randomisation was reported, and the data are before and after rehabilitation. The outcomes recorded were endurance, the 1-minute sit-to-stand test (TLC1), anxiety, depression, and hyperventilation syndrome. After rehabilitation, the paper states that endurance was multiplied by 3 on average (1.5 and 7.1). It reports improvement in TLC1 in 69% of patients. Anxiety improved in a third of patients and depression in half. Hyperventilation syndrome regressed in 54% of cases. The paper did not report harms or withdrawals for harms. The authors conclude that, as for chronic respiratory diseases, RR improves exercise capacity but also hyperventilation syndrome and psychological impact, which are particularly important in this condition. Limitations are not reported.

  44. Home-Based Pilot Pulmonary Program for Dyspneic Patients Post-COVID-19.2023 · no comparison group · 19 in the study · 18 started · 18 with outcome data
  45. Tele-pulmonary rehabilitation with face to face in COVID-19 pandemic: A hybrid modeling.2023 · no comparison group · 31 in the study
    Summary

    This single-arm study examined changes after a hybrid tele-pulmonary rehabilitation (tele-PR) and face-to-face program in post-COVID-19 patients with persistent symptoms. Thirty-one patients referred to a pulmonary rehabilitation unit after COVID-19 with active symptoms were enrolled and analysed. Initial and final assessments and the first two sessions were face-to-face; the rest was an eight-week supervised home-based synchronized video-conference tele-PR program, two days a week. Exercise training included endurance and resistance training: 30 minutes of endurance exercise at 85% of each patient’s VO2 peak, and strengthening with two sets of 12-18 repetitions at 30-50% of a maximum repetition. Inspiratory muscle training was performed twice a day at 30-50% maximum inspiratory pressure for 5-10 minutes if necessary; education and counseling were included, and oxygen support was given when needed to keep oxygen saturation above 90%. Outcomes were measured before and after tele-PR. The paper reports significant improvements in mMRC (p<0.001), BORG at rest (p=0.008) and after exercise (p<0.001), ISWT and ESWT (both p<0.001), MIP (p=0.014), MEP (p<0.001), right and left handgrip (both p<0.001), deltoid 1RM (p=0.002), quadriceps 1RM (p=0.001), BMI (p=0.002), NEADLS (p=0.001), and fatigue severity scale (p<0.001). FFMI (p=0.079), HADa (p=0.948), and HADd (p=0.314) did not change significantly. Two patients did not attend the PR program; side effects were not reported. The authors state no control group and a single center.

  46. [Patient-Reported Outcomes (PROs) 3 and 6 Months After Pulmonary Rehabilitation Following COVID-19].2023 · no comparison group · 224 in the study
    Summary

    This prospective observational study enrolled 224 rehabilitation patients with long COVID, including the subgroups “Fortwährend-symptomatische-COVID-19” and “Post-COVID-Syndrom” (PCS). The setting and treatment duration were not reported. Patients received pulmonary rehabilitation (PR), and patient-reported outcomes (PROs) for exertional dyspnoea, quality of life, pain, fatigue, depression and anxiety were recorded at PR start, PR end, and after 3 and 6 months. There was no comparison group. During PR, all PROs improved significantly. After PR, improvements either persisted with a large pre-post effect size (exertional dyspnoea, quality of life), decreased slightly to small pre-post effect sizes (depression, fatigue), or returned to baseline (anxiety, pain). PCS patients had greater burden at T1 in depression, fatigue and pain but did not differ in courses. Female patients had higher burden at T1 in depression and fatigue and higher pre-post effects than male patients. Harms and withdrawals were not reported. The authors conclude that improvements in PROs occurred in both subgroups only during PR, not during follow-up.

  47. Telerehabilitation with ARC Intellicare to Cope with Motor and Respiratory Disabilities: Results about the Process, Usability, and Clinical Effect of the "Ricominciare" Pilot Study.2023 · no comparison group · 21 in the study
    Summary

    This single-center, not controlled, prospective, pre–post-intervention pilot study enrolled 21 people with post-COVID-19 condition (11 COV19) or Parkinson’s disease (10 pwPD), and all completed the study. Participants received the ARC Intellicare system for home telerehabilitation: 45 min exercise sessions at home, 5 days/week for 4 weeks, with an at least 30 min/week video call with the investigator using the ARC app; assessment was at enrollment (T0) and at the end of the 30-day intervention period (T1). There was no comparison group. The mean total System Usability Scale score was 77/100 at baseline and remained stable at 78/100 after 30 days of treatment (p = 0.91). On average, the whole sample achieved 80% adherence calculated on days and 77% on repetitions; sixteen subjects (76%) reached the 80% Adherence-Days endpoint, and 15 (76%) reached the 70% Adherence-Repetitions endpoint. In the whole sample, BaDI dyspnea improved (Z = −3.0; p = 0.003), BFI fatigue improved (Z = 3.5; p = 0.005), 2MWT distance improved (Z = −3.2; p = 0.001), BDI (Z = 3.1; p = 0.002), BAI (Z = 2.5; p = 0.01), EQ-5D (Z = 2.6; p = 0.0084) and EQ-5D VAS percentage (Z = −2.7; p = 0.007) improved. The mBI score improved but did not reach statistical significance. In pwPD, 2MWT did not reach statistical significance despite walking 8.1 m more on average at the end of treatment. The abstract states no side effects were reported, while the results state no adverse events were reported except for fatigue in 10% of pwPD.

  48. Long-term laryngological sequelae and patient-reported outcomes after COVID-19 infection.2023 · no comparison group · 57 in the study
    Summary

    This retrospective chart review examined long-term laryngeal problems after COVID-19 at the Yale COVID clinic between July 2020 and August 2021. Of 57 patients who met inclusion criteria, all had PCR-positive COVID-19 and laryngeal dysfunction. There was no comparison group. Treatments were voice therapy (recommended for 24; 17 underwent), respiratory retraining therapy (recommended for 5; 2 underwent), and procedural interventions such as dilations, steroid injections, excision of stenosis, and cordotomies (10 underwent). Voice therapy follow-up was a mean 260 days (±136 days); procedural patients’ median time to the last follow-up visit at which improvement was reported was 298 days (IQR: 173–408). Outcomes included symptom improvement or resolution, QOL indices (DI, CSI, EAT-10, VHI-10, RSI), and GRBAS ratings. Of 17 voice-therapy patients, 11 (64.7%) reported improvement and 2 (11.8%) resolution; 3 reported persistent symptoms and 1 persistent dysphonia. VHI scores decreased for improvers, and GRBAS scores improved or remained stable. QOL and GRBAS grade scores did not demonstrate other trends. Both respiratory-retraining patients reported improvement in dyspnea. Among 10 procedural patients, all ten (100%) had laryngotracheal stenosis and reported improvement; 7 (70%) needed more than one procedure. Five of these ten had follow-up QOL data showing improvement. Side effects and withdrawals due to harms were not reported. The authors state the study was retrospective, had a moderate sample size, had missing QOL and clinician voice data, and was not powered to detect differences in QOL scores, stroboscopy findings, and interventions between diagnoses.

  49. A Physiotherapy Treatment Plan for Post-COVID-19 Patients That Improves the FEV1, FVC, and 6-Min Walk Values, and Reduces the Sequelae in 12 Sessions.2022 · no comparison group · 42 in the study
    Summary

    This cross-sectional study asked whether a physiotherapy plan changed post-COVID-19 sequelae in 42 patients at the Physical Therapy Unit of the Universidad Autónoma de Aguascalientes (April to September 2021). Patients had SARS-CoV-2 infection diagnosed by antigen test at least 1 month before starting. All received 12 physiotherapy sessions in 4 weeks, three times per week; there was no comparison group. Assessments before and after included a DASS-21 test, spirometry, a 6-min walk test, and a hand dynamometer test. The abstract reports a decrease of around 50% of post-COVID-19 sequelae. Dyspnea was reduced to 65.6%, chronic fatigue to 78.2%, and chronic pain to 83.3%; dry and productive cough showed 83.3 and 50.0% reductions. DASS-21 results showed a reduction in moderate and severe anxiety, mild anxiety increased 48%, moderate, severe, and extremely severe stress were not detected after therapy, and mild and moderate depression improved by 18% and 6%. FEV1 changed from 78.86% to 87.02% (difference 7.167%), FVC from 76.32% to 83.88% (difference 7.561%), and FEV1/FVC differed by −0.019. Maximal functional capacity differed by 0.577 METs; 6-min walk test performance improved by 13%; SpO2 changed from 94.07 to 95.47 (difference 1.40%). Basal heart rate showed no significant difference (2.36 beats per minute). Handgrip changed by 2.90 Kg (left) and 2.24 Kg (right). Harms and withdrawals were not reported. The authors state limitations about psycho-emotional evaluation and need for different clinical tests.

  50. Supervised hospital based pulmonary rehabilitation outcome in long COVID-experience from a tertiary care hospital.2022 · no comparison group · 71 in the study
    Summary

    This retrospective observational study enrolled 71 long COVID patients in the post COVID pulmonary ward of Kalinga Institute of Medical Sciences, Bhubaneswar, a tertiary care institute. All received supervised pulmonary rehabilitation for a minimum of three weeks, daily for 30 minutes, with no comparison group. The study measured oxygen saturation, mMRC dyspnea grade, cough score, six-minute walk distance and biomarkers before and after rehabilitation. Sixty-one patients were in the full recovery group and 10 in the partly recovered group. In the full recovery group, mean SPO2 rose from 90.03±3.89 to 95.82±1.69 (p=0.0001); mean 6MWD rose from 177.28±135.42 m to 415.48±144.73 m (p=0.0001); mMRC Grade 4 fell from 45 (%) to 0 (p<0.0001); cough Grade 3 fell from 49 (%) to 0 (p<0.0001), while mMRC Grade 2 increased from 5 (%) to 10 (%). In the partly recovered group, the text states no significant improvement in the same parameters, although Table 2b reports mean SPO2 rose from 87±4 to 91±2 (p=0.01); 6MWD was 166.25±170.87 m to 168±70.19 m (p=0.9700), mMRC Grade 4 was 8 to 8 (p=1.0), and cough Grade 3 was 6 to 6 (p=1.0). Overall, 61 (85.91%) were discharged after cure and 10 (14.09%) with O2 support; no deaths were reported and the authors state there was no adverse outcome. Limitations were small sample size, single center study and retrospective data.

  51. Effects of pulmonary rehabilitation on major symptoms of long COVID (post-COVID-19 syndrome)2022 · no comparison group · 39 in the study
    Summary

    Thirty-nine patients with a documented COVID-19 infection and persistent symptoms (long COVID) were included and took part in a pulmonary rehabilitation (PR) program between Feb.-Dec. 2021. The program comprised, at the very least, 18 endurance and 10 resistance training sessions and 6 educational sessions (dyspnea management, psychological support and counselling). The main delay between first symptoms and PR enrolment was 297±131 days. Main symptoms were dyspnea (n=34), fatigue (n=29), concentration disorders (n=16) and musculoskeletal pain (n=15). Exercise tolerance, dyspnea (D-12), fatigue (MFI-20) and quality of life were assessed before (T1) and after (T2) PR. After PR, D-12 decreased from 15.5±8 to 8.3±5.6 (p<.05) and MFI-20 decreased from 65.6±14.3 to 53.2±12.8 (p<.05). QoL physical (PCS) improved from 34.8±9.7 to 42.7±8.3 (p<.01), QoL mental (MCS) from 40.3±9.3 to 48.8±8.5 (p<.01), and ET from 516.6±131.6 m to 602.6±118.8 m (p<.05). No comparison group, randomisation, or crossover was reported. The number analysed was not reported. Harms and withdrawals were not reported. The abstract does not state limitations.

  52. Do not forget the lungs: preliminary feasibility study on I/E mode physiotherapy for people recovering from COVID-19.2022 · no comparison group · 20 in the study
    Summary

    This preliminary feasibility study enrolled twenty patients with post-COVID syndrome and mild-to-moderate obstructive syndrome early after hospital discharge. Participants performed guided in/expiratory (I/E) modulation physiotherapy using the I/E mode for 3 15-min sessions/day for 15 consecutive days. There was no comparison group. Lung function parameters, dyspnea, Quality of Life scores, and exercise capacity were assessed before and after treatment. All patients concluded the treatment. The abstract reports significant improvements in symptoms (chest pain during deep inspiration, chest tightness, inability to yawn, fatigue during activities of daily living [ADL], desaturation ≥4% during ADL) and in health status (BCSS -1.75, P=0.0003; CAT -5.2, P=0.0001). Lung function improved (FVC +10.9%, P=0.0002; FEV1 +8%, P=0.0001) and respiratory muscle strength improved (MIP +13.8%, P<0.0001; SNIP +13.6%, P=0.0122; MEP +7.6%, P=0.0045). Exercise capacity improved (6MWT +14.2%, P=0.005). At the end of treatment, only 2 patients reported symptoms and ADL-induced desaturation, while 14 still had fatigue during ADL. The abstract does not report side effects. The authors state that chest physiotherapy using an I/E device to actively recruit peripheral lungs in COVID-19 patients early after hospital discharge improved lung function tests as well as respiratory muscle strength, exercise capacity and Quality of Life. Limitations are not stated in the abstract.

  53. A RETROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECT OF PULMONARY REHABILITATION IN PATIENTS WITH POST-COVID-19 LUNG DISEASE2022 · no comparison group · 57 in the study
    Summary

    This retrospective observational study examined pulmonary rehabilitation in patients with post-COVID-19 lung disease. A total of 57 patients were included and their data analysed. Patients underwent an eight-week supervised pulmonary rehabilitation protocol consisting of breathing strategies, strength training for upper and lower limb muscle groups, endurance training, and balance and coordination training. There was no comparison group; outcomes were taken at commencement and after completion of rehabilitation. The outcomes were the 30 second sit to stand test (STST), 30 second wall push up test, St. George's Respiratory Questionnaire (SGRQ), and Modified Borgs Scale. The paper reports a median (IQR) difference in Borg's scale pre and post pulmonary rehabilitation of 5 (3). The median (IQR) difference in SGRQ pre and post pulmonary rehabilitation was 40.04 (22.92). The median (IQR) difference in 30 second STST pre and post pulmonary rehabilitation was 7 (4). The median (IQR) difference in 30 second wall push up test pre and post intervention was 8(5). Harms, side effects, and withdrawals were not reported. The text does not state limitations.

  54. Is pulmonary rehabilitation an effective programme to manage post-COVID breathlessness?2022 · no comparison group · 131 in the study · 88 with outcome data
    Summary

    Clark et al. retrospectively reviewed patients referred to pulmonary rehabilitation (PR) from the Cheshire and Merseyside long COVID service from March to April 2021. In total 131 patients were referred for PR; 88 patients were included in the analysis, and 43 were excluded due to incomplete records. The duration of PR was not reported. Scores following completion of PR were compared with initial scores. Of the 88 patients, 48 (54.5%) completed the PR programme. Following completion of pulmonary rehabilitation, 37 (42.0%) of all patients reported improvement in their symptoms, either an increased exercise tolerance, reduction in their Borg or MRC scores or improved breathing management. The paper also reports that eight (9.1%) self-discharged prior to starting PR, and 23 (25%) had poor adherence to the PR programme and were discharged without completing the programme. Of all patients who completed PR, three (6.3%) required further management of their symptoms. The authors state that despite some patients having no objective improvement in symptoms, feedback was positive, including that it was ‘helpful and beneficial’ to their recovery. Limitations the authors state include that 43 were excluded due to incomplete records and that some outcomes were not recorded in the discharge reports.

  55. Pulmonary Rehabilitation in Post-COVID-19 Patients Improves Lung Function and Mechanics and Skeletal Muscle, and Immune Response2022 · no comparison group · 104 in the study · 33 started · 33 with outcome data
    Summary

    This clinical study asked whether a 12-week pulmonary rehabilitation program would improve lung function, lung mechanics, muscle strength, and pulmonary and systemic immune responses in people with moderate to severe post-COVID-19. Participants were referred by family physicians after hospital discharge. Initially 104 patients were enrolled, and 33 ultimately accepted to participate and completed the study; no control group was included. The program combined aerobic treadmill training for 30 min at 70% to 80% of maximal heart rate and resistance training (deadlift, incline bench press, seated row, abdominal exercises, dumbbell shoulder press) at 8 to 12 repetitions per set, three sets per exercise, three sessions per week for 12 weeks. Evaluations were before and after the 12-week training period. The Results text reports improvements in FVC% (p < 0.0166), VC IN% (p < 0.009), FEV1% (p < 0.0356), and PEF% (p < 0.0087), but no discernible influence for FEV1/FVC and FEF measured at 25%, 50%, and 75% (p > 0.05). The abstract reports improvements for FEV1/FVC (p < 0.01), MEF25% (p < 0.006), MEF50% (p < 0.03), and MEF75% (p < 0.02). Table 1 reports changes in body weight, BMI, waist circumference, fat mass, fat-free mass, resting heart rate, systolic and diastolic blood pressure, SpO 2 %, FeNO, grip strength, MIP, and MEP, with p values. Side effects were not described.

  56. EFFECTIVENESS OF REHABILITATION FOR PATIENTS WITH POST-COVID-19 SYNDROME2022 · no comparison group · 38 in the study
    Summary

    This retrospective study analysed 38 outpatients with post-COVID-19 syndrome, mean age 53 years, at a physical medicine and rehabilitation department in Sisak. The study had no comparison group. All patients received an individual treatment plan based on patient education, general conditioning exercises, breathing exercises, respiratory muscle strengthening, balance and proprioception exercises, and strengthening of targeted muscles under a respiratory physiotherapist. Rehabilitation lasted 5 weeks, with sessions 3 days per week. Outcomes measured before and after rehabilitation were VAS pain, modified Borg dyspnoea scale, 6-minute walking distance, right hand grip strength, Barthel index, and Short Physical Performance Battery. The paper reports a statistically significant reduction in VAS pain (t-test = 2.24, p = 0.03) and modified Borg dyspnoea (t-test = 5.63, p = 0.00), an increase in 6MWD (t-test = -6.42, p = 0.00), right hand grip strength (t-test -2.91, p = 0.01), Barthel index (STS = 2.75, p = 0.04), and SPPB (STS = 3.34, p = 0.002). The text did not report harms, withdrawals, or worsening. No limitations were stated in the text.

  57. Impact of early pulmonary rehabilitation in postacute COVID Disease: A single-center experience from India - A quasi-experimental study.2022 · no comparison group
    Summary

    This quasi-experimental study assessed pulmonary rehabilitation in patients who recovered from COVID-19 and had persistent exertional dyspnea and fatigue after 3 weeks of recovery. The title describes it as a single-center experience from India. The abstract states that post-COVID patients reported persistent exertional dyspnea, cough, fatigue, or chest pain. Pulmonary rehabilitation was given for 4 weeks; there was no comparison group. Baseline and postintervention assessments of 6 MWD, Visual Analog Scale for Fatigue (VAS-F), peak flow, and Hamilton rating scales (HAM) were done after 4 weeks. The abstract reports significant improvement in peak flow, 6 MWD, Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), and VAS-F (P < 0.01) after 4 weeks of pulmonary rehabilitation. The number of patients enrolled or analysed is not reported in the abstract. Harms and withdrawals are not reported. The authors conclude that early pulmonary rehabilitation in post-COVID syndrome can contribute to statistically significant improvement in functional and psychological parameters as well as post-COVID fatigue. Limitations are not reported in the abstract.

  58. Multicomponent Exercise Program to Improve the Immediate Sequelae of COVID-19: A Prospective Study with a Brief Report of 2-Year Follow-Up.2022 · no comparison group · 39 in the study
    Summary

    This prospective study assessed a multicomponent exercise program (MEP) for immediate sequelae of COVID-19. Thirty-nine patients referred from ICU, Pneumology, Internal Medicine and Rehabilitation Services of Rey Juan Carlos Hospital after COVID-19 hospital admission were included. Participants received the MEP for seven weeks, twice a week for 14 sessions: cycloergometer interval training, elastic-band strengthening of lower and upper limbs, and individualized respiratory physiotherapy exercises. There was no control or placebo group; outcomes were measured before and after treatment and at a 2-year follow-up. Five patients did not complete the entire program. Changes were reported in Steep Ramp Test (112.84 ± 49.52 to 188.39± 64; p = 0.00; n = 28), SF-36 health state score (4.45 ± 0.6 to 3.82 ± 0.8; p = 0.005; n = 22), mMRC (2.48 ± 0.98 to 1.62 ± 1.12; p = 0.023; n = 21), 6MWT distance (343 ± 107.8 to 444.55 ± 111.15; p = 0.000; n = 31), oxygen saturation (95.23 ± 2.42 to 96.33 ± 1.83; p = 0.023; n = 30), resting heart rate (88.77 ± 15.29 to 83 ± 13.25; p = 0.033; n = 31), and number of stops (0.32 ± 0.54 to 0.03 ± 0.18; p = 0.005; n = 31). CAT/COPD showed no significant difference (17.29 ± 3.02 to 12.50 ± 8.66; p = 0.075; n = 14). At 2-year follow-up, 37 of 39 completed; 81% were much-slightly better and 84% had no dyspnea at all or only on walking fast or climbing a gentle slope. No adverse effects were reported.

  59. Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life.2022 · no comparison group · 64 in the study · 58 with outcome data
    Summary

    This prospective observational cohort study enrolled 64 consecutive adults at an outpatient pulmonary rehabilitation center in Vienna, Austria, with persistent symptoms after laboratory-confirmed COVID-19; 58 were included in the per-protocol analysis. Participants received a 6-week multi-professional, individualized pulmonary rehabilitation program with endurance, strength, and inspiratory muscle training 3 times per week for 3–4 h each, plus education. There was no comparison group. The primary endpoint was change in 6-min walk distance (6MWD). Secondary endpoints included the PCFS scale, Borg and modified Medical Research Council (mMRC) dyspnea scales, 1-MSTST, maximal workload, Fatigue Assessment Scale (FAS), and EuroQol 5-dimension quality-of-life measures. The paper reports that 6MWD increased by 62.9 m (±48.2, p < 0.001); PCFS decreased from a median of 2 (IQR, 2–3) to 1 (IQR, 0–2; p < 0.001); Borg dyspnea decreased to 7 (IQR, 4–7; p < 0.001); and mMRC decreased to 1 (IQR, 0–1; p < 0.001). Maximal workload increased by 21.8 W (±74.0; p = 0.03) and 1-MSTST by 9.2 more repetitions (±7.7; p < 0.001). FAS decreased by a median of 6.0 points (p < 0.001), and EQ-5D VAS increased by 14.9 percent points (±13.2; p < 0.001); the EQ-5D index score increased by 0.04 points (±0.14; p = 0.075). Six patients discontinued rehabilitation prematurely. No adverse events were recorded during rehabilitation, and no patients had blood oxygenation below 90% or required oxygen therapy. The authors state observational design precludes causal inference, missing values affected some secondary outcomes, and results cannot be generalized to all COVID-19 survivors.

  60. Concurrent aerobic and strength training program in post-COVID adult patients.2022 · no comparison group · 26 in the study
    Summary

    This quasi-experimental before-and-after study examined an eight-week concurrent aerobic and strength training programme in post-COVID adult survivors with decreased physical capacity. Twenty-six patients with poorer functional capacity were selected, using <500 m in 6MWT and <19 in the STST and no prior severe cognitive or functional impairment; the programme was conducted between September 2020 and September 2021. Participants received aerobic exercise (30 min on a cycle ergometer or walking) and strength training (two sets of 10–12 repetitions of eight muscle groups), along with strengthening the respiratory muscles. They trained three days a week in person, with home recommendations to complete at least three days of aerobic endurance and two days of strength training per week. There was no control group; outcomes were compared before and after the programme. The authors report significant improvement in 6MWT, STST and dynamometry in both hands, and improvement in hand grip strength. The QuickDASH score barely changed, and there was no improvement in the anxiety and depression scale. The paper does not report side effects or withdrawals. The authors state that the main limitation was the absence of a control group.

  61. Effectiveness of a Primary Care Telerehabilitation Program for Post-COVID-19 Patients: A Feasibility Study.2021 · no comparison group · 150 in the study · 115 with outcome data
    Summary

    This multicentric observational prospective study assessed a telerehabilitation program in seven primary care centers in San Bernardo, Santiago, Chile, in adults with post-COVID-19. Of 150 patients who started, 115 completed the program. The program was 24 sessions of supervised home-based exercise training over nine weeks, with 2 and 3 sessions per week. There was no comparison group. Outcomes were measured at the beginning and at the end of the program: 1-min sit-to-stand test, SF-36, fatigue and dyspnea. The 1-min STST changed from 20.5 ± 10.2 to 29.4 ± 11.9 repetitions (p < 0.001), and patients under the 2.5 percentile decreased from 51.3% to 15.7% (p < 0.001). The SF-36 global score changed from 39.6 ± 17.6 to 58.9 ± 20.5; fatigue and dyspnea improved significantly. In non-hospitalized versus hospitalized patients, all outcomes improved except fatigue in non-hospitalized patients (p = 0.065) and general health perception in hospitalized patients. In ICU-admitted versus non-ICU-admitted patients, all outcomes improved except four SF-36 dimensions. Thirty-five patients abandoned the program (23%). Side effects were not reported, and withdrawals for harms were not reported. The authors state limitations including no control group, no lung function study, and possible selection bias.

  62. Overview of Symptoms of Ongoing Symptomatic and Post-COVID-19 Patients Who Were Reffered to Pulmonary Rehabilitation - First Single-Centre Experience in Croatia.2021 · no comparison group · 63 in the study
    Summary

    This single-centre study included 63 patients (32 male, 31 female; mean age 52.9 years) with ongoing symptomatic and post-COVID-19 conditions who attended a standard, in-person pulmonary rehabilitation program. The study had no comparison group and was not randomised. Pulmonary function, expiratory and inspiratory muscle strength, hand grip strength, and the six-minute walk test were performed prior to and after pulmonary rehabilitation. The abstract reports a statistically significant difference in six-minute walk distance, inspiratory and expiratory muscle strength, and hand grip strength between first and final testing; the direction of these differences was not reported in the recorded data. Side effects, withdrawals, and the number of patients analysed were not reported. The authors conclude that their results are similar to previous studies and that the most common acute-phase symptoms were fatigue, cough, and dyspnea, with fatigue and respiratory problems during the ongoing symptomatic and post-COVID stage. They state that further larger studies are needed to clarify which acute disease symptoms are predominant in patients referred to pulmonary rehabilitation.

  63. Respiratory rehabilitation for Covid-19 related persistent dyspnoea: A one-year experience.2021 · no comparison group · 39 in the study · 25 with outcome data
  64. Late Breaking Abstract - Effects of pulmonary rehabilitation on major symptoms of long COVID (post-COVID-19 syndrome): preliminary results2021 · no comparison group · 15 in the study
    Summary

    This conference abstract reports preliminary findings of an inpatient pulmonary rehabilitation program for long COVID at Clinic La Solane between Feb.-May 2021. The abstract states the aim was to assess feasibility and efficacy of pulmonary rehabilitation to relieve the major long COVID symptoms. Fifteen patients with documented COVID-19 infection (ambulatory care: n=11, hospitalization: n=4) and persistent symptoms (>28 days) were enrolled. The program included endurance and resistance training, dyspnea management, psychological support and counselling; mean duration was 36±13 days. There was no comparison group. Dyspnea (D-12) and fatigue (MFI-20) were assessed by questionnaires before (T1) and after (T2) PR, and exercise tolerance and quality of life were also reported. All patients completed the PR and no adverse effect was reported. After PR, D-12 decreased significantly by 71% (T1:18.5±6.7; T2:6.2±4.2; p<.001) and MFI-20 by 27% (T1:70±11.6; T2:50.7±9.4; p<.001). Exercise tolerance and quality of life also improved (all p<.05). The authors state that a larger series of patients would be useful to confirm these preliminary findings.

  65. Short-term Effects of a Three-week Inpatient Post-COVID-19 Pulmonary Rehabilitation Program - a Prospective Observational Study2021 · no comparison group · 120 in the study · 108 started · preprint
    Summary

    This prospective observational study examined a three-week inpatient pulmonary rehabilitation program for post-COVID-19 patients. A total of 120 patients referred to the Bad Reichenhall Clinic were asked; 108 were included and assigned by referral mode to group A (55), group B (32), or group C (21). All received a tailored multimodal program including physical training (endurance and strength), respiratory physiotherapy, and other components; there was no separate comparison group. Outcomes included dyspnea (NRS and mMRC), 6-minute walking distance (6MWD), lung function, fatigue, quality of life, depression, anxiety, patient ratings, and complications. At the end of PR, NRS exertional dyspnea changed from 5.56 to 3.41 (change -2.15, p<0.001), mMRC from 2.26 to 1.51 (change -0.74, p<0.001), and 6MWD from 419 to 530 m (change 111 m, p=0.001); 66.1% had a clinically relevant exertional dyspnea improvement. Resting dyspnea showed no significant differences between subgroups, and mMRC clinically relevant improvement occurred in slightly more than 50% without differences between subgroups. Fatigue decreased in groups A and B but not significantly in group C; group C showed no improvement in VC, TLC, FEV1, TLCO, and PImax. Events included one psychiatric hospital transfer not related to PR, one patient quitting PR because of disc prolapse, one withdrawal of consent, and two dropouts for medical conditions not related to PR; all other 105 patients participated in at least 90% of prescribed therapies without related side effects. Limitations include the observational design, single clinic, and small group C.

  66. The imperative for multidisciplinary follow-up: A case of severe long COVID managed in primary care2026 · case report · 1 in the study
    Summary

    This case report described one 76-year-old male with severe Long COVID and pulmonary fibrosis, managed in primary care with multidisciplinary follow-up involving pulmonology, internal medicine, and physical therapy. The report aimed to illustrate multidisciplinary primary care management. There was no comparison group. Treatments included prednisolone orally in several schedules: 20 mg/day with a tapering schedule over 4 weeks; 20 mg once daily for 5–10 days per course; and a gradual taper starting at 40 mg daily for 4 weeks. He also received fluticasone/vilanterol 184/22 mcg inhaler, 1 inhalation once daily; rivaroxaban 15 mg orally twice daily for 21 days, then 20 mg orally once daily, with a planned total treatment duration of 6 months; and physical therapy/respiratory rehabilitation. Reported outcomes by June 2023 included resolution of fatigue, occasional residual cough, improved restriction without new thrombotic events, and enhanced quality of life through rehabilitation. By March 2023, computed tomography angiography and repeat functional tests showed improvement in ventilatory restriction and no new thrombotic events. Clinical status stabilized by June 2023. A deep vein thrombosis in the left lower limb was reported two weeks post-discharge. The report states no new thrombotic events by June 2023; withdrawals and their reasons are not reported. The authors do not state limitations.

  67. Novel Respiratory Therapy for the Improvement of Post COVID Condition Symptoms: A Case Series.2025 · case report
    Summary

    This case series examined an Integrative Breathing Therapy (IBT) protocol for patients diagnosed with post COVID condition symptoms who attended an otolaryngology clinic and presented with signs and symptoms of dysfunctional breathing (DB). The text did not report how many patients were enrolled or analysed and described no comparison group. Treatment involved 6–12 sessions of weekly 1-hour group telehealth sessions combined with 2–4 individual sessions. The authors state that a systematic evaluation of biomechanical, biochemical, and psychophysiological dimensions of DB was performed for each patient to enable targeted patient-centered care, and patients then received intensive breathing retraining. Outcomes reported were parameters of DB measured, symptoms, and daily function. All participants showed improvements in the parameters of DB measured, and participants also reported a reduction in symptoms and improved daily function. The paper did not report side effects, withdrawals, or worsening. The authors conclude that patients with long COVID who present with signs and symptoms of DB might respond positively to comprehensive and intensive breathing retraining that addresses biochemical, biomechanical, and psychophysiological dimensions of breathing. They state that more research is required to further refine this protocol and confirm its effectiveness through a controlled trial.

  68. Post-COVID central hypersomnia, a treatable trait in long COVID: 4 case reports.2024 · case report · 530 in the study · 4 started · 4 with outcome data
    Summary

    This paper reports four case reports from a post-COVID clinic that evaluated 530 patients referred between May 2021 and January 2023 and covered a population of around 300,000 inhabitants. The four patients had post-COVID central hypersomnia after polymerase chain reaction-confirmed SARS-CoV-2 infection; three met criteria for idiopathic hypersomnia and one for type II narcolepsy. Sleep studies and sleep latency tests were performed. Three patients were prescribed methylphenidate: 40 mg/d in Patient 1, 20 mg/d in Patient 2, and 10 mg/three times daily in Patient 4 (taken only on days when work required more concentration, about 3 times/week). Patient 2 later tapered to 10 mg/d and stopped gradually after 2 months with no recurrence of hypersomnia. The paper reports a favorable response to methylphenidate in three cases and spontaneous resolution in one case. Patient 1's sleep requirements decreased back to 8–9 h/day from up to 12–14 h per day, and he returned to school. Patient 2 was able to return to work with 20 mg/d. Patient 4 had a good effect on sleepiness. One harm was recorded: a trial to stop methylphenidate in Patient 1 failed after 4 months with a resurgence of hypersomnia (sleep duration more than 11 h per day). There was no comparison group. The authors state that the causal link is not formally proven and the small number of cases limits conclusions about treatment and evolution.

  69. Physical Medicine and Rehabilitation Management in Patients with Long COVID-19 and Thymoma-associated Myasthenia Gravis: A Case Report2024 · case report · 1 in the study
    Summary

    This case report describes one 44-year-old woman with long COVID-19 syndrome and thymoma-associated myasthenia gravis who was consulted to a rehabilitation department in preparation for surgery. She received pulmonary rehabilitation consisting of aerobic exercise using an ergo cycle with oxygen supplementation and breathing exercises twice a week, for a total of 6 times. Before exercise she was educated to take pyridostigmine 1 hour earlier. There was no comparison group. After 1 series of pulmonary rehabilitation, the fatigue severity scale decreased from 62 to 51, chest expansion enlarged from 2–3–4 cm to 3–3.5–4 cm, and the single breath count test rose from 7 to 17. The sit-to-stand test for 30 seconds was 9 times, still the same as the previous examination, and the 6-minute walk test result was 255 meters. Complaints of fatigue were much reduced, but shortness of breath still existed during daily activities; she could carry out daily activities independently, walking for about 10-15 minutes, and was less likely to use oxygen supplementation, but still often felt tired with household activities. The patient was asked to observe for signs of exacerbation; no harms were reported, and withdrawals were not reported. The authors state no limitations.

  70. Use of Locally Produced Novel Low-Cost 3D Printed Respiratory Muscle Strength Trainer Device (RMSTD) for Long COVID-Rehabilitation: An Innovative Case Report.2024 · case report · 1 in the study
    Summary

    This case report describes one 36-year-old male with long COVID after severe COVID-19 requiring ICU admission, assessed at Green Pastures Hospital and Rehabilitation Centre. There was no comparison group. He received a hospital-made RMST device set at 10 cm H2O displaced, with ten short forced exhalations per cycle for five cycles and five long forced exhalations held for five seconds, hourly and as needed; he was also taught lower abdominal and box breathing techniques, and received metformin in divided doses. Treatment covered 6 days of hospital admission followed by six weeks of outpatient therapy. Within 24 hours of admission he used the RMST device without supplemental oxygen and maintained SpO2 of 90%; supplemental oxygen was completely weaned on day 5. By the end of the SLP evaluation, respiratory rate was 15–17 breaths per minute and SpO2 96% while using the RMSTD. By discharge on day 7, he independently used thoracic and diaphragmatic breathing techniques, completed the RMST regime at 40 cm H2O displaced with twenty repetitions per cycle, and had sustained breathing of 15 seconds. At discharge he achieved 290 m in the 6MWT with Borg 13–15; SpO2 was lowest recorded 83% at the end of 6MWT, recovering after 2 minutes of rest to greater than 93%. After six weeks of outpatient therapy he used RMSTD at 80 cm H2O and performed 390 m in the 6MWT with Borg maximum of 11; at the end of therapy MBI was 100.

  71. Clinical outcome of supervised pulmonary telerehabilitation program among adult patients with post-acute COVID-19 symptoms (PACS): A case series.2023 · case report · 13 in the study · 9 with outcome data
    Summary

    This case series reports outcomes for adults with post-acute COVID-19 symptoms (PACS) at the Philippine Heart Center. 13 patients met inclusion criteria and were enrolled in a supervised pulmonary telerehabilitation program; nine completed the 24 sessions and are presented. Sessions were scheduled at 2–3 sessions per week, with health education between sessions. There was no comparison group; outcomes were assessed before and after treatment in completers. Assessments included the Six-Minute Walk Test (6MWT), cardiopulmonary exercise test VO2 peak, pulmonary function (FVC and FEV1), St. George's Respiratory Questionnaire (SGRQ), and Hospital Anxiety and Depression Scale (HADS). The authors report improved 6MWT exercise capacity for all patients; most had improvement in VO2 peak and SGRQ, and six had improvement on FEV1. The text reports a mean increase of 12.9% in VO2 peak and a mean 38.69% change in 6MWT. Anxiety and depression showed a decreasing trend. VO2 peak percent-predicted changes were mixed. Reasons for drop-out were mainly conflict of schedule for completing the program during office hours due to work commitment. There were no reported injuries (falls, trauma or fracture) or further complications (shortness of breath, chest pain or loss of consciousness) at any part of the program. The authors state further support for the effectiveness of PR patients with PACS is mandated.

  72. Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report.2023 · case report · 1 in the study
    Summary

    This case report described one 60-year-old Hispanic patient who developed severe COVID-19 pneumonia in April 2020, treated at home because the healthcare system was oversaturated, and later had post-acute COVID-19 syndrome. After persistent dyspnea and fatigue, the patient began a bronchodilator twice daily for nine months with low-dose inhaled corticosteroids (160 µg of budesonide and 4.5 µg of formoterol fumarate dihydrate); pulmonary rehabilitation was reinstated. Earlier treatment also included corticosteroids, oxygen via a nasal cannula, and pulmonary rehabilitation. There was no comparison group; outcomes were within-patient before/after measures. At 36 months, restrictive parameters remained stable and DLCO normalized; 6MWT performance was 87% but significant desaturation persisted. CT showed reduced GGO and air trapping, while traction bronchiectasis persisted. FOT and MBW scores improved without normalization. The report also states that oscillometric and MBW measurements improved after a year of follow-up. Side effects and withdrawals were not reported. The authors state that more studies are needed.

  73. Efficacy of a rehabilitation protocol on pulmonary and respiratory muscle function and ultrasound evaluation of diaphragm and quadriceps femoris in patients with post-COVID-19 syndrome: a series of cases.2022 · case report · 9 in the study
    Summary

    This series of cases assessed the efficacy of a pulmonary rehabilitation (PR) program on pulmonary and respiratory muscle function and on ultrasound evaluation of the diaphragm and quadriceps femoris in patients with post-COVID-19 syndrome. Nine patients performed PR twice a week for six weeks. The PR program consisted of lung expansion therapy, respiratory muscle training, upper limb strength exercises, and aerobic exercises on a treadmill. There was no comparison group; outcomes were measured before and after the program. After the program, the authors observed increased peak expiratory flow (26.03%), forced vital capacity (FVC) (7.14%), forced expiratory volume in the first second (FEV1) (9.55%), and ratio between FEV1/FVC (6.19%). All parameters of respiratory muscle strength and endurance were improved. Diaphragmatic thickening fraction and thickness of quadriceps femoris also improved, whereas echo intensity of quadriceps reduced. The text does not report side effects or withdrawals. The text does not report any patients who worsened or stopped treatment. The setting is not reported. The authors do not state limitations. The authors conclude that the RP protocol improved pulmonary function, respiratory muscle strength and endurance, and thickness of diaphragm and quadriceps femoris, and reduced echo intensity of quadriceps in patients with post-COVID-19 syndrome.

  74. Effect of Supervised Home-Based Training on Functional Outcome in Severe Exercise Intolerance in Post-COVID Syndrome2021 · case report · 1 in the study
    Summary

    This case report describes one 56-year-old female with post-COVID syndrome after hospital discharge following COVID-19 pneumonitis and acute respiratory distress syndrome. A supervised low-resource home-based pulmonary rehabilitation program was started a month after discharge and followed for 6 weeks with supplemental oxygen and progressive metabolic equivalent of task level training. The program included functional training, strength training, flexibility training, diaphragmatic breathing and lung expansion exercises, nutritional counseling, and education sessions. There was no comparison group. The authors measured functional independence with the functional independent measure (FIM) scale, 6-minute walk distance, walking distances, and adverse events. The FIM score was 77/126 at baseline and 110/126 by end of 6 weeks. The 6-minute walk distance was 250 m at end of 6 weeks. By the end of 6 weeks, the patient was independent in most self-care activities and ambulatory in and around the house. There were no episodes of any adverse events. The authors state that further research is required at the community level to study the effect of pulmonary rehabilitation on the long-term consequences of this disease.

  75. Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study.2021 · case report · 1 in the study
    Summary

    This case report describes one 51-year-old gentleman who presented to a London District General Hospital during the COVID-19 pandemic and was later reviewed in a post-COVID-19 clinic with post-COVID-19 pneumonitis. At 6 weeks post-discharge he was referred to community pulmonary rehabilitation and given a self-directed exercise booklet. At 12-week post-discharge he began a 3-week course of oral prednisolone (30 mg OD for 7 days, 20 mg OD for 7 days, 10 mg OD for 7 days), followed by a further 4-week course of prednisolone 10 mg OD; pulmonary rehabilitation commenced 8 weeks after discharge for 8 weeks, with exercises completed two times per week. The paper reports before-and-after changes: 6MWT distance 490 m to 645 m, a reported increase of 155 m; 1-min sit-to-stand 23 to 37, an increase of 14; MRC score 2 to 0; FACIT-Dyspnoea 19/60 to 0/60. PFTs changed from FEV1 2.07 (60% of predicted), FVC 2.45 (58% of predicted) and TLCO 5.61 (58% of predicted) to FEV1 2.73 (80%), FVC 3.19 (75%) and TLCO 7.21 (74%). The authors state causality is difficult to prove from this single case. Side effects and withdrawals are not reported.

  76. The breath and mind connection in young people with post-COVID syndrome: feasibility and acceptability of a pilot randomised co-designed intervention.2026 · combination: given with other treatments · 32 randomised
    Summary

    This randomised pilot trial assessed acceptability and feasibility of a co-designed intervention for children and young people with post-COVID syndrome attending a regional tertiary multidisciplinary service. Thirty-two young people consented and were randomised to standard clinical care (n = 15) or intervention plus standard clinical care (n = 17). The intervention comprised four 3.5-h online group sessions over six months, based on narrative therapy and breathing exercises, plus an interactive digital resource; the comparator received standard clinical care. The primary outcome was the Strengths and Difficulties Questionnaire Impact Score, with secondary outcomes including the Nijmegen questionnaire, Chalder Fatigue, EQ-5D-Y, wellness rating, pulmonary function and exercise testing. The abstract reports no statistically significant improvement in the SDQ over time or between groups. Nearly all secondary outcome measures showed statistically significant improvement over time but not between groups. Thirty-two of 66 eligible young people were recruited; four groups were offered over six months; 17/17 attended one of four possible online workshops. The abstract reports 14/17 completed the session, while the discussion reports 15/17 completed a group. Two did not complete the session (one developed a headache and one struggled with the group environment). Median ratings were 8 for online delivery, 7 for usefulness, 7.5 for sharing ideas and 8 for recommending the group. The authors state the study was not powered to detect change over time.

  77. Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.2024 · how it is prescribed, safety only · 200 with outcome data
    Summary

    This single-cohort retrospective study with a follow-up survey investigated symptomatic treatment use and patient-reported improvement in post-COVID syndrome. It included 200 patients attending the post-COVID center of the University Hospital of Erlangen between December 2022 and July 2023, with symptoms persisting at least three months after SARS-CoV-2 infection; vaccine-related symptom onset was excluded. Baseline records captured symptomatic therapies from three months post-infection until presentation. A follow-up questionnaire was completed by 165 patients (response rate 82.5%), a mean 6.3 months (SD = 2.2) after initial consultation. Treatment duration was not reported. There was no control group; patients rated improvement within the same cohort for each therapy they used, using 0 = no improvement to 3 = very strong improvement. Among therapy users, strong to very strong improvement was reported by 12 of 38 for beta-blockers, 8 of 27 for antibiotics, 5 of 15 for plasmapheresis, and 8 of 73 for outpatient psychotherapy. Vitamins and nutritional supplements were rated 9 of 135. No between-group comparison was reported. Harms, side effects, worsening and withdrawals were not reported. The authors state that the study gives initial insights into utilization and patient-reported symptom improvement.

  78. The Impact of Pulmonary Rehabilitation in Patients with Post-COVID-19 Syndrome: A Systematic Review.2026 · systematic review
    Summary

    This systematic review examined pulmonary rehabilitation for adults with post-COVID-19 syndrome. The authors searched PubMed, Embase and the Cochrane Central Register of Controlled Trials from January 2021 to January 2026, with the last search on 31 January 2026, and included 20 randomised controlled trials involving 2101 adult patients. Included trials compared pulmonary rehabilitation with in-hospital rehabilitation, telerehabilitation, standard care, educational counselling or sham devices, and assessed exercise capacity, pulmonary function, respiratory and peripheral muscle strength, quality of life, dyspnea, fatigue, anxiety and depression. Findings across the included trials were mixed. Some trials reported improvements in exercise capacity, such as one trial with a rehabilitation-group increase of +47.7 m on the 6MWT while the control group decreased by 14.2 m. Other trials reported no significant between-group differences for VO2max, quality of life, anxiety, depression or dyspnea. Trials comparing in-hospital rehabilitation with telerehabilitation generally reported improvements in both groups without significant between-group differences, except one trial reported a fatigue advantage for in-hospital rehabilitation. The extracted data include no side-effect counts or withdrawal numbers. The authors state that only half of the included trials had low risk of bias and note short-term outcomes, small samples, heterogeneous protocols, English-only inclusion, and no quantitative meta-analysis or GRADE assessment.

  79. The health effects of diaphragmatic breathing: A systematic review.2026 · systematic review
    Summary

    This systematic review asked whether diaphragmatic breathing (DB) affects health in adults, using randomized controlled trials (RCTs) that compared DB with control conditions. The authors searched six electronic databases through January 2025 and included 48 RCTs in adults aged 18 years or older with any health status. The review grouped participants into nine condition groups, including post-COVID-19 syndrome. For long COVID, Palau 2022 compared DB with usual care in groups of 6/7 and 9/4 participants; Abo 2024 compared standard care plus incentive spirometry, standard care plus DB, and standard care in groups of 12/8, 12/8, and 10/10 participants with post-COVID-19 condition and diaphragmatic dysfunction. Across two post-COVID-19 studies, the review reports improvements in dyspnea, exercise capacity, respiratory muscle strength, and diaphragmatic function, with 6-minute walk distance increases of 135–175 m. Safety was underreported: 18.75% of studies reported adverse events, and no serious adverse events were noted. In Niu 2024, one patient in the DB intervention group had persistent intolerable diarrhea after one week and discontinued; one control patient discontinued due to lack of cough improvement. The authors state that the evidence base is limited by heterogeneity and methodological concerns.

  80. Does pulmonary rehabilitation improve fatigue in patients with post-COVID-19 syndrome? A meta-analysis of randomized clinical trials.2026 · systematic review
    Summary

    This systematic review and meta-analysis asked whether pulmonary rehabilitation reduces fatigue in people with post-COVID-19 syndrome. The review searched four databases to 21 October 2024 and included 13 studies in the systematic review and 10 in the meta-analysis. Pulmonary rehabilitation was compared with a control group. Fatigue was the outcome. In the meta-analysis, the result was SMD = –0.59, 95% CI = –0.89, −0.28; p = 0.0002, n = 973, in favor of pulmonary rehabilitation compared with the control group, with statistically significant differences between groups. The review did not report one uniform program length. Two included studies reported adverse events of pulmonary rehabilitation, and 3 reported no adverse effects; the remaining studies did not provide this information. Listed events included dizziness, fatigue, occasional ventricular premature beat and occasional atrial premature beats, and syncope with vomiting, unilateral knee pain, severe or not severe anxiety, and headache; counts were not reported. People who worsened or stopped treatment were not reported. The authors state limitations including heterogeneous and subjective fatigue instruments and that participants could not be blinded.

  81. Systematic Review of Randomized Clinical Trials for the Treatment of Long COVID Syndrome.2026 · systematic review
    Summary

    This systematic review asked whether treatments for long COVID improve outcomes. It searched MEDLINE through PubMed from 2020 to August 2024 and included 43 randomized clinical trials of people with long COVID. The trials compared interventions with control groups or other treatments and reported a primary outcome. Treatments included nutraceuticals, respiratory muscle training, supervised exercise or pacing, brain stimulation, and medications. Outcomes included symptoms, exercise capacity, Vo2 max, fatigue, cognitive functions, inspiratory pressure, pain, and olfactory and gustatory function. The review reports that all studies testing supervised exercises improved the primary outcome except for one; all but one brain stimulation study improved the primary outcome; and only 2 studies using medications improved the primary outcome. Nirmatrelvir/ritonavir did not improve symptoms; donepezil and lithium did not improve their primary outcomes; thermal water inhalation and a metabolic modulator did not improve the primary outcome. Creatine improved fatigue; vitamin C improved exercise capacity; inspiratory muscle training improved symptoms, exercise capacity and inspiratory pressure. Reported harms included 33% with adverse events (dry mouth) with amantadine, 16% nausea with creatine, 17%–37% adverse events with TMS, two to four percent TMS discontinuation, and 8% inspiratory muscle training discontinuation. The authors state the evidence was mostly low certainty.

  82. Rehabilitation in long COVID: a systematic review and meta-analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis asked whether rehabilitation programmes help adults with long COVID. It included 12 studies with 1403 participants. The interventions combined structured exercise with an educational component and were compared with usual care or control groups. Outcomes included exercise capacity, quality of life, pulmonary function, dyspnoea, anxiety, depression and fatigue. In the short term, exercise capacity on the 6-min walk test improved with a mean difference of 102.34 m (95% CI 44.48 to 160.21 m; p<0.0001) in four RCTs. Dyspnoea on the mMRC improved in the RCT subgroup with a mean difference of −1.44 (95% CI −2.72 to −0.16). Anxiety on HADS-A reduced with a mean difference of −1.64 (95% CI −3.02 to −0.26; p=0.02). Fatigue showed no statistical difference (MD 7.96, 95% CI −2.11 to 18.02), and FEV1 showed no difference (SMD=0.11; 95% CI −0.12 to 0.34; p=0.33). Quality of life on EQ-5D-5L showed no significant difference (MD 0.07; 95% CI −0.09 to 0.22). Long-term HRQoL and dyspnoea showed no significant effects (SMD −0.74; 95% CI −2.54 to 1.06 and SMD −0.56; 95% CI −1.72 to 0.60). Long-term functional capacity showed a significant effect (SMD 0.88; 95% CI 0.56 to 1.19; p<0.0001). Worsening or stopping was not reported. None of the included studies systematically monitored or documented post-exertional malaise, and adverse events were generally under-reported.

  83. Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
    Summary

    This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.

  84. Effects of Exercise-Based Pulmonary Rehabilitation in Patients with Long COVID: A Systematic Review and Meta-Analysis.2026 · systematic review
    Summary

    Fifteen studies (n = 803) were included in this systematic review and meta-analysis of adults with Long COVID, defined as persistent symptoms continuing from 12 weeks after SARS-CoV-2 infection; searches covered MEDLINE/PubMed, Web of Science, PEDro and EMBASE. Participants received in-person outpatient pulmonary rehabilitation (OPR) with supervised physical exercise as an essential component; protocol duration varied. Randomized trials compared OPR with a control group. Outcomes included FEC by 6MWT and 30″SST, QoL (SF-12, EQ/VAS), pulmonary function (FVC, FEV1, FEV1/FVC), dyspnea (mMRC, Borg), and fatigue. Pooled observational studies showed improvement in 6MWT (MD 53.72 m, 95% CI 43.69–63.75) and 30″SST (MD 4.68 repetitions, 95% CI 3.59–5.77). In randomized trials, QoL improved in physical (MD 8.04, 95% CI 3.02–13.05) and mental (MD 6.60, 95% CI 2.01–11.18) SF-12 domains, and mMRC dyspnea impact fell (MD −0.82, 95% CI −1.38–−0.25). Observational EQ/VAS QoL improved (MD 14.16, 95% CI 3.23–25.09) and Borg exertional dyspnea fell (MD −1.14, 95% CI −1.51–−0.77). Pulmonary function showed no changes. Some studies reported no QoL or dyspnea improvement. Three studies reported adverse events; one study identified a case of PEM. Withdrawals were not reported. The authors rate certainty low or very low.

  85. Effects of exercise programs on cardiopulmonary function and signs and symptoms in patients with post-COVID-19 condition: a systematic review and meta-analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis asked whether exercise programs lasting at least 6 weeks affect cardiopulmonary function and symptoms in post-COVID-19 condition. It included 10 randomized controlled trials comprising 602 participants; the review reports a comparison with control groups. Exercise programs were varied and included aerobic, resistance, breathing, thoracic mobility, chest expansion, and respiratory muscle training, delivered home-based, center-based, or combined. Outcomes included 6MWD, FVC, FEV1, FEV1/FVC, mMRC, physical pain, physical health, mental health, emotional role, and quality of life. Pooled results showed improvement in 6MWD (MD 77.5 m, 95% CI 63.3 to 91.8), FVC (MD 0.11 L, 95% CI 0.07 to 0.15), and FEV1 (MD 0.13 L, 95% CI 0.04 to 0.23). mMRC improved (RR 0.48, 95% CI 0.31 to 0.73). FEV1/FVC showed no significant difference (FEV1/FVC = 2.52%, p = 0.15). Physical pain, physical health, mental health, and emotional role showed significant improvement (all p < 0.01). Only four studies explicitly reported no adverse events during the intervention; the remaining studies did not provide safety information. The review did not report withdrawals in the recorded data. The authors state limits including heterogeneity and limited publication-bias assessment.

  86. Exercise effectiveness on fatigue in Long-COVID: systematic review and meta-analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis examined exercise for fatigue in adults with Long COVID (symptoms ≥3 months). The authors searched 7 databases in July 2025 and included 14 randomized controlled trials. Exercise groups were compared with usual care. In pooled analyses, the exercise group increased grip strength by 3.86 kg (MD 3.86 kg, 95% CI 2.23-5.50; P < .00001), respiratory muscle strength by 15.54 cmH2O (MD 15.54 cmH2O, 95% CI 8.73-22.34; P < .00001), and 6-minute walk distance by 93.57 m (MD 93.57 m, 95% CI 60.34-126.80; P < .00001). Sit-to-stand repetitions increased (SMD 1.43, 95% CI 0.40-2.46; P = .006) and sit-to-walk speed decreased by 1.23 s (SMD −1.23, 95% CI −2.11 to −0.34; P = .007). The exercise group reduced dyspnea incidence (RR 0.33, 95% CI 0.19-0.56; P < .0001), dyspnea severity (SMD −0.89, 95% CI −1.52 to −0.27; P = .005), fatigue incidence (RR 0.45, 95% CI 0.28-0.74; P = .002), and fatigue severity (SMD −0.59, 95% CI −0.96 to −0.21; P = .002). Subgroup analyses for fatigue severity found multimodal exercise reduced fatigue severity (SMD −0.45, 95% CI −0.85 to −0.06; P = .03), whereas single-modality exercise did not (SMD −0.84, 95% CI −1.71 to 0.03; P = .06). Attrition rates ranged from 0% to 30.38%; no adverse events were reported in the included studies, but most trials provided limited information regarding PEM monitoring and adverse event ascertainment. The authors describe the certainty of evidence as moderate to very low.

  87. Post-Covid Respiratory Rehabilitation: A Systematic Review of Physiotherapy Protocols Across Countries2026 · systematic review · preprint
    Summary

    This systematic review and meta-analysis asked whether physiotherapy-based respiratory rehabilitation helps people with post-COVID-19 conditions. It included 35 randomized controlled trials with 2,128 participants recruited from hospital, outpatient rehabilitation, community, or other clinical settings across countries. Interventions included pulmonary rehabilitation, aerobic and resistance exercise, breathing exercises, inspiratory muscle training, home-based rehabilitation, and telerehabilitation; duration and delivery varied. Comparators included usual or standard medical care, no intervention, wait-list control, attention control, or alternative rehabilitation approaches. Outcomes included the six-minute walk distance, FEV₁, FVC, oxygen saturation, respiratory muscle strength, dyspnoea, fatigue, and health-related quality of life. The review concluded that rehabilitation improves functional exercise capacity, with low certainty, while effects on pulmonary function remain uncertain; FEV₁ and FVC effects were not statistically significant. Evidence for dyspnoea, fatigue, quality of life, respiratory muscle strength, and oxygen saturation generally favoured rehabilitation but was heterogeneous. The review stated rehabilitation was generally well tolerated with no significant adverse events, though safety reporting was inconsistent. People who worsened or stopped treatment were not reported. The authors state that protocols varied considerably, which may have contributed to heterogeneity, and that methodological limitations reduced certainty.

  88. Dropouts in Exercise Rehabilitation Program in Patients With Long COVID: A Systematic Review.2025 · systematic review
    Summary

    Objective: to describe dropout rates, reasons, and factors associated with dropout during rehabilitation programs for patients with long COVID. The review included 23 studies with 1,523 patients with long COVID (mean age 53.0 ± 6.4 yrs; 51% female). Eligible programs were exercise interventions lasting at least 4 weeks for patients aged 18 or older of both sexes. The review did not compare one exercise regimen against another; it pooled dropout data and compared dropout ratios across study variables. The main outcome was dropout rate, recorded as absolute numbers and frequency, and the secondary outcome was reasons for dropout. Of 1,523 patients enrolled, 216 withdrew, constituting 14.2% of the total sample. Grouped dropout reasons were not reported (31.0%), health issues (23.1%), did not complete assessments (19.4%), loss of interest (15.7%), lack of adherence (6.9%), and adherence to other interventions (3.7%). Individual included studies listed side effects (n = 5), symptoms exacerbation (n = 1), musculoskeletal issue (n = 1), other acute health conditions (n = 2), and hospitalization (n = 1) as dropout reasons. The review reports no significant associations between dropout rate and remaining variables. The authors state that dropout rates were 14% and that health-related issues and incomplete assessments were the most common reasons.

  89. Effectiveness of physiotherapy modalities on persisting dyspnoea in long COVID: A systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether physiotherapy treatments reduce persisting dyspnoea in long COVID. The reviewers searched MEDLINE, PEDro, WOS, Scopus, VHL and the Cochrane Library for studies published between September 1st, 2019 and July 2nd, 2023; the protocol was registered as CRD42023427464. They included comparative trials of adults with persistent breathlessness following COVID-19, regardless of initial severity, in whom physiotherapy was implemented as treatment for dyspnoea. 19 studies including 1292 adults fulfilled the inclusion criteria. Treatments were grouped as high-intensity rehabilitation, low-to-moderate intensity rehabilitation, respiratory muscle training, and other/passive techniques; dyspnoea was assessed with dyspnoea-specific, functional, or health-related quality-of-life scales. The authors report that physiotherapy and especially pulmonary rehabilitation may help alleviate respiratory symptoms. They state that high-intensity rehabilitation shows particularly more promising results than low-to-moderate rehabilitation or respiratory muscle training, whereas results for low-to-moderate intensity and respiratory muscle training groups were non-significant. For low-level laser therapy, the review states it seems to have significantly reduced dyspnoea and markers of inflammation in people with long-covid. The recorded data include no side-effect, worsening, or withdrawal counts. The authors state limitations including heterogeneity of interventions and controls, risk of bias from open or assessor-only blind studies, and short-term follow-up.

  90. Effects of therapeutic interventions on long COVID: a meta-analysis of randomized controlled trials.2025 · systematic review
    Summary

    This meta-analysis pooled 51 RCTs with 4026 participants with Long COVID, searching PubMed, Cochrane Library, Embase, Web of Science, SPORTDiscus (EBSCO), CINAHL (EBSCO), and Rehabilitation & Sports medicine source (EBSCO) to July 20, 2025. Trials compared exercise training, respiratory muscle training, telerehabilitation, tDCS, olfactory training, steroid sprays, or PEA-LUT with no intervention, standard primary care, or placebo; follow-up ranged from 14 to 180 days. Outcomes included cardiopulmonary function, exercise capacity, fatigue, dyspnea, and olfactory recovery. Exercise training showed significant better 6MWT (MD 83.20; 95% CI 52.04–114.37) and 30sSTS (MD 3.05; 95% CI 1.96–4.13), but no significant difference for HADS-depression, HADS-anxiety, SF-12-PCS, FVC (% predicted), FEV1, VE/VO2, VE, RER, or FEV1/FVC. Respiratory muscle training showed significant better 6MWT (MD 89.54; 95% CI 9.86–169.23) and MIP (cm H2O) (MD 19.69; 95% CI 10.14–29.24), with no significant difference for FVC, FEV1, MFIS, HADS, or MEP. Telerehabilitation showed significant better 6MWT (MD 34.14; 95% CI 2.54–65.74), 30sSTS (MD 1.41; 95% CI 0.67–2.15), and FSS (MD −1.59; 95% CI −2.64 to −0.53). tDCS showed significant lower MFIS-physical (MD −2.29; 95% CI −4.36 to −0.22). Olfactory training and steroid sprays showed no significant differences; PEA-LUT showed significant higher TDI Score (MD 4.66; 95% CI 2.16–7.15). No side-effect or withdrawal counts were reported; the authors noted exercise may pose a risk of symptom exacerbation in post-exertional malaise. They reported high risk of bias in 33 studies and high heterogeneity.

  91. Effectiveness and tolerance of exercise interventions for long COVID: a systematic review of randomised controlled trials.2025 · systematic review
    Summary

    This systematic review included eight randomised controlled trials of exercise interventions in adults with long COVID, conducted in Spain, France, Turkey, China and Poland. Follow-up periods ranged from 2 to 28 weeks (mean=8.5 weeks); sample sizes ranged from 39 to 119 (mean=56). Interventions included supervised strength and aerobic exercise, telerehabilitation with aerobic exercise, breathing exercises plus a walking programme, virtual reality aerobic exercise, and hospital-based pulmonary rehabilitation. Comparators included a WHO self-management leaflet, short educational instructions, a brochure, no treatment, standard physiotherapy, in-person versus virtual reality exercise, and home-based versus inpatient rehabilitation. Outcomes included dyspnoea, fatigue, physical function, HRQoL, mental health and general symptoms. The review reports short-term improvements in dyspnoea, fatigue, physical function and the physical domain of HRQoL, with no between-group differences in some outcomes including anxiety and depressive symptoms and ME/CFS symptoms. Of five studies reporting adverse events, four recorded none; one reported no serious adverse events but more mild adverse events in the intervention group in the first 6 weeks, mostly chest tightness, weakness or reduced strength, and cough. One of 252 participants discontinued exercise due to tolerance-related issues (chest pain); in the eighth study, 1 of 26 discontinued, reason not provided. The authors state the evidence base is limited by small sample sizes and short follow-up.

  92. Post-Acute COVID-19 Syndrome (PACS) and Exercise Interventions: A Systematic Review of Randomized Controlled Trials.2025 · systematic review
    Summary

    This systematic review asked whether exercise interventions affect health-related quality of life and functional fitness in adults with Post-Acute COVID-19 Syndrome. It searched databases and clinical registers up to July 2025 and included 20 randomized controlled trials. Exercise programmes varied: aerobic training, resistance or concurrent training, breathing exercises, strength-based exercises, pilates, yoga disciplines and telerehabilitation; one study used continuous aerobic training at 50% of workload. Durations included a 2-week protocol and an 8-week protocol. Comparators included usual care, waitlist, no intervention, general guidance, another exercise setting or another exercise delivery. Outcomes were HRQoL and functional fitness. Some trials reported significant HRQoL improvements (Refs. [30,39,46]) and positive SF-12 physical and mental components (Refs. [27,29,35]). Ref. [32] found no significant quality-of-life change between supervision by a general or specialized physiotherapist, though the SF-12 physical component changed. Ref. [33] found virtual reality was not superior to traditional methods. Ref. [31]’s 2-week breathing- and strength-based protocol and Ref. [41]’s 8-week breathing, pilates and yoga protocol were described for respiratory function. Overall dropout rates were below 37%; treatment-attributed harms were not reported. The authors state limits include heterogeneity of protocols and non-comparable frequency, duration, and modality.

  93. Effect of pulmonary rehabilitation for patients with long COVID-19: a systematic review and meta-analysis of randomized controlled trials.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether pulmonary rehabilitation affects adults with long COVID-19. The authors searched randomized controlled trials published before April 2024 and included 37 studies with 3363 patients. Pulmonary rehabilitation was compared with controls receiving usual care, no treatment, educational material, a sham device, or unsupervised rehabilitation. Programs were grouped by duration (≤4, 4–8, and >8 weeks) and by exercise type (breathing, multicomponent, or both). Outcomes included 6MWT, lung function (FEV1, FVC, MIP, MEP), HRQoL, fatigue, 30STST, handgrip, dyspnea, depression, anxiety, perceived effort, and adverse events. The review reports improvement in 6MWT with a mean difference of 77.95 m (95% CI 50.91–104.99 m), and improvements in 30STST, handgrip, lung function, HRQoL, fatigue, dyspnea, and anxiety, but no effect on depression was detected. Subgroups: ≤4 weeks improved 6MWT but not FEV1, FVC, HRQoL, or fatigue; 4–8 weeks improved 6MWT, FEV1, FVC, HRQoL, and fatigue; >8 weeks improved HRQoL and fatigue but no additional 6MWT, FEV1, or FVC. Breathing exercises improved 6MWT, lung function, and HRQoL without fatigue effect; multicomponent exercises improved 6MWT and fatigue without lung function or HRQoL effects; combined exercises improved 6MWT, FEV1, FVC, HRQoL, and fatigue. Adverse events were reported in 16 RCTs: nine found none in either group; two reported events in both groups; one reported minor oxygen desaturations in the intervention group; three reported control-group events; one reported reinfection without specifying group. GRADE certainty was low to moderate, and the authors state bias may have overestimated outcomes.

  94. The effect of pulmonary rehabilitation for post-acute sequelae of SARS-CoV-2 infection in patients: a systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis examined pulmonary rehabilitation for adults with post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. Ten randomized controlled trials involving 673 participants were included; trials were identified through a search of PubMed, Embase, Web of Science, and the Cochrane Library. Pulmonary rehabilitation was compared with usual care, no treatment, educational materials, or a sham device, and duration varied across trials. Outcomes included six-minute walk distance, dyspnea, fatigue, quality of life, and maximal inspiratory pressure. Compared with usual care, pulmonary rehabilitation improved six-minute walk distance (mean difference 76.85 meters; 95% CI 57.35–96.36; p < 0.001), maximal inspiratory pressure (mean difference 17.63 cmH2O; 95% CI 4.50–30.76; p = 0.009), fatigue (SMD −1.15; 95% CI −1.83 to −0.48; p < 0.001), and quality of life (SMD 1.73; 95% CI 0.55–2.91; p = 0.004). The pooled dyspnea result favored pulmonary rehabilitation but was not statistically significant (mean difference −0.41; 95% CI −1.51 to 0.68; p = 0.46). Subgroup analyses found no statistically significant differences between telerehabilitation and face-to-face pulmonary rehabilitation for exercise capacity (p = 0.84), dyspnea (p = 0.86), fatigue (p = 0.93), or quality of life (p = 0.44). The review did not report counts of participants who stopped or side effects; it noted that patients with post-exertional symptom exacerbation may not benefit from traditional aerobic-based pulmonary rehabilitation and may even deteriorate. The authors state limitations include substantial heterogeneity, limited eligible RCTs and small sample sizes, possible missed studies, and lack of long-term follow-up.

  95. Psychotherapy in patients with long/post-COVID - A systematic review on the feasibility, acceptability, safety, and efficacy of available and emerging interventions.2025 · systematic review
    Summary

    This systematic review asked whether psychotherapy for long/post-COVID has been studied and what is known about feasibility, acceptability, safety, and efficacy. It searched PubMed, PsycInfo, and Web of Science on February 8, 2024 and included 12 studies of people with long/post-COVID; reported sample sizes in the recorded data include 16, 30, 33, 44, 51, 57 per group, 63, 64, 123, and 224. Treatments were psychotherapy, mostly CBT-based, often delivered within multimodal rehabilitation; one RCT compared CBT for post-COVID fatigue with care as usual. The recorded data do not state treatment durations. Outcomes included fatigue, pain, dyspnea, anxiety, depression, quality of life, cognitive symptoms, and physical functioning. Many pre-post improvements were reported. In the RCT, between-group differences favored CBT for fatigue, physical functioning, somatic symptoms, social functioning, and concentration problems at T1 and T2 (Cohen’s d=0.74 at post-treatment; Cohen’s d = 0.65 at six-month follow-up). Some findings were not significant: Hasting et al. reported no significant improvement in fatigue or sleepiness; Huth et al. reported no significant improvement in somatic symptom distress, depression, anxiety, or psychobehavioral features; Hayden et al. found no significant improvement in pain or anxiety at 6-month follow-up. García-Molina et al. reported poorer performance at 6-month follow-up in the intervention group. Harms included adverse events in Huth et al. (85.4%; severe 29.3%) and Kuut et al. (8 during CBT; 20 during care as usual; no serious adverse events); Compagno et al. reported no adverse cardiovascular events or clinical complications, and Fontana et al. reported no adverse events. Dropouts included 20.3% in Huth et al., 13 % in Kuut et al., twelve in Páez et al., 3 in Hayden et al., and two in Hasting et al.

  96. Identifying Factors That Might Affect Outcomes of Exercise-Based Therapies in Long-COVID.2024 · systematic review
    Summary

    This systematic review examined exercise-based therapies for people with Long-COVID; it included 39 studies. The search was performed from 13 February 2024 to 27 February 2024 in Pubmed, PEDro, BioMed Central, EBSCOhost, ProQuest and the ZBSport. Treatments included supervised exercise training and programs combining physical training with respiratory training, pacing or physiotherapy; some combined programs lasted >5 weeks with three individualized sessions per week. The review reports no comparison group. Outcomes covered Long-COVID symptoms, quality of life, physical fitness and pulmonary parameters. In one named study (Binetti et al.), a 3-month protocol showed no significant improvements in Long-COVID symptoms or physical fitness. Adverse events were documented in 16 studies: no adverse events were identified in 12/16 studies, and 4/16 studies reported adverse events related to the intervention. One study recorded 6–9% adverse events and 2–5% serious adverse events in the intervention and usual care groups; 21 serious adverse events and 19 admissions to hospital or prolongation of admission were reported, and one serious adverse event (syncope with vomiting 24 h after training) was possibly related to the intervention. Intervention-related adverse events included unilateral knee pain, severe anxiety before the session and headache. In a pacing study, four patients were unable to comply with guidance. There were no cases of exacerbation of symptoms after exercise during weekly monitoring. The authors state that comparison was difficult because the same parameters were examined using a wide variety of measurement methods.

  97. Effectiveness of telerehabilitation versus face-to-face pulmonary rehabilitation on physical function and quality of life in people with post COVID-19 condition: a systematic review and network meta-analysis.2024 · systematic review
    Summary

    This systematic review and network meta-analysis asked whether pulmonary rehabilitation delivered face-to-face or by telerehabilitation improves physical function and quality of life in adults with post COVID-19 condition compared with usual care. The authors searched PubMed, Cochrane Library, and Web of Science from 2020 to January 5th, 2024, and included 10 studies with 765 adults diagnosed with PCC. Interventions were exercise-based pulmonary rehabilitation delivered face-to-face or by telerehabilitation; comparators were usual care, described as education, no intervention, or waitlist. Outcomes were physical function and quality of life in physical and mental domains. In the multivariate network meta-analysis, moderate quality evidence found face-to-face rehabilitation superior to usual care or telerehabilitation for all outcomes. In univariate analyses, moderate quality evidence found telerehabilitation superior to usual care for physical function and the mental domain of quality of life; low quality evidence found face-to-face rehabilitation superior to usual care and telerehabilitation for physical function and the mental domain. For the physical domain of quality of life, telerehabilitation versus usual care showed no significant differences. No side effects or withdrawals were recorded in the extracted data. The authors state limitations including small sample sizes, no long-term follow-up, and varying definitions of usual care.

  98. Effectiveness of pulmonary rehabilitation programmes and/or respiratory muscle training in patients with post-COVID conditions: a systematic review.2024 · systematic review
    Summary

    This systematic review asked whether pulmonary rehabilitation programmes and/or respiratory muscle training affect respiratory sequelae in people with post-COVID-19 condition. The authors searched PubMed, PEDro, Embase, Cochrane, Scopus, and Web of Science and included five randomized trials with 52, 32, 60, 39, and 80 participants. The trials compared different supervised, non-virtual programmes: diaphragm release plus inspiratory muscle training versus inspiratory muscle training; virtual-reality pulmonary rehabilitation versus traditional pulmonary rehabilitation; aerobic, muscle-strengthening, and respiratory exercise versus the same plus an active cycle of breathing technique; a tailored multicomponent exercise programme versus WHO guidelines; and multicomponent exercise, inspiratory muscle training, both combined, or WHO guidelines. Outcomes included 6-minute walk test distance, dyspnea, fatigue, lung function, maximum inspiratory pressure, and quality of life. Findings varied by trial. For maximum inspiratory pressure, one trial reported an increase of 48.17% (p < 0.001) in the intervention group with no significant change in the control group. For 6-minute walk test distance, one trial reported greater improvement in the intervention group (p < 0.001); another reported improvement in both groups with no significant between-group difference; another reported improvement in both groups (p > 0.001), with Group B improving 21.61% and Group A 11.09%. Dyspnea and fatigue results were mixed across trials. Quality of life improved in one trial (p = 0.003) and showed no significant change in any of four groups in another. Side-effect counts for the included trials were not reported. The authors state that a limited number of trials met the criteria.

  99. An update of the literature about rehabilitation tools used in the treatment of COVID-19-related disabilities: a systematic review of literature.2024 · systematic review
    Summary

    This systematic review aimed to describe the effects of rehabilitation tools used across phases of COVID-19. A literature search of MEDLINE (PubMed), Scopus and Physiotherapy Evidence Database (PEDro) was conducted. The review included 2994 participants: 1225 patients for acute-COVID, 1331 patients for post-COVID, and 438 patients for long-COVID. Of the initial 907 hits, 45 randomized controlled trials were included. The trials studied respiratory rehabilitation alone or with exercises, tele-rehabilitation, endurance training, virtual reality, and electrostimulations in different settings and phases of infection. Outcomes were clinical, quality of life and impairment outcome measures. The text does not report a comparison group, treatment duration, withdrawals, worsening, or side effects for the review. The authors concluded that, despite heterogeneity, different outcome measures and small sample sizes, pulmonary rehabilitation, tele-rehabilitation and low/moderate intensity aerobic and endurance exercises seemed to improve clinical and quality of life outcomes at short (8 weeks) and mean time (2 months) after treatments in all phases of the infection.

  100. The pulmonary rehabilitation effect on long covid-19 syndrome: A systematic review and meta-analysis.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether pulmonary rehabilitation improves dyspnea, fatigue, physical function, quality of life, anxiety and depression in adults with long COVID-19, and compared face-to-face with telerehabilitation. It included 16 studies and 1027 adults; searches covered PubMed, Web of Science, and Cochrane Library to January 2023. Pulmonary rehabilitation was delivered face-to-face or by telerehabilitation, and comparisons included usual care, sham procedures, or no control. Outcomes were dyspnea, physical function, quality of life, anxiety, depression and fatigue. Meta-analysis found significant effects on dyspnea (SMD = 1.29, 95% CI [0.43 to 2.15]; I2 = 93.7%), physical function (SMD = −0.60, 95% CI [−0.96 to −0.25]; I2 = 85.4%), global quality of life (SMD = −1.07, 95% CI [−1.70 to −0.45]; I2 = 94.7%), mental quality of life (SMD = −0.36, 95% CI [−0.53 to −0.19]; I2 = 0%), physical quality of life (SMD = −0.68, 95% CI [−0.95 to −0.41]; I2 = 61.1%), anxiety (SMD = 0.32, 95% CI [0.16 to 0.48]; I2 = 4%) and depression (SMD = 0.37, 95% CI [0.18 to 0.56]; I2 = 16.4%). Fatigue was not significant (SMD = 0.61, 95% CI [−0.10 to 1.32]; I2 = 91%). Face-to-face physical quality of life improved (SMD = −0.91, 95% CI [−1.13 to −0.69]), while telerehabilitation did not (SMD = −0.23, 95% CI [−0.47 to 0.02]). No harms or withdrawals were recorded in the extracted data. The authors state limits including small sample sizes and high risk of bias.

  101. Effects of Exercise Rehabilitation on Cardiorespiratory Fitness in Long-COVID-19 Survivors: A Meta-Analysis.2024 · systematic review
    Summary

    This meta-analysis asked whether exercise rehabilitation improves cardiorespiratory fitness in long-COVID-19 survivors. Twelve eligible studies (five RCTs and seven non-RCTs) with 682 participants were analysed after searches through PubMed, CINAHL, Embase, Scopus and the Cochrane Library to November 2023. All included studies studied combined exercises; programmes were delivered in centre-based, telerehabilitation and home-based settings. In RCTs, exercise rehabilitation was compared with control programmes; non-RCTs were single-group pre-post studies. Outcomes were VO2peak and six-minute walk distance (6MWD). For VO2peak, exercise rehabilitation had a comparable effect to control (SMD 0.26, 95% CI −0.11 to 0.64, I2 0%, two studies), and there was no effect of pre-post changes (mean difference 1.72, 95% CI −2.21 to 5.66, I2 0%, three studies). For 6MWD, the exercise group had a significantly longer distance than control (SMD 0.85, 95% CI 0.11 to 1.59, I2 76.4%, three studies) and a significant pre-post improvement of 76.46 m (mean difference 76.46, 95% CI 59.19 to 93.71, I2 0%, six studies). Subgroup analyses reported improvements in some groups, including aerobic exercise combined with resistance and respiratory exercise and centre-based training. Side effects and withdrawals were not reported in the extracted data. The authors state low to very low certainty, heterogeneity in 6MWD (I2 76.4%), risk of bias, small samples and few studies.

  102. Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
    Summary

    This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.

  103. Effectiveness of Rehabilitation Interventions on Adults With COVID-19 and Post-COVID-19 Condition. A Systematic Review With Meta-analysis.2024 · systematic review
    Summary

    This systematic review with meta-analysis asked whether rehabilitation interventions help adults with COVID-19 or post COVID-19 condition (PCC). It included 40 studies with 2445 participants; patients were adults hospitalized in any setting or discharged at home, with any COVID-19 severity or PCC. Interventions included pulmonary rehabilitation, self-activities, qigong exercise and acupressure rehabilitation program (QARP), yoga and naturopathy, Mandala coloring, cognitive motor training, and FES-cycling. Comparisons were usual care or no intervention. Pooled analyses compared pulmonary rehabilitation with usual care in post COVID-19 patients: exercise capacity favored pulmonary rehabilitation (MD 65.06, 95% CI 42.87 to 87.25; 2 studies, 184 participants); FEV1 favored pulmonary rehabilitation (MD 0.16, 95% CI 0.05 to 0.28; 2 studies, 179 participants); FEV1/FVC favored pulmonary rehabilitation (MD 0.05, 95% CI 0.01 to 0.09; 2 studies, 174 participants); FVC showed no effect (MD 0.19, 95% CI -0.03 to 0.42; 2 studies, 179 participants). Self-activities plus usual care compared with usual care showed an anxiety effect (MD -12.03, 95% CI -21.16 to -2.90; 2 studies, 207 participants). Narrative findings said QARP and “twist and raise” walking technique seem to reduce dyspnea and weakness; yoga and naturopathy, Mandala coloring, and respiratory exercise seem to reduce anxiety and depression; cognitive motor training seems to improve cognitive function; FES-cycling seems useful for erect position restoration and walking capacity. Li 2022 reported no serious adverse events; another study reported headache and dizziness events but no significant difference between groups. Worsening or stopping was not reported. The authors state very uncertain evidence and very low certainty.

  104. The effectiveness of exercise in alleviating long COVID symptoms: A systematic review and meta-analysis.2024 · systematic review
    Summary

    This systematic review and meta-analysis examined exercise interventions for long COVID symptoms. Nine studies involving 672 individuals were included; trials were based in eight countries, mainly in Europe and the Western Middle East. The included RCTs compared exercise with active or passive controls such as usual care, waitlist, exercise education, and sham respiratory devices. Exercise types included supervised combined aerobic and resistance exercise, aerobic exercise, multimodal exercise, breathing exercise, inspiratory muscle training, and Taichi, with printed durations such as 2-week, 5-week, 6-week, 8-week, 10-week, and 12-week. Outcomes were fatigue, dyspnea, anxiety, depression, and cognitive impairment. Exercise significantly improved long COVID fatigue (ES = 0.89, 95% CI: 0.27 to 1.50) and dyspnea (ES = 1.21, 95% CI [0.33, 2.09]), whereas no significant effect was identified on long COVID anxiety, depression, and cognitive impairment. Reported harms included symptom exacerbation in the sham group (One person/88) and dizziness (One minor/150); withdrawals included 57/148 and 21 dropouts. The authors state most included studies used subjective measurements and were at high risk of bias, and long-term effects remain unknown.

  105. Effectiveness of telerehabilitation in patients with post-COVID-19: a systematic review and meta-analysis of randomised controlled trials.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether telerehabilitation helps patients with post-COVID-19. It included 16 RCTs with 1129 participants; 15 RCTs with 1095 participants and 16 comparisons entered the meta-analysis. Telerehabilitation was delivered at home and included breathing exercises, exercise programmes, cognitive behavioural therapy and muscle training, with durations such as 6, 8 or 17 weeks. Comparators were no rehabilitation, usual care, educational material or sham training. Outcomes covered clinical symptoms, physical function, pulmonary function, psychological function, quality of life and harms. Pooled analyses found improvements in physical function. The pooled results did not show significant improvements in clinical symptoms, pulmonary function, psychological function or quality of life. Some individual trials reported improvements in quality-of-life or symptom measures. The overall treatment completion rate was 78.26% (1073 cases), with 557 cases in the experimental group and 516 in the control group. Adverse events included eight hospitalisations unrelated to treatment in Li et al, eight adverse events during cognitive-behavioural therapy and 20 during usual care in Kuut et al, one symptom exacerbation in the control group in Corral et al, and one withdrawal due to dizziness in Philip et al.

  106. Effects of rehabilitation interventions for old adults with long COVID: A systematic review and meta-analysis of randomised controlled trials.2024 · systematic review
    Summary

    This systematic review and meta-analysis examined rehabilitation interventions for old adults with long COVID. It searched PubMed, EMBASE, Web of Science, Scopus, and Cochrane Library databases to 15 November 2023 and included 11 RCTs involving 832 participants (64.37 ± 7.94 years; 52.2% were men) with a mean/median age of 60 or older. Rehabilitation interventions included exercise training and respiratory rehabilitation; duration was not reported. They were compared with control groups (usual/standard care/placebo). Outcomes included 6 MWT, 30 seconds STS, HGS, FEV1/FVC, fatigue, quality of life, independence in activities of daily living, depression, and anxiety. Compared with controls, the review reported improvement in 6 MWT (MD = 15.77 m, 95% CI = 5.40, 26.13, P < 0.01), 30 seconds STS (MD = 4.11 n, 95% CI = 2.46, 5.76, P < 0.001), fatigue (SMD = −0.66, 95% CI = −1.13, −0.19, P < 0.01), independence in activities of daily living (SMD = 0.31, 95% CI = 0.13, 0.48, P < 0.001), depression (SMD = −0.89, 95% CI = −1.76, −0.02, P < 0.05), anxiety (SMD = −0.81, 95% CI = −1.58, −0.05, P < 0.05), and all SF-36 quality-of-life domains. HGS was not significant (MD = 1.67 kg, 95% CI = −0.84, 4.18, P > 0.05), and FEV1/FVC was not significant (MD = 3.45%, 95% CI = −1.43%, 8.33%, P > 0.05). Side effects and withdrawals were not reported.

  107. A Systematic Review of Telemedicine-Driven Pulmonary Rehabilitation after the Acute Phase of COVID-19.2023 · systematic review
    Summary

    This systematic review evaluated telemedicine-driven pulmonary rehabilitation in post-acute COVID-19. Seven studies published between 2021 and 2022, involving a total of 412 patients, were included after a search across PubMed, Web of Science, Cochrane, and Scopus up until April 2023. The review reported telerehabilitation programs; duration was not recorded in the supplied data. Findings were reported across included studies, some comparing telerehabilitation with control groups or hospitalized groups. Outcomes included physical health (VAS fatigue score, VAS pain score, 6MWD), mental health (SF-36 and SF-12 mental domains), quality of life (SF-36 and SF-12 total scores), and pulmonary function (mMRC, STST, VAS dyspnea). Some studies reported significant improvements, for example 6MWD in the telerehabilitation group compared to controls (p < 0.001) and SF-12 mental domain scores (p < 0.001). Martin et al. found no significant difference in VAS dyspnea scores between telerehabilitation and control groups (p = 0.966) but a significant difference in STST change (p = 0.004). Dalbosco-Salas et al. reported a higher pain score after telerehabilitation compared with hospitalized patients (p < 0.001). Numbers who worsened or stopped were not reported. The authors conclude that telemedicine-driven pulmonary rehabilitation can have beneficial effects on physical and mental health, quality of life, and pulmonary function, but state limitations including heterogeneity, a relatively small number of included studies, and need for caution due to population and severity differences.

  108. Rehabilitation Interventions for Physical Capacity and Quality of Life in Adults With Post-COVID-19 Condition: A Systematic Review and Meta-Analysis.2023 · systematic review
    Summary

    This systematic review with bayesian meta-analysis searched MEDLINE, Scopus, CINAHL, and the Clinical Trials Registry from January 2020 until February 2023 and included 14 trials (1244 patients; 45% female participants; median [IQR] age, 50 [47 to 56] years) with post–COVID-19 condition. It examined respiratory training and exercise-based rehabilitation interventions against placebo, usual care, waiting list, or control. The median follow-up for the primary outcome was 6 (5.5-7.0) weeks. For functional exercise capacity (6-minute walking test; 7 trials, 389 participants), the pooled SMD was −0.56 (95% CrI, −0.87 to −0.22). For lower limb muscle function (4 trials, 371 participants), the SMD was −0.77 (95% CrI, −1.94 to 0.44), with uncertain magnitude and direction. Dyspnea (8 trials, 573 participants) had SMD −1.00 (95% CrI, −1.94 to −0.10). FEV1 (6 trials, 363 participants) showed no difference: SMD −0.16 (95% CrI, −0.42 to 0.11); FVC showed no difference: SMD −0.13 (95% CrI, −0.38 to 0.12). Overall quality of life (5 trials, 366 participants) had SMD −0.41 (95% CrI, −0.73 to −0.06). Adverse events: OR 1.68 (95% CrI, 0.32 to 9.94); Five trials gave no adverse-event information, four trials (5 records) reported no related adverse events, and adverse events were reported in 5 trials. Fatigue evidence was limited and could not be synthesized. Worsening or stopping was not reported.

  109. Non-Pharmacological Therapies for Post-Viral Syndromes, Including Long COVID: A Systematic Review.2023 · systematic review
    Summary

    This systematic review asked whether non-pharmacological treatments help post-viral syndromes (PVS), including Long COVID. It included five RCTs of five different interventions (Pilates, music therapy, telerehabilitation, resistance exercise, neuromodulation). Studies came from China (n = 1), Norway (n = 1) and Brazil (n = 3); four RCTs enrolled adults and one enrolled children and young people aged 12–20 years. Conditions were PVS after SARS-CoV-2, EBV or Chikungunya virus. Comparators were control, care as usual, usual treatment or sham tDCS. In the 6-week telerehabilitation trial, 6MWD increased by 17.1 m (SD 63.9) in controls and 80.2 m (SD 74.7) with telerehabilitation; the adjusted between-group difference was 65.5 m (95% CI 43.8 to 87.1; p < 0.001). There were no improvements in spirometry-measured pulmonary function or mental health components of the SF-12, and dyspnoea improvement was not statistically significantly different at 28 weeks. At 12 weeks follow-up, resistance exercise improved the 30-s CST (p = 0.04, d = 0.39) but not FPWT, 4SCPT or DASH; 70% reported PGIC improvement in the intervention arm only. Pilates improved pain intensity (relative risk 0.48, 95% CI 0.28–0.82; number needed to treat two patients, 95% CI 7–2) and all secondary outcomes. Active tDCS and sham did not differ substantially on VAS at four time points; pain decreased over time only with active tDCS (p < 0.05). Music therapy plus CBT showed no statistically significant differences in any outcome. No side-effect or withdrawal counts were recorded.

  110. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic Review and Meta-Analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis asked whether pulmonary rehabilitation affects dyspnea, physical function, quality of life, psychological state, and fatigue in adults with subacute and long COVID-19. The authors searched PubMed, Web of Science, and Cochrane Library from inception to January 2023. Thirty-four studies were included, involving 1970 patients with subacute and long COVID-19. Pulmonary rehabilitation was compared with usual care in randomized controlled trials and was also examined in observational studies. In the randomized controlled trials, the meta-analysis reported a large effect on dyspnea (Hedge’s g = −1.12 [−1.813, −0.427]), a moderate effect on physical function (Hedge’s g = 0.771 [0.363, 1.178]), a large effect on quality of life (Hedge’s g = 1.6 [0.266, 2.934]), and a moderate effect on depression (Hedge’s g = −0.295 [−0.446, −0.145]). It reported no significant effects on anxiety or fatigue. In observational studies, it reported improvement in quality of life (Mean = 12.916 [4.438, 21.395]) and a decrease in perceived fatigue (Mean = −1.701 [−1.778, −1.624]), with no significant changes in dyspnea, physical function, anxiety, or depression. Harms, withdrawals, and worsening were not reported. The authors state that pulmonary rehabilitation has the potential to improve health outcomes, but conclusions should be taken with caution due to the high risk of bias of included studies.

  111. Long COVID and Physical Therapy: A Systematic Review.2023 · systematic review
    Summary

    The review searched Scopus, PubMed, Cinahl and WOS and included six studies of adults with long COVID or a post-COVID-19 condition. It aimed to analyse treatment programmes for long COVID based on physical activity. Interventions included inspiratory muscle training, pulmonary tele-rehabilitation, multicomponent exercise, resistance and aerobic training, and an online breathing and well-being programme. Durations reported were 12 weeks for a home inspiratory muscle training programme, 6 weeks for pulmonary tele-rehabilitation, 8 weeks in two exercise studies, 6 weeks for the online programme, and eight weeks for inspiratory muscle training. Study sizes were 26, 30, 80, 39, 192 and 281 participants. The review states that all studies except McNarry’s had statistically significant results, with the intervention group showing statistically significant results compared with control groups. Drop-outs were reported for personal reasons, difficulty attending and deterioration; no counts were given. The authors conclude that these investigations support the hypothesis that physical activity interventions may have positive effects on post-COVID recovery. They state limitations from sample sizes, potential for bias, inadequate control of confounding variables and even the cross-sectional approach.

  112. Efficacy and Safety of Respiratory Telerehabilitation in Patients with Long COVID-19: A Systematic Review and Meta-Analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis asked whether respiratory telerehabilitation helps adults with Long COVID-19. The authors searched MEDLINE, Scopus and PEDro from database inception until July 2023 and included 10 randomized controlled trials, with 866 patients with Long COVID-19. Trials compared respiratory telerehabilitation with no intervention, usual care, placebo, or face-to-face intervention. The review pooled quality of life, dyspnea, lung function, anxiety and depression, respiratory muscle strength, functional capacity, lower limb strength and adverse events. The meta-analysis reported significant differences in favour of respiratory telerehabilitation for quality of life (SMD = 0.59; 95% CI = 0.09; 1.09; p = 0.02), dyspnea (SMD = 4.95; 95% CI = 2.81; 7.08; p < 0.00001), respiratory muscle strength (MD = 13.71; 95% CI = 5.41; 22; p < 0.001), functional capacity (SMD = 0.75; 95% CI = 0.39; 1.11; p < 0.0001), and lower limb strength (SMD = 0.67; 95% CI = 0.15; 1.18; p = 0.01). It reported non-significant differences for FVC (MD = 0.21; 95% CI = −0.17; 0.60; p = 0.28) and anxiety and depression (SDM = −0.05; 95% CI = −0.23; 0.12; p = 0.55). For adverse events, the difference between groups was not statistically significant (OR = 0.53; 95% CI = 0.27; 1.02; p = 0.06).

  113. Tele-Rehabilitation Interventions for Motor Symptoms in COVID-19 Patients: A Narrative Review.2023 · systematic review
    Summary

    This narrative review searched the literature in December 2022 for studies published during 2020–2022 on remote motor tele-rehabilitation for paucisymptomatic acute and post-acute COVID-19 patients. The number of patients enrolled or analysed is not reported. The reviewed programs used tele-rehabilitation, including strength-based and breathing-based programs in a study; durations and delivery modes varied across the included studies. Outcomes included the short performance physical battery (SPPB), timed up and go (TUG) test, physical capacity, and clinical improvement. The review reports that Estebanez-Perez et al. and Kortianu et al. found SPPB parameters increased from baseline, indicating improvement in observed functional abilities. For Estebanez-Perez et al., no baseline inter-group differences were found, but changes in physical capacity were more significant in the hospitalized group. Pehlivan et al. reported positive developments on the TUG test but no significant differences in SPPB score. Rodriguez-Blanco et al. reported clinical improvements in both strength-based and breathing-based groups. The review notes dropout rates between 10 and 32%. The authors state limitations including absence of a control group, limited follow-up, exclusion of severe dyspnea, unclear prior rehabilitation, age and technology selection, and home-based assessment.

  114. Rehabilitation and COVID-19: systematic review by Cochrane Rehabilitation.2023 · systematic review
    Summary

    This systematic review asked what evidence exists on interventions for rehabilitation for COVID-19-related limitations of functioning in adults with COVID-19 or post COVID-19 condition (PCC). It included 53 RCTs with 3882 randomized participants; included adults were hospitalized or managed at home, and the review covered non-severe, severe, critical COVID-19 and PCC. Interventions were compared with usual care, sham/placebo, no treatment, or another active intervention; duration was not reported. Outcomes covered body functions, activities and participation, quality of life, and adverse events. The review synthesized evidence narratively. It reports that the effect of breathing and strengthening exercise programs on dyspnea and physical exercise capacity compared to no treatment in non-severe COVID-19 patients is uncertain. Multicomponent telerehabilitation may slightly increase physical exercise capacity compared to educational intervention in adults with PCC, but uncertainty remains about its effect on lung function and physical exercise capacity compared to no treatment; it reported no evidence of an effect on FVC and FEV1/FVC% for multicomponent telerehabilitation compared to no treatment in PCC. The effect of inspiratory muscle training on maximal inspiratory pressure compared to no treatment in adults with PCC is uncertain. For harms, four grouped studies and fourteen studies reported no adverse events; five and three mild adverse events (transient skin redness) occurred in active HD-tDCS and sham groups, respectively; one person in the sham group presented symptom exacerbation; olfactory training had two (0.8%) headache reports and one (0.4%) worsening parosmia report. The authors state they cannot provide robust suggestions for practice.

  115. Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
    Summary

    This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.

  116. Telerehabilitation improves physical function and reduces dyspnoea in people with COVID-19 and post-COVID-19 conditions: a systematic review.2022 · systematic review
    Summary

    This systematic review examined telerehabilitation for people with COVID-19 and post-COVID-19 conditions, including six trials with 323 participants. Breathing exercises delivered via telerehabilitation were compared with no intervention; in pooled data from two studies (89 participants), 6-minute walk distance was MD 101 m higher (95% CI 61 to 141), 30-second sit-to-stand performance was MD 2.2 repetitions higher (95% CI 1.5 to 2.8), Multidimensional Dyspnoea-12 scores were MD 6 lower (95% CI 7 lower to 5 lower), and Borg perceived effort was MD 2.8 lower (95% CI 3.3 lower to 2.3 lower), with low certainty. Exercise delivered via telerehabilitation compared with no exercise improved 6-minute walk distance (MD 62 m, 95% CI 42 to 82; four studies), 30-second sit-to-stand performance (MD 2.0 repetitions, 95% CI 1.3 to 2.7; two studies) and Multidimensional Dyspnoea-12 scores (MD 1.8 lower, 95% CI 2.5 lower to 1.1 lower; one study), with low certainty. Among 174 adverse events, 78 were in the control group and 96 were in the telerehabilitation group; median events per participant were 0 in both groups. One participant reported a problem with the telerehabilitation device, which could not be resolved, and decided not to participate. The authors state that the small number of studies and the different forms of telerehabilitation, with few participants, impose limitations on the strength of the evidence.

  117. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis.2022 · systematic review
    Summary

    This systematic review and meta-analysis asked why post-COVID breathlessness occurs, who is affected, and which treatments have been studied. It searched PubMed and Embase for papers published from 1 January 2020 to 1 November 2021 and included 119 eligible papers. In the prevalence meta-analysis, 102 papers with a total of 42 872 COVID-19 survivors were synthesised; mean/median follow-up ranged from 1–12 months. Pooled prevalence was 26% (95% CI 23–29) when presence/absence was measured directly, 41% (95% CI 34–48) with MRC/mMRC scale, and 51% (95% CI 42–60) with other scales. Hospitalised patients had 27% versus 17% in nonhospitalised; 1–6 months was 28% versus 20% at 7–12 months. For treatments, one RCT in Iran (55 outpatients with mild COVID-19) reported persistent dyspnoea 15% versus 42%, p=0.035 for sofosbuvir/daclatasvir plus hydroxychloroquine versus hydroxychloroquine alone. One RCT in China (120 formerly hospitalised survivors with residual dyspnoea) reported lower mMRC dyspnoea level immediately after a 6-week home-based telerehabilitation programme (p=0.001) but not at 28-week follow-up. Seven observational studies suggested rehabilitation exercises were associated with reduced persistent breathlessness; a small observational study reported Pycnogenol-Centellicum supplementation was associated with improved breathlessness. Side effects and withdrawals were not reported. The authors state substantial between-study heterogeneity and limited evidence precluded quantitative treatment syntheses.

  118. Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis.2022 · systematic review
    Summary

    The review asked whether pulmonary rehabilitation affects post-COVID-19. It included 3 studies with 233 patients. Interventions were respiratory rehabilitation versus no care, IMT+IBE versus IBE, and TERECO+education versus education. Comparisons were reported at 6 weeks for Liu and Li and at 2 weeks for Abodonya. Outcomes included 6-MWT, pulmonary function, dyspnea, quality of life, activities of daily living, anxiety and depression. Liu reported a longer 6-MWT distance with respiratory rehabilitation than no care at 6 weeks (212.3 ± 82.5 vs. 157.2 ± 71.7; p < 0.05) and a between-group change difference of 48.1 (95%CI 8.89 to 87.31). Abodonya reported a significant between-group change in 6-MWT at 2 weeks (38.8, 95%CI 13.97 to 63.63). Li reported a significant between-group change in 6-MWT at 6 weeks (65.45, 95%CI 43.80 to 87.10; p < 0.001). No significant difference was found for Liu FIM (p > 0.05) or SDS (p > 0.05), and Li mental component (2.18, 95% CI 0.54 to 4.90; p = 0.116). No severe adverse event was reported by the three studies; Li did not find any serious adverse events, and the other two studies did not report on adverse events.

  119. Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review.2022 · systematic review
    Summary

    This systematic review asked whether rehabilitation interventions help adults with post-acute COVID-19 syndrome (PACS). The authors searched MEDLINE, Embase, Cochrane Register of Controlled Trials, CINHAL, Scopus, Prospero, PEDro and the International Clinical Trials Registry Platform up to November 2021 and included five RCTs with 512 participants (aged 49.2–69.4 years, 65% males). Trials tested exercise-based rehabilitation, including home-based exercise and an unsupervised six-week home-based pulmonary rehabilitation program, respiratory physiotherapy, breathing exercises with bhastrika pranayama versus incentive spirometry, and low- versus high-intensity aerobic training, compared with no or minimal rehabilitation or another active intervention. Outcomes included measures of symptoms, function, quality of life and independence. Rehabilitation seemed to improve dyspnea, anxiety and kinesiophobia; pulmonary function results were inconsistent; improvements were detected in muscle strength, walking capacity, sit-to-stand performance and quality of life. One trial found no significant difference in FIM independence, and one failed to show differences in lung function. A dyspnea gain was not maintained at medium- or long-term follow-up. In one trial, 174 adverse events occurred, with no serious adverse event; during follow-up eight individuals (7.62%), five in the experimental group and three in the control group, were hospitalized for non-life-threatening events, none associated with COVID-19 or the experimental intervention. Attrition ranged from 0% to 32.1%, with mean final attrition of 12% of baseline enrollment. The authors state that heterogeneous outcome measures and missing data prevented a meta-analysis.

  120. Mapping the occupational therapy process in response to COVID-19 and long COVID: A scoping review.2026 · review
    Summary

    This scoping review asked what occupational therapy process was reported for people with COVID or long COVID; no ME/CFS was mentioned. Three databases were searched for papers published 2020–2023 in English, Portuguese or Spanish. From 455 texts, 25 studies were selected, spanning children to older adults and settings from intensive care to community and telehealth; inpatient hospital units were most frequent. The review mapped evaluation, intervention and outcomes. Standardised assessments covered occupational history, activity limitations, body functions, cognition and emotional regulation; interventions were educational, compensatory, restorative or acquisitional. Findings were reported study by study; intervention duration was not reported. Jung et al. reported time-use occupational therapy was greater than control for occupational balance, QoL and mental health, p < 0.001. Rodrigues et al. reported experimental and control groups both had less fatigue and anxiety; the experimental group also had more well-being and less shortness of breath, ES small to medium. Trzmiel et al. and Zasadzka et al. reported both groups improved significantly but no difference between groups. Pre–post and cohort reports included less depression with online CBT; less dyspnoea and more QoL/endurance with telerehabilitation; 75% had more function; 86% were discharged from hospital; and 56 of 122 (46%) were fully rehabilitated. Case studies reported better ADL, mobility, strength, problem-solving, sleep, fatigue management or return to work; a case study reported no difference in leisure. No harms were recorded.

  121. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

  122. Exercise and Cardiovascular Risk Modulation in Post-COVID Syndrome.2026 · review
    Summary

    This narrative review asked how exercise might modify cardiovascular risk in post-COVID syndrome (PASC). It searched PubMed/MEDLINE, Embase, Scopus and Web of Science for publications from January 2020 through March 2026; no overall number of included studies or participants was reported. The review summarized exercise studies in people with post-COVID syndrome or COVID-19 survivors. Interventions included aerobic, resistance, combined, respiratory, supervised endurance and concurrent training, compared with non-exercise, usual care, or unsupervised home-based groups. Durations included 8 weeks, a 12-week supervised program. Du et al. included 33 randomized controlled trials and 2,895 participants; Tartibian et al. included 296 COVID-19 survivors aged 20–93 years; Ferrari et al. analyzed 1,171 participants from eighteen RCTs; one prospective trial had 24 patients. Reported findings included improved functional capacity, dyspnea and quality of life; increased VO₂peak and reduced fatigue; improved functional capacity and muscle strength, with low to very low certainty; and reductions in CRP and pro-inflammatory chemokines. Effects on quality of life and cardiopulmonary efficiency outcomes were less consistent. The review stated the evidence does not yet demonstrate that exercise reverses accelerated vascular aging or reduces major adverse cardiovascular events. It reported no side-effect counts and stated post-exertional symptom exacerbation should be monitored for 24–48 h post-exercise. No counts of people who worsened or stopped were reported.

  123. Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.2025 · review
    Summary

    This scoping review asked which interventions may support return-to-work (RTW) or work ability in people living with Long COVID. The authors searched five electronic databases and grey literature up to January 3, 2025, and included 19 intervention studies and 12 clinical practice guidelines; study designs included cohort, quasi-experimental, observational, interventional, RCT and case-report designs. No comparison group was analysed. Interventions included multimodal and interdisciplinary work-focused rehabilitation, psychoeducation, pacing, breathing strategies, cognitive rehabilitation and workplace RTW planning, plus enhanced external counterpulsation, CICT and pulsed electromagnetic field therapy. Reported durations included a 3-day concentrated program, a 36-hour CICT intervention, and follow-up at six months and one-year. Findings varied: some studies reported improvement in workability, sick leave, fatigue, functional status, cognitive function or RTW; others reported no RTW improvement (Derksen et al. 2023), no significant overall RTW enhancement with physical conditioning (Hasenoehrl et al. 2023), 72% still unable to RTW after rehabilitation (Muller et al. 2023), and a 2% RTW improvement with a psychotherapy-based inpatient program (Kupferschmitt et al. 2023). The review states that graded exercise is contraindicated for people with PEM and that interventions ignoring PEM risk worsening fatigue.

  124. Creatine and post-viral fatigue syndrome: an update.2025 · review
    Summary

    This narrative review summarizes creatine as a diagnostic and therapeutic target for post-viral fatigue syndrome (PVFS), including post-COVID fatigue and related conditions; setting and participant source are not reported. It lists interventional studies in Table 1, including RCTs, open-label studies and case studies in PVFS and fibromyalgia, with n values including 53, 43, 30, 21, 15, 12, 11, 8 and 1. Printed interventions include creatine monohydrate, guanidinoacetic acid, creatine with breathing exercises, creatine with/without glucose, creatine with polinutrients, psychotopics or existing therapy. Printed doses include 2.4 g/d, 3.0 g/d, 4.0 g/d, 8.0 g/d, 16.0 g/d and 20.0 g/d for 5 days then 5.0 g/d; durations include 4 wks, 6 wks, 8 wks, 10 wks, 2 mos, 3 mos, 4 mos and 6 mos. The table reports “No effects” for one RCT (n=53), “No changes in fatigue and exercise tolerance” for studies with n=12, n=8 and n=15, and “Reduced post-exercise malaise” for an RCT with n=8. A six-month regimen of creatine monohydrate (4 g/day) was reported to show significant improvements in patient- and clinician-reported outcomes and enhanced brain and muscle bioenergetics in 12 patients. A three-month RCT combining creatine (4 g/day) with breathing exercises reduced respiratory discomfort and improved cognitive function in 8 patients. The text reports no side effects or withdrawals. The authors state that small sample sizes, inconsistent dosing and a narrow range of biomarkers limit current trials.

  125. Physiotherapy interventions in post- and long-COVID-19: a scoping review of the literature up to February 2023.2025 · review
    Summary

    This scoping review asked what physiotherapy interventions and treatment parameters have been published for post- and long-COVID-19. The authors searched PubMed, EBSCO, Scopus, Web of Science, Embase, PEDRO, Cochrane and WISO in March 2023 and included 6 studies; they state no published study focusing on long-COVID-19 was identified. The included studies covered respiratory therapy, aerobic training, strength training, and in a study ‘hands-on’ physiotherapy. Comparisons varied: some randomised trials compared training or breathing interventions between groups, while case reports described before-and-after courses. Reports included 60 patients (31 female, 29 male), 52 men, 65 men, 32 patients (20 female, 12 male), and case reports of a 37-year-old woman and a 60-year-old woman. Measured outcomes included fatigue, walking distance, dyspnoea, quality of life, muscle strength, lung function and adverse events. Reported changes included fatigue reduction, for example Nagy study group from 43.36 to 28.68 and control group from 42.47 to 39.77, and walking distance increases, for example Rutkowski VR group from 502 to 558 m and control group from 512 to 552 m. Muscle mass and lung function were reported as unchanged; one case report reported decreased quality of life. The authors state treatment descriptions were often inadequate and the data were summarised descriptively, limiting conclusions about effectiveness.

  126. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  127. Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
    Summary

    This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.

  128. Health care for patients with long COVID: a scoping review.2024 · review
    Summary

    This scoping review examined health care for patients with Long Covid-19. It included 13 studies identified in electronic databases, carried out in several countries and published in English. Included studies reported telerehabilitation with physical exercises, physical exercise interventions, outpatient pulmonary rehabilitation, standard physical therapy, cognitive behavioral therapy with antidepressants and non-benzodiazepine tranquilizers, and supervised concurrent training with or without inspiratory muscle training; an exercise intervention was reported at 8 weeks. Some studies compared supervised therapeutic exercise with a WHO self-management rehabilitation leaflet, physical training rehabilitation with standard physical therapy, and physical exercise with breathing training and controls. Outcomes included physical capacity, quality of life, symptoms, fatigue, dyspnea, and stress, anxiety and depression. The review reports improvements after telerehabilitation in physical capacity, quality of life, fatigue and dyspnea; improvement in fatigue after physical intervention; reduction in dyspnea after 8 weeks of physical exercise; increase in 6-minute walk distance and decrease in dyspnea after outpatient pulmonary rehabilitation; maximum inspiratory mouth pressure increased by 28%; MDP score after physical training rehabilitation was 42% lower than after standard physical therapy; and improvement in stress, anxiety and depression with CBT plus antidepressants and tranquilizers. It also reports that some fatigue and quality of life results did not show significant improvements compared to the control group, and that participants reported relapses when performing physical exercise. No side-effect counts were reported. The authors state the selected studies did not provide specific guidelines and that there is a clear gap in the literature on how to identify and clinically manage people with this condition.

  129. Tailored Physical Activity Interventions for Long COVID: Current Approaches and Benefits-A Narrative Review.2024 · review
    Summary

    This narrative review examined physical activity and exercise for people with long COVID. It included 18 studies identified through PubMed, EBSCO (EDS), and Google Scholar, covering publications from December 2019 to June 2024. The review itself had no comparison group, and intervention duration was not reported. It summarized exercise interventions including aerobic and resistance training, flexibility, balance and pulmonary rehabilitation. Outcomes included long COVID symptoms, fatigue, functional capacity, quality of life, mental well-being, exercise capacity and pulmonary function. Torres et al. case studies reported significant improvements in lung function, cardiorespiratory fitness, endurance capacity and muscle strength after exercise using FITT-VP and CERT. Binetti et al. reported enhanced 6 min walk test results and reduced fatigue with supervised exercise. A systematic review of seven studies reported improvements in muscle strength, functional capacity, fatigue and quality of life. A meta-analysis reported improved 6 min Walk Test, 30 s Sit-to-Stand Test, Timed Up-and-Go test, Forced Vital Capacity and Forced Expiratory Volume. A study comparing HIIT and MIT found both improved mental well-being, with HIIT more beneficial for reducing depression. The review reported few adverse events and emphasized gradual increases to avoid exacerbating symptoms. The authors state limitations including potential biases in study selection, reliance on published literature, and heterogeneity complicating direct comparisons.

  130. Pulmonary Rehabilitation for People With Persistent Symptoms After COVID-19.2024 · review
    Summary

    This narrative review examined pulmonary rehabilitation for adults with long COVID because persistent breathlessness and fatigue reduce functional capacity and resemble chronic respiratory disease. Searches were conducted in February 2023 and updated in November 2023 in PubMed (MEDLINE) and CINAHL. The review reports no number enrolled or analysed and no comparison group. It summarises named studies rather than reporting its own results. In Barbara et al., 50 patients with long-COVID received aerobic exercise training plus strength training; exercise capacity increased from 17.8 mL/kg/min to 20.5 mL/kg/min. Another Barbara et al. trial reported muscle strength increased for all major muscle groups ranging from 16% to 33%. Gobbi et al. reported a 28-day resistance programme combined with aerobic exercise improved skeletal muscle mass regardless of baseline muscle mass (“normal” +10.7% or “low” +8.5%). Nambi et al. found no change in muscle mass in males with long-COVID and sarcopenia despite improved hand grip strength. Daynes et al. reported a cohort of 30 individuals (87% previously hospitalised) with clinically important fatigue improvement and functional capacity improvement in most individuals, with no individuals worsening in both fatigue and functional capacity. Al-Chickanie et al. and Dalbosco-Salas et al. reported fatigue improvement. Side-effect counts were not reported. The authors state PR programmes can provide benefit and support, but there is a lack of evidence for adapted PR programmes with a control group.

  131. Long COVID and rehabilitation.2024 · review
    Summary

    This review examined current knowledge of long COVID and rehabilitation in adults and children. It did not report its own enrolled cohort or setting. It summarized a randomized controlled trial that recruited 39 long COVID patients with mild COVID infection in the acute stage; the intervention group received an 8-week supervised aerobic and resistance exercise program at low to moderate intensity, while the control group undertook general physical activity in line with WHO guidelines, without supervised sessions. The review reports significant between-group differences in changes of exercise capacity, strength, quality of life, dyspnea, fatigue, and depression in favor of the intervention group. Mean VO2max improved by 2.1 ml/kg/min−1 (5.7%, standard deviation 9.2%) in the intervention group, while it remained stationary in the control group. A tendency for a greater proportion of participants in the intervention group to report a symptom-free status was reported (42.1% vs. 16.7%, p = 0.091). Another observational study in 58 patients with persistent symptoms after COVID infection reported an increase of 6-min walking distance by 62.9 ± 48.2 m after a 6-week pulmonary rehabilitation program; about 70% of the participants had an increase greater than the minimal clinically important difference. For telerehabilitation, a limited number of clinical trials with small sample sizes showed it might decrease dyspnea and improve functional capacity, with rates of adverse events similar between patients undergoing telerehabilitation and their controls. The review states that no evidence of the effectiveness of rehabilitation on long COVID has yet been provided by randomized controlled trials.

  132. Pulmonary Rehabilitation for Diseases Other Than COPD.2024 · review
    Summary

    This review asked what the literature says about pulmonary rehabilitation (PR) for non-COPD diagnoses, including PASC/long COVID. The authors searched PubMed from March 2024 to June 2024 using terms for PR and exercise training with condition keywords, filtering for English-language randomized controlled trials, clinical trials, observational trials, meta-analyses, and guidelines. No number of included studies or patients, duration of PR, comparison group, follow-up, harms, or withdrawals was reported. For interstitial lung disease, the review reports significant improvements in exercise capacity, health-related quality of life (HRQoL), and dyspnea, with benefits similar to those seen with COPD; milder disease was said to have more sustained benefits longer term. In asthma, benefit was reported in severe disease, lower exercise activity, elevated body mass index, or comorbid conditions, and breathing exercises can improve breathlessness. In PASC, patients lack benefits in HRQoL measurements, while PR improves performance on the post-COVID-19 functional status scale. In bronchiectasis, benefit was reported when airflow limitation or exacerbations affect symptoms and HRQoL. Stable pulmonary hypertension was reported to improve exertional capacity without change in disease severity. In lung cancer, PR was reported to reduce perioperative complications and preserve fitness during treatment.

  133. [Evidence map on post-acute COVID-19 sequelae and rehabilitation: Update as of July 2022Mapa de evidencia sobre las secuelas y la rehabilitación tras la COVID-19 aguda: versión actualizada en julio del 2022].2023 · review
    Summary

    This evidence map updated a review of interventions for rehabilitation of post-acute COVID-19 sequelae in people who had symptomatic COVID-19 and post-acute sequelae; the population was predominantly adults. The update searched Biblioteca Virtual em Saúde and PubMed and was dated 27 July 2022. It included 32 review studies. Interventions were grouped as multimodal, pharmacological, therapeutic, and complementary therapies; no single treatment duration was reported. There was no comparison group; the map plotted associations between interventions and health outcomes. Effects were classified as positive, potentially positive, inconclusive, not informed, or no effect. The map reported 166 associations; the update analysed 69 associations. Exercise (isolated, multicomponent, or multimodal) had 23 positive effects and four potentially positive effects. Exercise prescription was reported with positive effects for functional exercise capacity, lung function, and quality of life; exercise had positive effects for mental health, dyspnoea, fatigue, exercise capacity, and muscle strength, while depression was not informed and lung function was absent and functional independence inconclusive. Pharmacological and complementary interventions for sensory functions had 15 associations. No study reported negative or potentially negative effects. Worsening, discontinuation, and side-effect counts were not reported. The authors state the literature remains incipient and many included items were protocols.

  134. [The role of the cardiopulmonary exercise test and pulmonary rehabilitation in long COVID-19].2023 · review
    Summary

    This literature review asked how exercise testing and respiratory rehabilitation are used in long COVID, defined as persistent symptoms at 4 weeks after SARS-CoV-2 infection. A systematic search of Google Scholar covered articles published from 2019 to February 2022. The review included studies of rehabilitation after COVID-19; patients were after mild-to-critical infection, and programs included endurance, strength, respiratory physiotherapy, inspiratory muscle training, and telerehabilitation. Comparators were no rehabilitation, other rehabilitation, or non-COVID-19 rehabilitation groups. Outcomes included Barthel index, SPPB, 6-minute walk test (TM6), functional respiratory tests, DLCO, dyspnea, quality of life, anxiety/depression, hyperventilation, and V’O2. In 140 patients, median Barthel rose from 55 to 95 and SPPB from 4.2% to 66.7% predicted. In 28 patients, TM6 improved by +130 m; in another study TM6 improved +205 m versus +93 m. In 22 patients, V’O2 rose from 66% to 91% predicted at 3 months. Some studies found no significant decrease in anxiety/depression, and one found quality of life still decreased with no difference. Telerehabilitation protocols reported absence of adverse events. The authors call for more studies.

  135. Exercise Training in Non-Hospitalized Patients with Post-COVID-19 Syndrome-A Narrative Review.2023 · review
    Summary

    This narrative review summarized seven studies of exercise interventions in adults with post-COVID-19 syndrome (PCS), identified through MEDLINE and Scopus. Interventions included exercise training, pulmonary rehabilitation, digital physiotherapy, and blended community-based rehabilitation; reported program lengths included 6 weeks and 4 weeks. Some trials compared exercise with self-management rehabilitation recommendations or inspiratory muscle training. Outcomes included VO2max/VO2peak, maximal workload, 6MWT, SPPB, DASI, SF-12, EQ-5D-5L, and PCFS. Estimated VO2max increased by 2.1 mL/kg/min in EX and by 2.9 mL/kg/min in CT and 2.5 mL/kg/min in CTRM, with no changes in the control groups. VO2peak improved by 2.4 mL/kg/min; maximal workload by 21.8 W after 6 weeks of pulmonary rehabilitation; 6MWT by 68.9 m and 57.6 m; SPPB by +1.22 points after 4 weeks of digital physiotherapy. DASI and EQ-5D-5L increased. SF-12 physical domain showed a group effect from 35.7 to 47.8, while CT, CTRM, and RM showed pre–post increases without between-group differences; mental health increased in CTRM only from 39.5 to 44.8. PCFS < 2 changed from 3 to 14 with CT. No adverse events were reported. Dropouts were n = 6, n = 4, n = 1, and n = 3 in named studies; reasons included adherence problems, personal issues, injury and sickness, SARS-CoV-2 reinfection and fear of reinfection. Authors state no risk-of-bias and quality assessment was performed; they assume high risk of bias and low quality; heterogeneity was broad.

  136. Digital Interventions for Treating Post-COVID or Long-COVID Symptoms: Scoping Review.2023 · review
    Summary

    This scoping review asked what evidence-based digital interventions exist to help manage physical and mental health in people with post-COVID/long-COVID symptoms. The search took place between May and July 2022 in Proquest, Ebsco, PubMed, PubPsych, and Scopus, and 8 original studies matched inclusion criteria. The studies included adults from Ireland, the United Kingdom, Chile, Greece, China, and Austria; samples were 27 (21 for analyses), 150 (115 completed), 11, 10 (8 at all measurement points), 149 (76 pre-post measurements), 35 (22 completed), 120 (105), and 7. Interventions included online breathing/vocal sessions, telerehabilitation exercise programs, a 7-week online rehabilitation course, a fatigue app, and online peer-support groups. Most studies had no control group; one randomized controlled trial compared intervention with control. Outcomes included breathlessness, fatigue, physical capacity, quality of life, anxiety/depression, and patient experience. Some studies reported improvements in breathlessness, physical capacity, fatigue, pain, anxiety, and some quality-of-life domains; the randomized trial reported 6-min walking distance increases of 17.1 m in the control group and 80.2 m in the intervention group, and 90.4% versus 61.7% dyspnea free without long-term effects. Other outcomes did not improve, including bowel, bladder, concentration, short-term memory, unpleasant dreams, balance, gait speed, and some mental-health domains. Dropouts ranged from 0%-20% in pretest studies to 23%, 37%, 13%, and 49% in other studies. Negative emotions and uncertainty about peer advice were reported.

  137. Rehabilitation of Patients with Post-COVID-19 Syndrome: A Narrative Review.2023 · review
    Summary

    This narrative review asked whether rehabilitation helps people with post-COVID-19 condition. It searched PubMed and Web of Science to October 31, 2022, and included 10 articles; no overall number of participants enrolled or analysed was reported. The reviewed programs included pulmonary rehabilitation, physical exercise, respiratory muscle training, resistance and aerobic training, home-based inspiratory muscle training, tailored multicomponent exercise, and telerehabilitation. Comparisons were usual care, no treatment, WHO rehabilitation guidelines, self-management, or lower- versus higher-intensity aerobic training. Outcomes included FVC, 6MWD, HRQOL, dyspnea, QOL, functional capacity, and adverse events. Reina-Gutiérrez et al. reported predicted FVC increased by 5.5%, 6MWD by 44.55 m, and HRQOL by 3.9 points versus baseline. In McNarry et al. (281 participants), home-based IMT improved K-BILD breathlessness domains, Transition Dyspnea Index, respiratory muscle strength, and estimated aerobic fitness, but no between-group difference was found in K-BILD total score. Jimeno-Almazán et al. (39 participants) reported VO2 max +5.7%, sit-to-stand −22.7%, bench press +6.3%, and half squat +16.9% (P<0.05). Nambi et al. (76 participants) found improvement in both low- and high-intensity groups, with more improvement in the low-intensity group. Huang et al. reported telerehabilitation superiority for dyspnea, limb muscle strength, ambulation capacity, and depression, with no significant difference for anxiety or QOL. Vieira et al. (6 trials, 323 participants) reported improved 6MWDT, 30-s sit-to-stand, Dyspnea-12, and Borg scores. Ahmadi Hekmatikar et al. reported exercise without any adverse events or hospital re-admission, and the review stated no cases of worsening symptoms after rehabilitation.

  138. Cognitive dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation.2023 · review
    Summary

    This Review-Symposium addressed cognitive dysfunction in post-COVID-19 condition (PCC). It was not a randomised study and had no comparison group; enrolled, started and analysed patient numbers are not reported for the review itself. The review describes findings from other studies rather than its own cohort. Manera et al. reported that systemic steroids were associated with improved MMSE scores in a subgroup with COVID-19 and concurrent other infections. A recent preprint study reported that patients with acute COVID-19 who received nirmatrelvir were 26% less likely to develop PCC. In 64 patients with persistent symptoms after COVID-19, a 6-week interdisciplinary individualized pulmonary rehabilitation program was followed by improvement in 6-min walk distance and in the Fatigue Assessment Scale; In another study, a 12-week rehabilitation program was associated with a significant decrease in the proportion of patients reporting a cognitive deficit; the authors note both studies were observational without a control group. A case study reported measurable improvement of microcirculation in the eyes and general PCC symptoms after an aptamer directed to inactivate GPCR autoantibodies. A proof-of-concept study of computerized cognitive training demonstrated potential benefits. Harms reported include exercise increasing fatigue in ME/CFS and systemic exertion intolerance disease, and some patients experiencing severe fatigue and worsened symptoms with intensive cognitive interventions. The authors conclude that evidence specific to COVID-19-related cognitive impairments is limited.

  139. Rehabilitation Strategies for Post-COVID-19 Syndrome: The Role of Physical Therapy in Addressing Long-Term Pulmonary, Musculoskeletal, and Neurological Complications2022 · review
    Summary

    This review examined evidence-based rehabilitation strategies for post-COVID-19 syndrome (long COVID). It does not report the number of patients, where they were treated, or a comparison group; the review itself had no comparison group. The review describes physical therapy approaches including pulmonary rehabilitation, resistance training, flexibility exercises, functional mobility training, balance and cognitive rehabilitation, tele-rehabilitation, and multidisciplinary coordination. Cited programmes included a 12-week aerobic training program and 12-week musculoskeletal rehabilitation programs. Outcomes described included lung function, respiratory discomfort, six-minute walk distance, peak VO2, muscle strength, functional independence, stiffness, pain, risk of falling, postural control, functional mobility scores, and cognitive test scores. The review reports that cited studies found diaphragmatic breathing improved lung function and reduced respiratory discomfort; a 12-week aerobic training program increased six-minute walk distance and peak VO2; resistance training improved muscle strength and functional independence; dynamic stretching decreased stiffness and pain; functional mobility training helped independence and reduced risk of falling; balance exercises increased postural control and decreased risk of falls; a systematic review found 20-30% improved respiratory efficiency; 12-week musculoskeletal rehabilitation programs improved functional mobility scores by 40%; neurological rehabilitation had a 50% reduction in risk of falling and a 30% improvement in cognitive test scores. No side effects or withdrawals were reported for the review. The authors state rehabilitation services are still limited, especially in rural and deprived areas, and that no adequate standardized rehabilitation protocols currently exist for clinicians.

  140. Post-Acute Sequelae of COVID-19: The Potential Role of Exercise Therapy in Treating Patients and Athletes Returning to Play.2022 · review
    Summary

    This review examined exercise therapy for post-acute sequelae of COVID-19 (PASC), also called Long COVID Syndrome (LCS), in patients and athletes returning to play. The authors state they performed a literature search of electronic databases, mainly PubMed, to analyse studies of exercise training and rehabilitation programs after COVID-19. The review reports no own enrolled or analysed participant numbers and no comparison group; it summarises other studies. For post-COVID-19 patients, Daynes et al. was described as a 6-week rehabilitation program including aerobic exercise (walking/treadmill-based), strength training of upper and lower limbs, and educational discussions; the review states it documented improved clinical outcomes of walking capacity and symptoms of fatigue, cognition, and respiratory symptoms. Barbara et al. was described as aerobic and resistance training (8 weeks) in LCS patients, with benefit on cardiorespiratory and musculoskeletal fitness; the review also states LCS patients demonstrated an increase in musculoskeletal fitness after 8 weeks of resistance training. Outcomes mentioned include walking capacity, fatigue, cognition, respiratory symptoms, and cardiorespiratory and musculoskeletal fitness. The recorded data contain no withdrawals, adverse events, or side-effect counts for these studies. The authors state limited research on PASC symptoms among athletes and that recommendations for athletes are not based on solid evidence.

  141. The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature.2022 · review
    Summary

    This rapid review asked whether pulmonary rehabilitation (PR) is clinically effective for post-COVID symptoms. Nine studies were included from MEDLINE, Pubmed, and EMBASE; most were small, experimental or quasi-experimental, including 1 randomized controlled trial (RCT). All study participants had been hospitalized for acute COVID-19. PR programmes commonly included exercise training, education and/or counselling. One RCT compared PR with no rehabilitation; other studies used before-and-after or historical comparisons. Outcomes included exercise capacity, pulmonary function, quality of life, dyspnea, fatigue, anxiety and depression, and activities of daily living. Across studies, PR was followed by improvements in exercise capacity, pulmonary function, and/or quality of life; select studies reported improvements in dyspnea, fatigue, anxiety and depression. In the RCT, pulmonary function, quality of life, and anxiety improved, while there was no statistically significant difference in activities of daily living. Daynes reported HADS anxiety and depression changes that were not statistically significant. No worsening of outcome measures, nor adverse events were reported (n = 309 participants across included studies). The authors state most studies were likely low quality and that evidence is limited.

  142. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments.2021 · review
    Summary

    This narrative review asked how long COVID is characterised and what treatments might apply, noting limited literature on pathophysiology, risk factors and treatment. It searched PubMed, with the last search on 5th February 2021 and a brief update on 15th April 2021; no review-level numbers enrolled, started or analysed are reported. The reviewed studies concerned discharged COVID-19 patients with on-going symptoms, elderly COVID-19 survivors, and COVID-19 survivors with palpitations or tachycardia. A personalized multidisciplinary rehabilitation approach involving breathing, mobilisation and psychological interventions was reported in 23 discharged patients; lung function and physical capacity improved, but most participants' lung function did not heal completely and persistent neurological symptoms remained. A case series of seven discharged patients reported combined breathing and light exercise rehabilitation healed and improved fatigue symptoms in five and two cases, respectively. One RCT of 72 elderly survivors reported that a 6-week rehabilitation program involving breathing, stretching and home exercises improved lung function, exercise capacity, quality of life and anxiety, but not depression. A small study of 24 survivors with palpitations or tachycardia reported ivabradine relieved racing heart rate compared with carvedilol. An international survey found 85.9% of participants with long COVID experienced symptom relapse after mental or physical activities. The review also states GET and CBT may pose potential harm in some instances and rehabilitation may not be suitable for critical COVID-19 survivors with severe pulmonary or cardiac damage. The authors call for future research on repurposed drugs.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime